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ABSTRACT
Men who have sex with men (MSM) are at increased risk of anal cancer as a result of anal HPV
infection. Routine HPV vaccination is recommended for all MSM up through age 26; however,
vaccine uptake among this population is low. The Integrative Model of Behavioral Prediction
(IM) was used to identify, describe, and explain psychosocial factors related to HPV vaccine
decision-making for young MSM. A sequential mixed-methods approach consisting of semistructured interviews, a quantitative survey, and a qualitative open-ended survey was used to
address the following aims: (1) Determine salient outcome, normative, efficacy, and control
beliefs related to HPV-vaccination among young MSM; (2) Identify information needs and
trusted sources of information regarding HPV vaccination among young MSM; and (3) Develop
and test a structural equation model guided by the Integrated Model of Behavioral Prediction.
The purpose and objectives of this research address priorities outlined in the Institute of
Medicine’s report on health disparities among lesbian, gay, bisexual, and transgender (LGBT)
populations. Results highlight the lack of information and knowledge regarding HPV prevention
in this population. The majority of respondents had heard of the HPV vaccine but generally
perceived it as a women’s health issue. Attitudes toward vaccination were generally positive, as
was behavioral intention to get vaccinated within the next 12 moths. Salient behavioral beliefs
described physical benefits such as lowering risk and promoting overall health. Psychological
benefits were described as protecting sex partners and providing peace of mind. There was some
concern regarding the risks of vaccination including contracting HPV from the vaccine, not

vii

knowing if it would be effective, and potential side effects. Normative influences on decisionmaking were minimal. Availability, cost, and convenience were among the most salient external
control factors. Issues surrounding disclosure of sexual minority status influenced control factors
including self-efficacy. Addressing the specific beliefs and concerns expressed by MSM can help
to improve the effectiveness of health education interventions promoting vaccination. Empirical
findings support the proposed behavioral model of vaccine decision-making.

viii

CHAPTER 1: INTRODUCTION

The incidence of anal cancer is increasing in the U.S. and men who have sex with men
(MSM) are disproportionally at risk (Daling et al., 2004; Johnson, Madeleine, Newcomer,
Schwartz, & Daling, 2004; Joseph et al., 2008). Between 1973 and 2000, the incidence of anal
cancer in the U.S. increased among both men and women; however, the incidence among men
increased at a higher rate (160% vs. 78%) (Johnson et al., 2004). The incidence rates of anal
squamous cell carcinoma (SCC), the dominant histologic anal cancer type in the U.S., increased
an average of 2.6% per year between 1998 and 2003 (Joseph et al., 2008). The demographic
trends in anal cancer changed after 2000, when the combined incidence of SCC and carcinoma in
situ were higher in men than in women (Nelson, Levine, Bernstein, Smith, & Lai, 2013). Most
of this increase, however, has been attributed to the HIV epidemic and the disproportional risk
faced by MSM (Cress & Holly, 2003; Daling et al., 2004; Nelson et al., 2013).
It is estimated that the incidence of anal cancer is approximately 12.5-36.9 cases per
100,000 MSM compared to just 1 case per 100,000 heterosexual males (~ 20 times higher for
MSM) (D’Souza et al., 2008; Daling et al., 1987). This rate is substantially greater in MSM
infected with HIV. Since 1996, the anal cancer incidence of HIV-positive MSM was estimated to
range from 59.4-96.2 cases per 100,000 (Machalek et al., 2012).
Further evidence indicates that a sizable proportion of MSM exhibit anal squamous
intraepithelial lesions (ASILs), which are considered biological precursors of anal cancer. In
their investigation of HIV-negative MSM recruited from four U.S. cities, Chin-Hong and
1

colleagues (2005) found that 20% of MSM had ASILs, with 5% of these classified as high-grade
lesions (i.e., invasive cancer precursors). A study of HIV-positive MSM found the prevalence of
ASILs to be approximately 81% with 13% classified as high-grade lesions (Palefsky et al.,
2005). Similar rates of ASILs were reported in studies of MSM residing in European countries
(Kreuter et al., 2010; Piketty et al., 2004). The high rate of ASILs among populations of MSM,
as well as the increase risk of invasive anal cancer, suggests that anal cancer prevention targeting
MSM is of significant public health importance.
Overall, the current risk for anal cancer for MSM is comparable to women’s risk for
cervical cancer prior to widespread implementation of cytological screening (Qualters, Lee,
Smith, & Aubert, 1992). While most attention has focused on the well-established link between
human papillomavirus (HPV) and cervical cancer, infection with oncogenic HPV types (e.g.,
HPV -16 and -18) is also a primary causal factor in the etiology of anal cancer (Grulich et al.,
2012). In a meta-analysis of anal HPV-related disease, the prevalence of anogenital HPV
infection was as high as 92.6% and 69.9% in studies of HIV-positive and HIV-negative, MSM,
respectively (Machalek et al., 2012). The prevalence of oncogenic high-risk types was also high
in these populations, averaging 73.5% in HIV-positive and 37.2% in HIV-negative MSM. These
infections are effectively prevented through prophylactic vaccination (Giuliano et al., 2011).
In 2009 the U.S. Food and Drug Administration approved the quadrivalent HPV vaccine,
Gardasil, for the prevention of genital warts in males ages 9-26. Indications of Gardasil were
extended in 2011 to include the prevention of anal cancer and anal intraepithelial neoplasia in
both males and females. The Centers for Disease Control and Prevention (CDC) recently
recommended routine vaccination of males aged 11 and 12, and catch-up vaccination in males
between the ages of 13 and 21. Permissive use was recommended for men between the ages of
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22 and 26; however, the Advisory Committee on Immunization Practices (ACIP) recommended
routine vaccination of MSM up through age 26 (Centers for Disease Control and Prevention,
2011b). There is a paucity of behavioral research focusing on adult MSM ages 18-26 regarding
their readiness to initiate HPV vaccination.
Preliminary research suggest that a reasoned action approach, as represented in the
Integrative Model of Behavioral Prediction (IM), is a viable theoretical framework from which to
understand HPV vaccine decision-making and to design tailored interventions. According to this
model, health education interventions must address the salient HPV-related outcome, normative
and control beliefs expressed by young MSM in order to effectively promote vaccination among
this population. These beliefs and perceptions cannot be generalized a priori from other research
domains or study populations but require careful formative elicitation research conducted with
the priority population. The salient beliefs elicited in the current study can be used to create
innovative culturally appropriate interventions promoting HPV vaccination among young MSM.
Statement of Need
There is limited theory-based research on HPV vaccine acceptability and intentions
among men in general, and even fewer studies focusing on MSM for whom the need is even
greater. Overall, men have been found to have limited knowledge about HPV (Gerend &
Magloire, 2008; Klug, Hukelmann, & Blettner, 2008), to be largely unaware of the link between
HPV infection and cancer in men (Gerend & Barley, 2009), and to have widely varying attitudes
toward HPV vaccination (Liddon, Hood, Wynn, & Markowitz, 2010). The few studies that have
focused on MSM have reported a wide range of HPV awareness, knowledge, and vaccine
acceptability in MSM (Reiter, Brewer, McRee, Gilbert, & Smith, 2010; Simatherai et al., 2009;
Tider, Parsons, & Bimbi, 2005; Wheldon, Daley, Buhi, Nyitray, & Giuliano, 2011). Much of this
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research is limited by its focus on MSM living in a few large metropolitan cities, and by
measures that did not assess knowledge of the oncogenic risk of HPV infection in men. One
national study of MSM found high awareness of HPV but limited knowledge about the direct
health effects of HPV infection on males (Gilbert, Brewer, Reiter, Ng, & Smith, 2010). For
example, although 79% of men in this study had heard of HPV, only 32% knew HPV could
cause anal cancer.
Collectively, the utility of this body of research for intervention planning is limited by
three important caveats: (1) most of this data were collected with regard to a hypothetical HPV
vaccine since, at the time, no vaccine had been approved for the prevention of HPV in males; (2)
participants were on average much older than males who are in the current recommended age
range for HPV vaccination; and (3) social and cultural beliefs and perceptions salient to young
MSM were not explored. These limitations in the extant literature limit the ability of public
health professionals to tailor health education interventions to the specific needs of gay, bisexual,
and other MSM. Widespread acceptance and uptake of the HPV vaccine is needed in order for
prophylactic vaccination to be an effective—both in terms of reach and cost—public health
strategy to decrease the burden of HPV-related cancers among male sexual minorities. Health
education research aimed at promoting vaccination is therefore an essential component of such a
strategy.
Research Plan
Purpose of the Study
The long-term goal of this research is to decrease the incidence of anal cancer and other
HPV-associated diseases among MSM by preventing infection of HPV types -6, -11, -16 and -18
through vaccination. The purpose of this study was to understand the factors important to young
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MSM when making decisions about HPV vaccination. A multi-phase, multi-method study was
conducted in order to develop measures of relevant theoretical constructs and to test an
integrative model of HPV vaccine intentions in a sample of young MSM. The following aims
were addressed: (1) Determine salient outcome, normative, efficacy, and control beliefs related
to HPV-vaccination among young MSM; (2) Identify information needs and trusted sources of
information regarding HPV vaccination among young MSM; and (3) Develop and test a
structural equation model guided by the Integrated Model of Behavioral Prediction that identifies
the psychosocial determinants of young MSM’s HPV vaccine intentions. The specific aims and
associated research questions are summarized in Table 1.
The goal of this research is to inform health education interventions that will increase
HPV vaccine uptake among young adult MSM; however, since the vaccine has only recently
been approved for males, and the number of young MSM who have actually received the HPV
vaccine is very small, it is not possible at this time to study vaccine uptake directly. Therefore,
the main outcome of interest for this research is intent to receive the HPV vaccine, which is
theoretically the most proximal determinant of future vaccination (Montano & Kasprzyk, 2008).
The target population for this research includes (1) men between the ages of 18 and 26,
(2) who reside in the United States, (3) are able to read and comprehend English, (3) who have
not initiated the HPV vaccine series, and (4) who have ever engaged in sexual contact with
another male or who identify as gay or bisexual. This conceptual population includes both gay
identified and non-gay identified MSM in order to be inclusive of all those who engage, or may
engage at some point, in similar behaviors that increase the risk of HPV infection. It also focuses
on adult males who do not need parental permission to receive the vaccine.

5

Rationale for the study
The use of empirically supported behavioral models of HPV vaccination specific to MSM
will increase the efficacy of health education messages and interventions targeting MSM, which
will result in greater rates of vaccination and decreased risk of anal cancer and other HPVassociated diseases. By identifying the salient psychosocial factors associated with HPVvaccination among young MSM and testing a theoretical behavioral model that identifies specific
beliefs and perceptions that can affect intentions to get vaccinated, the outcomes of this research
can be used to develop tailored health education programs aimed at increasing vaccine uptake
among this population. The strategies for behavioral change, for example, would differ
significantly if this research identifies normative influences as the strongest predictor of vaccine
intentions and attitudinal factors as largely unimportant. Furthermore, by eliciting salient
influential individuals or groups, and measuring indirect effects of normative influences
(normative beliefs and motivation to comply), the final model will provide a rich source of
information to plan behavior change strategies.
Future directions include the use of Intervention Mapping to apply the determinants of
HPV vaccine intentions identified in the current study to the creation of specific change
objectives, which represent empirically validated “pathways” that can yield the most immediate
changes in motivation and behavior (Bartholomew, 2011). This approach will also involve the
identification of relevant stakeholders and community resources that can be leveraged to
disseminate health education messages and programs, with the ultimate goal of increasing HPV
vaccine awareness, acceptability, and uptake among diverse populations of young MSM.
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Table 1: Aims and Research Questions
Research Aim
Research Aim #1: (a) Describe salient outcome,
normative, efficacy, and control beliefs related to
HPV-vaccination among young MSM
(b) Determine factors that underlie these beliefs

Research Question
1. What do YMSM believe are the advantages
and/or disadvantages of receiving the HPV vaccine?
2. (a) How do YMSM perceive others who receive
the HPV vaccine? (b) Who are the individuals
and/or groups that influence YMSM decisions
regarding HPV vaccination?
3.What factors or circumstances would enable
YMSM to initiate HPV vaccination and what
factors or circumstances would inhibit their ability
or willingness to get vaccinated?

Research Aim #2: Identify information needs and
trusted sources of information regarding HPV
vaccination among young MSM.

4. What sources of health-related information do
YMSM access and trust? What information would
help influence their HPV vaccine decisions?

Research Aim #3: Develop and test a structural
equation model guided by the Integrated Model
(IM) of Behavioral Prediction that identifies the
psychosocial determinants of young MSM’s HPV
vaccine intentions

5. What are the structural relationships between
factors from the IM and what is their relationship to
HPV vaccine intentions?
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CHAPTER 2: LITERATURE REVIEW

Human papillomavirus as a public health problem
Human papillomavirus (HPV) is a common infectious agent that infects the epithelial
tissues after abrasion or trauma (Schiller, Day, & Kines, 2010). Though there are many types of
HPV, it is principally known and described as a sexually transmitted infection (STI). Currently
there are more than 40 known HPV types that infect epithelial tissues in anogenital regions of
males and females. Assessment activities surrounding the study of HPV as a public health
problem include epidemiological investigations designed to quantify the distribution and
determinants of HPV infection and HPV-related diseases. These types of surveillance activities
are essential to inform policy development and the assurance of provisions and resources.
It is estimated that 6.2 million sexually active Americans between the ages of 15 and 44
will acquire HPV every year (Weinstock, Berman, & Cates, 2004). Given that cross-sectional
studies often find a 50% prevalence of HPV infection, it's likely that a larger proportion of the
population gets HPV infection during the lifetime (Dunne et al., 2007; Dunne, Nielson, Stone,
Markowitz, & Giuliano, 2006). The majority of HPV infections will spontaneously regress with
only a small percent of HPV infections persisting beyond two years (Baseman & Koutsky,
2005). Prevalence estimates of HPV in the U.S. vary as a result of geographic variations in study
samples, anatomical sites from which specimens were collected (e.g., cervicovaginal, glans,
corona, prepuce, anus, etc.), as well as the processing methods used to analyze the samples
(Dunne et al., 2006; Nielson et al., 2007; Smith & Travis, 2011). Estimates range from just 1.3%
8

to 72.9% in studies assessing multiple anatomical sites (Dunne et al., 2006). Because of the
wide-ranging prevalence estimates across populations, an overall estimate of HPV infection is
not useful. This is further substantiated when one considers sex differences in HPV prevalence
and persistence.
Unlike patterns of HPV infection in females, the prevalence of genital HPV in males does
not concentrate as highly in younger age cohorts indicating sex differences in persistence or
reinfection (becoming infected with same HPV-type after initially clearing the infection) (Smith,
Melendy, Rana, & Pimenta, 2008). These sex differences may also be reflected in observations
of lower antibody prevalence for specific HPV types and lower titer levels in males compared to
females (Giuliano et al., 2008). Therefore, age does not appear to be as strongly associated with
genital HPV prevalence in males, in general, as it is in females. It is still unknown if age-based
sex differences exist in anal HPV infection.
Results are more conclusive, however, with regard to determinants of infection. Sexual
behavior is consistently associated with HPV prevalence in both males and females. A greater
number of lifetime and recent sex partners increase risk of HPV (Svare et al., 2002). Having
multiple sex partners is also positively associated with co-infection with multiple HPV types
(Nielson et al., 2009; Rousseau et al., 2003). For men, multiple-type HPV infections may be
more common in particular anatomical sites such as the penile shaft and to a lesser extent the
glans penis/coronal sulcus; whereas other sites such as the perianal and anal canal may be less
likely to harbor multiple type infections (Nielson et al., 2009).
Therefore, the prevalence and type of HPV infection also appears to vary across men
based on their history of same-sex sexual behaviors. Men with a history of oral and/or anal sex
with men have been shown to have a higher prevalence of specific anal HPV genotypes when
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compared with men without a history of same-sex behavior (Nyitray, da Silva, Baggio, Lu,
Smith, Abrahamsen, Papenfuss, Quiterio, et al., 2011). For example, the prevalence of combined
genotypes 6/11, the two HPV types responsible for the majority of anogenital warts, were found
to be more common in men who have sex with men (MSM) and men who have sex with men
and women (MSMW) when compared to men who have sex with women (MSW) (Nyitray, da
Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Quiterio, et al., 2011). Similarly, the
prevalence of any HPV type at the perianal region or in the anal canal is strongly associated with
a history of same-sex sexual behavior. And while anal HPV infection among MSW is not
uncommon, these type-specific infections tend to co-occur at anal and genital sites in MSW, but
less so among MSM (Nyitray, da Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Quiterio, et
al., 2011). This pattern of infection suggests self-inoculation between anatomical sites among
MSW (Hernandez et al., 2008).
Among MSM and MSMW, there are a number of factors associated with the prevalence
of anal HPV infection. One of the strongest behavioral factors is history and frequency of
receptive anal intercourse (Chin-Hong et al., 2004; Vajdic et al., 2009). Infection with HIV also
increases risk of HPV. MSM seropositive for HIV were significantly more likely to be infected
with both oncogenic and nononcogenic HPV types compared to HIV seronegative MSM (Vajdic
et al., 2009; van der Snoek et al., 2003).
Anal HPV infection is also common among females. In a recent cohort study of women,
the period prevalence over an average of 1.3 years for anal HPV infection was 70% (Goodman et
al., 2008). The incidence of infection (inclusive of 18 high-risk HPV DNA types) was nearly 20
per 1,000 woman-months after a year of follow-up. A greater number of sexual partners and
baseline cervical HPV infection was positively associated with anal HPV infection among
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women in this cohort study; however, anal intercourse was not significantly associated with anal
HPV infection. This finding is in accordance with some previous research on anal HPV infection
in women that failed to find an association between anal HPV infection and receptive anal
intercourse (Palefsky, Holly, Ralston, Da Costa, & Greenblatt, 2001). In contrast, research
among MSM has consistently found strong associations between receptive anal intercourse and
anal HPV infection (Chin-Hong et al., 2004; Vajdic et al., 2009). Collectively, these findings
suggest divergent routes of transmission responsible for the acquisition of anal HPV infection in
heterosexual men and women, compared to homosexually active men.
High-risk and low-risk HPV
A better approach to the surveillance and monitoring of HPV infections is to focus on
those specific types that result in the greatest disease burden given the wide variation in the
distribution of HPV infection among diverse populations, the various determinants that lead to
these infections, and the differences observed in persistence of infection. A small subset of
genotypes is responsible for the largest proportion of clinical diseases such as anogenital warts
and certain cancers. Those associated with anogenital warts are considered low-risk, as they do
not result in malignant cancers. Two types of low-risk HPV (type -6 and -11) cause
approximately 90% of genital warts. In contrast, 12-18 types of HPV are considered high-risk
because of their relationship with invasive cancer (Muñoz et al., 2003).
HPV-associate disease burden
Genital warts
Genital warts, or Condylomata acuminate, occur at multiple anogenital sites in both men
and women. They can also develop in the larynx, eyes, and nose. The majority of genital warts
are caused by HPV type -6 or -11 (Garland et al., 2009). Infection with these HPV types is very
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common in the United States. In a recently published study, the seroprevalence of HPV types
6/11 was 20.8% for females and 7.3% for males (Markowitz, Sternberg, Dunne, McQuillan, &
Unger, 2009); however, these are likely lower bound estimates due to lower antibody response
and titer levels for specific HPV types in males (Giuliano et al., 2008).
Despite the high prevalence of infection with these HPV types in the population, the
majority of infections do not result in genital warts because the infections are cleared by the
body’s immune system. Analysis of private insurance claims estimate the incidence density rate
of genital warts in the United States to be approximately 1.7 per 1,000 person years (Insinga,
Dasbach, & Myers, 2003). Self-report data from a population-based sample of men and women
aged 18 to 59 residing in the US indicated approximately 6% of this population has ever been
diagnosed with genital warts (Dinh, Sternberg, Dunne, & Markowitz, 2008). There is some
indication that the rate of genital warts is increasing in the United States and is highest among
men and women in their twenties (Insinga et al., 2003; Koshiol, Laurent, & Pimenta, 2004).
Furthermore, anogenital warts may be more prevalent among MSM, and are associated with
certain sexual behaviors and tobacco use (Hansen et al., 2010; Fengyi Jin et al., 2007; Wiley et
al., 2009).
Though anogenital warts are relatively benign, treatment options and the likelihood of
reoccurrence result in significant health care costs and utilization (Giuliano, 2007). Developing
anogential warts also exerts a significant psychosocial burden in both men and women and
negatively impacts their quality of life (Jeynes, Chung, & Challenor, 2009; Scarbrough Lefebvre,
Van Kriekinge, Gonçalves, & de Sanjose, 2011; Skaaby & Kofoed, 2011). Furthermore,
anogenital warts may increase the risk for HIV infection among high-risk populations of men
(Jin et al., 2010).
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Cervical cancer
Initial assessments of the public health impact of HPV began in the 1970s when genital
warts was linked to HPV infection in returning war veterans; however, it was not until the 1980s
that HPV infection was linked to squamous cell carcinomas of the cervix (Boshart et al., 1984).
It is now well understood that HPV infection is a necessary cause of cervical cancer
(Walboomers et al., 1999), which is the second most common type of cancer in women
worldwide and is estimated to develop in approximately 8.1/100,000 women every year in the
United States (Howlader et al., 2011). This rate is far less than the rate of cervical cancer in
previous decades, as the incidence in the United States has decreased almost 70% among white
women due to the widespread implementation of cytological screening (Devesa et al., 1987;
Kitchener, Castle, & Cox, 2006). Despite the success of these prevention efforts, cervical cancer
is still a significant cause of cancer-related morality in the United States, particularly among
Black and Hispanic women (Barnholtz-Sloan et al., 2009). Infection with a high-risk type of
HPV is a necessary cause of cervical cancer. Specifically, HPV-16 and -18 account for the
highest proportion of cervical cancers (Clifford, Smith, Plummer, Munoz, & Franceschi, 2003).
Other HPV-associated cancers
These same HPV types have also been implicated as primary causal agents of anal cancer
(Carter et al., 2001; Frisch et al., 1999; Melbye & Frisch, 1998), and are strongly associated with
cancers of the oropharynx, vulva, vagina, and penis (Gillison, Chaturvedi, & Lowy, 2008).
Collectively, these noncervical HPV-associated cancers result in over 19,000 cancers per year in
the United States. Among these, anal and oropharyngeal cancers represent the largest burden of
noncervical HPV-associated cancers. Furthermore, as shown below, there are notable disparities
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in the incidence of these cancers, particularly with regard to incidence among men (Palefsky,
2010b).
Head and neck cancer
In contrast to the declining rates of cervical cancer in the United States, rates of noncervical HPV-associated cancers are static or increasing (Gillison et al., 2008). For example,
persistent infection with high-risk HPV types can result in a series of invasive cancers in both
men and women including anal and head and neck cancers. Cancers of the head and neck include
all of those cancers developing in the oral cavity, salivary glands, sinus and nasal cavities,
pharynx, or larynx. The role of HPV infection in the development of head and neck cancer
depends largely on the site of the tumor. The association of HPV infection is strongest for
cancers of the oropharynx with approximately 60% of these cancers attributable to HPV
infection (Gillison et al., 2008). The burden of these HPV-related oral cancers has increased over
the last two decades, particularly among younger men (Chaturvedi et al., 2011; Marur, D’Souza,
Westra, & Forastiere, 2010; Westra, 2009). There are an estimated 7,000 cases of oropharyngeal
cancer annually in the US, with approximately 5,600 of those cases occurring among men (CDC,
2011). Similar to cervical cancer, HPV -16 and -18 are the most prevalent HPV types found in
oropharyngeal cancers (Giuliano et al., 2008).
Anal cancer
There is a growing body of evidence that suggests most anal cancers (more than 90%) are
caused by HPV infection (Gillison et al., 2008). In 2009, an estimated 5,290 men and women in
the U.S. were reported with cancers of the anus, anal canal, or anorectum (Jemal et al., 2009).
And while overall survival rates from anal cancer are similar to survival rates from other cancers
of the digestive system, there is a significant quality of life lost depending upon the
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recommended treatment (Allal, Sprangers, Laurencet, Reymond, & Kurtz, 1999). Furthermore,
the incidence of anal cancer is increasing, and certain subpopulations are at disproportional risk
of this disease. Between 1973 and 2000, the incidence of anal cancer in the United States
increased among both men and women; however, the incidence among men increased at a higher
rate (160% vs. 78%) (Johnson et al., 2004). The incidence rates of anal squamous cell carcinoma
(SCC), the dominant histologic anal cancer type in the U.S., increased an average of 2.6% per
year between 1998 and 2003 (Joseph et al., 2008). The demographic trends in anal cancer
changed after 2000, when the combined incidence of SCC and carcinoma in situ were higher in
men than in women (Nelson et al., 2013).
Most of this increase, however, has been attributed to the disproportional risk faced by
MSM (Cress & Holly, 2003; Daling et al., 2004). Epidemiological evidence strongly suggests
that MSM are at increased risk of developing anal cancer. The incidence of anal cancer in MSM
was estimated to be approximately 12.5-36.9 cases per 100,000 MSM compared to just 1 case
per 100,000 heterosexual males (Daling et al., 1987). A prospective cohort study of married
same-sex partners in Denmark found that homosexually partnered men had over 31 times the risk
of anal cancer compared to the rest of the general population (Frisch et al., 1997).
The prevalence of anal squamous intraepithelial lesions (ASILs), some of which are
likely biological precursors of anal cancer, provides additional evidence of anal cancer risk in
MSM. Analysis of anal cytology results among sexually active HIV-negative MSM determined
that 5% of the men had biological precursors of anal cancer (Chin-Hong et al., 2005). The risk of
ASILs increase significantly for HIV infected individuals. Prevalence estimates of ASILs from a
study of HIV-positive MSM were as high as 81% (Palefsky et al., 2005). These findings are
consistent with the incidence of anal cancer found in HIV-positive MSM (D’Souza et al., 2008).
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At nearly 80 cases per 100,000, HIV-positive MSM are nearly 40 times more likely to develop
anal cancer than HIV-negative MSM. Overall, risk estimates for anal cancer among MSM are
comparable, and even exceed, women’s risk for cervical cancer prior to widespread
implementation of cytological screening (Qualters et al., 1992).
Penile cancer
HPV infection is also associated with a number of penile cancers, which are rare
compared to other HPV-associated cancers. The estimated average annual number of HPVassociated cases of penile cancer in the US is 298 (Gillison et al., 2008). This low occurrence
equates to less than 1 case per 100,000 men. Unlike cervical cancer, in which HPV is a necessary
cause, penile cancer is a histologically heterogeneous disease where approximately 40-50% of
cases are associated with HPV infection (Giuliano et al., 2008). The association of HPV
infection with penile cancer is clarified when stratified by histology with a much larger
proportion of warty/basaloid cancers testing positive for HPV DNA (~75-80%) compared to the
more common squamous cell carcinomas (~30-60%) (Giuliano et al., 2008; Palefsky, 2010). Of
these HPV-associated penile cancers, the majority (~87%) can be attributed to infection with
HPV type 16 and/or 18 (Gillison et al., 2008).
HPV Prevention
The prevention of HPV infection among males has garnered increased attention in recent
years, both because of the indirect benefit to females resulting from lower population prevalence,
as well as the growing awareness of the health sequelae of HPV infection in men. Identifying
factors associated with the increased risk of HPV transmission provides targets for primary
prevention efforts. The primary modes of transmission of HPV include vaginal and anal
intercourse (Burchell, Winer, de Sanjosé, & Franco, 2006). Prevalence of HPV infection is
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commonly associated with a greater number of lifetime and recent sexual partners (Dunne et al.,
2006). Significantly decreasing exposure through the modification of sexual behaviors is
unlikely given the highly transmissible nature of HPV and increasingly permissive social norms
regarding sexual behavior (Thornton & Young-DeMarco, 2001).
In addition, the protective effect of condom use against HPV transmission during sexual
intercourse is undetermined (Manhart & Koutsky, 2002) and is likely site specific. Consistent
condom use with female partners seems to offer some degree of protection from genital HPV
infection, particularly at covered sites such as the penile shaft and glans (Baldwin et al., 2004;
Nielson et al., 2010). Always using condom was also found to be protective against anal HPV
infection among MSM (Nyitray, da Silva, Baggio, Lu, Smith, Abrahamsen, Papenfuss, Villa, et
al., 2011). Despite these findings, condom use was not associated with risk of anogenital warts
among men in a previous study (Wiley et al., 2005). The association between condom use and
HPV prevalence appears to be moderated in part by biological sex differences, given that women
appear to benefit less from condom use than men (Manhart & Koutsky, 2002; Vaccarella et al.,
2006). Studies investigating the association of condom use and HPV have several
methodological limitations (e.g., HPV sites measured) that limit our ability to draw valid and
reliable conclusions; however, it is clear that the overall impact of condom use as a viable HPV
prevention strategy is limited by the potential for transmission during noncoital sexual actively.
The data regarding the protective effects of male circumcision is more definitive. A
recent meta-analysis reviewed 23 articles published through September of 2010 and found
consistent evidence for reduced risk of HPV among circumcised men (Larke, Thomas, dos
Santos Silva, & Weiss, 2011). The strongest effect was for reduced prevalent infections,
particularly at the glans/corona and sites more proximal to the foreskin. There was further

17

evidence indicating that circumcision is protective against incident infections and may result in
increased clearance of acquired infections. There is some related evidence that the protective
effect of circumcision may decrease the prevalence of HPV-associated diseases. For example,
childhood circumcision is associated with reduced risk of invasive penile cancer (Larke et al.,
2011); and, among men with a history of multiple sex partners, a decreased risk of cervical
cancer has been observed in their female partners (Castellsagué et al., 2002). No data is available
regarding circumcision risk of anal HPV infection or anal cancer.
Circumcision as a population-based HPV prevention strategy is limited, however, by its
overall impact on HPV transmission as well as limited modifiability. Based on current data,
circumcision can reduce HPV transmission by an estimated 43% (Larke et al., 2011); however,
there is wide variation in this estimate and may be as low as 29%. Furthermore, the overall
prevalence of male circumcision in the United States has steadily decreased since the 1970s (Xu,
Markowitz, Sternberg, & Aral, 2007), and is associated with strong cultural values and
increasingly negative attitudes that may be resistant to modification (Zoske, 1998).
More recent efforts to prevent HPV infection involve prophylactic vaccination as a
primary prevention strategy. A quadrivalent HPV vaccine has been shown to have high efficacy
for preventing infection of HPV types -6, -11, -16, and -18, and also clinical diseases such as
anogenital warts and external genital lesions (Giuliano et al., 2011). The reported efficacy of the
quadrivalent vaccine in preventing infections (types -6, -11, -16, and -18), external genital
lesions, and genital warts was found to be approximately 90% in vaccinated males who were
naïve to the four HPV genotypes prior to vaccination. A bivalent HPV vaccine (types -16 and 18), Cervarix, is also available and is indicated for the prevention of cervical cancer; however,

18

the efficacy of Cervarix in preventing HPV 16/18 and associated cancers in males is currently
unknown.
In 2009, the U.S. Food and Drug Administration approved an HPV vaccine, Gardasil, for
the prevention of genital warts, and in 2010 approved the vaccine for the prevention of anal
cancer and anal intraepithelial neoplasia in both males and females. The most recent expansion
of the ACIP’s HPV vaccine recommendations to include routine vaccination of boys aged 11 or
12, catch-up vaccination of young men 13 through 21 years who have not been previously
vaccinated, and permissive vaccination of males 22 through 26 (Centers for Disease Control and
Prevention, 2011b). The ACIP also issued a risk-based recommendation for the routine
vaccination of MSM through age 26 (a nonavalent vaccine was approved by the FDA in 2014
but at the time of this writing this vaccine had not been recommended for adult males).
It should be noted that these recommendations create a 5-year period between the ages of
22 and 26 in which routine vaccination of males is not recommended unless the male belongs to
the “risk population” defined as “men who have sex with men” or if he is infected with HIV. It is
unclear if this risk population includes men who identify as a sexual minority (e.g., gay or
bisexual) but who have not yet been sexually active with men. Implementing these divergent
policy recommendations require population-based vaccine promotion programs targeting male
sexual minorities.
In order for the vaccine to be an effective strategy at reducing the incidence of HPV and
HPV-associated diseases, widespread acceptance and uptake of the vaccine is necessary. The
most recent estimates indicate low uptake of HPV vaccine among adult MSM. In 2011, just 5%
of MSM surveyed as part of the National HIV Behavioral Surveillance System had received one
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dose of the HPV vaccine. A Harris LGBT Interactive Panel survey conducted in 2013 reported a
13% uptake among MSM 18 to 26 years old.
HPV vaccine behavioral research
Currently there is little consensus in the extant research literature on the acceptability of
HPV vaccination in adult males. The results are difficult to compare given the differences in
methodology, the populations sampled, as well as whether the data were collected prior to the
FDA’s approval of the use of Gardasil in males. In addition, the age at which vaccination is
sought, either by the individual adult or his parent/guardian, determines who should be the focus
of the research. The research reviewed here will focus on studies from the perspective of adult
men, compared to the parents or guardians of adolescent males, due to the lack of research on the
latter. Furthermore, these two groups of males—those in the target age vs. those in the catch-up
group—will require unique interventions with divergent targets and strategies to increase vaccine
uptake.
Early studies on the acceptability of vaccination against sexually transmitted infections
among college students suggest that this population is overwhelmingly supportive of such
vaccinations (Boehner, Howe, Bernstein, & Rosenthal, 2003). These findings suggest that adult
college students have positive attitudes toward new vaccine technologies targeting sexually
transmitted infections and may adopt such technologies in large numbers; however, it is well
established that general attitudes toward a broad set of behaviors (e.g., vaccination against a class
of diseases) are poor predictors of actual behavioral performance compared to more specific
attitudes toward a well-defined behavior (Fishbein & Ajzen, 2010). Therefore, the major
weakness of this early work is the focus on hypothetical vaccines.
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The degree to which men are even aware and knowledgeable about HPV and the HPV
vaccine will significantly impact the likelihood that they will be receptive to vaccine
recommendations. A meta-analysis of research published between 1992 to 2006 found a wide
range of awareness and knowledge about HPV in both men and women (Klug et al., 2008). Since
the quadrivalent vaccine was not available to females until 2006, the research surveyed reflects
the awareness and knowledge of participants prior to widespread media coverage and marketing
of the vaccine. The authors found that awareness of HPV ranged from 13% to 92% and was
generally higher among women than men.
There is a widespread lack of knowledge that infection with HPV causes diseases such as
anogenital warts and cancers (Klug et al., 2008). This lack of knowledge was most evident prior
to the implementation of the HPV vaccination campaigns. In a survey of college freshmen
conducted in 2000, the majority of men (96%) and women (95%) had heard of genital warts, but
only 4% of men and 12% of females knew that HPV causes genital warts (Baer, Allen, & Braun,
2000). Similarly, students in this study were unaware of the etiological connection between
dysplasia of the cervix and penis and HPV infection, and expressed a poor understanding of the
transmission of HPV relative to that of genital warts. These findings are not limited to this single
study but are consistent with findings from a large body of research conducted during this time
period (Klug et al., 2008).
Limitations inherent in sex education programs that rely on the dissemination of “simple
messages of prevention” have been identified as one possible explanation for the wide-spread
lack of basic information about HPV (Braun & Phoun, 2010, p.50). The transmission dynamics
of HPV limit the ability to construct simple messages around preexisting “safer sex” discourses,
such as those applied to the prevention of HIV/AIDS. As a result, HPV as an important sexually
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transmitted infection was largely ignored (Braun & Phoun, 2010). Others have identified
incomplete media coverage of HPV that systematically lacked information about sexual
transmission and the relationship of HPV infection to clinical diseases (Anhang, Stryker, Wright,
& Goldie, 2004). These larger social phenomena provide a context from which to understand
public perceptions of HPV and identify potential barriers to vaccine promotion among men.
A series of media reports and a direct-to-consumer advertising campaign shortly followed
the initial FDA approval of Gardasil in 2006. In what was seen as an attempt to deemphasize the
sexual nature of HPV in order to limit the opposition of vaccinating young girls, the majority of
the initial media coverage and related advertisements failed to provide information about HPV
including its transmission, prevalence, and clinical manifestations other than cervical cancer
(Braun & Phoun, 2010; Mamo, Nelson, & Clark, 2010). As a result, the predominant focus on
Gardasil as cancer prevention technology is thought to have created unrealistic perceptions of the
probability of HPV infection resulting in cervical cancer—a proposition that has some empirical
support (Munsell, Gray, Reed, Vasquez, & Vlasak, 2010)—and may foster a general lack of
susceptibility or concern about HPV infection among men.
A number of studies have assessed men’s awareness of HPV and the HPV vaccine
following the licensure of the vaccine for females and the ensuing mass media attention (Allen,
Fantasia, Fontenot, Flaherty, & Santana, 2009; M. A. Gerend & Barley, 2009; M. A. Gerend,
Shepherd, & Monday, 2008; Jones & Cook, 2008; Nielsen, Munk, Liaw, & Kjaer, 2009). As
previously described, however, much of the reporting on the vaccine, as well as the formal
direct-to-consumer advertising campaign implemented by Merck, framed Gardasil almost
exclusively as a technology to prevent cervical cancer while omitting information about HPV as
a sexually transmitted infection (Braun & Phoun, 2010). As a result—though awareness of HPV
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increased among men following the availability of the vaccine for females—men’s knowledge of
HPV remained low (Klug et al., 2008). In fact, the initial marketing of Gardasil may have
actually created the perception that HPV is only of concern for females (Wailoo, Livingston,
Epstein, & Aronowitz, 2010).
After more than two years following the availability of Gardasil, male students
participating in a series of focus groups at a large urban university were well aware of HPV and
the HPV vaccine (Allen et al., 2009). However, there was a general sense expressed in these
groups that men were not susceptible to HPV or that HPV infection in men was not serious. In
fact, many of the men referred to HPV as a “women’s disease” (Allen et al., 2009). As late as
2009—just prior to the FDA’s approval of Gardasil for males—as many as 45% of male college
students in one survey believed that males could not even acquire HPV, and 74% of those who
were aware that men could become infected with HPV were under the impression that HPV
infection in men was rare (Katz, Krieger, & Roberto, 2011). The majority of these men reported
commercials and advertisements as the primary source of their information regarding HPV,
whereas few men had received information about HPV through health education programs or
healthcare providers (Katz et al., 2011).
Results from these studies demonstrate that awareness of HPV increased following the
initial licensing of Gardasil for females, but men continued to have poor knowledge of HPV in
general, and specifically regarding clinical manifestations of HPV infection in men (Liddon et
al., 2010; Nadarzynski, Smith, Richardson, Jones, & Llewellyn, 2014). Information about the
etiological relationships between HPV infection, genital warts and cancers in men was largely
absent from initial public discourse surrounding HPV. To date, behavioral surveys continue to
indicate that a large proportion of men remain unaware of the potential clinical manifestations of
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HPV. For example, in a series of recent studies men were largely unaware that genital warts are
caused by HPV infection (Gilbert et al., 2010; Nandwani, 2010; Tider et al., 2005; Wheldon et
al., 2011) and even fewer were aware that HPV is associated with oral, penile or anal cancers
(Gerend & Barley, 2009; Gilbert et al., 2010; Wheldon et al., 2011).
Brewer, Ng, McRee, and Reiter reported that a majority of heterosexual (62%) and
gay/bisexual (79%) men participating in a national survey of men in the United States were
aware of HPV but had low knowledge about HPV-related diseases (Brewer, Ng, McRee, &
Reiter, 2010). And while findings from this study suggest that gay and bisexual men—who were
hypothesized to be more sensitized to sexual health concerns—were more aware of HPV and had
higher knowledge of HPV-related diseases than heterosexual men, their level of knowledge was
still quite low (Brewer et al., 2010; Gilbert et al., 2010). For example, only 15% of gay/bisexual
men knew HPV infection can cause anal cancer. Furthermore, the majority of men in this study
expressed the belief that HPV vaccine would not benefit men.
There have been very few studies that have surveyed men about HPV following the
initial approval of Gardasil for men in late 2009. A recent study of Australian college students
found moderate knowledge of HPV but highlighted important misconceptions held by many of
the men sampled. Most men correctly identified that HPV causes cervical cancer, but few were
aware of HPV-related diseases in men (Petrovic, Burney, & Fletcher, 2011). Similarly, young
gay and bisexual men in the US exhibited high awareness of HPV as a cause of cervical cancer,
but were much less aware of the possible clinical manifestations in men (Wheldon et al., 2011).
More than 40% of men participating in this survey were unaware that genital warts are caused by
HPV infection, and less than half were knowledgeable about the link between HPV and oral,
anal, or penile cancers. In addition, more than a year following the approval of Gardasil for

24

males, only a quarter of the men in this sample were aware that an HPV vaccine was available to
them.
Barriers to HPV vaccine uptake among men
There are a number of important barriers to widespread uptake of HPV vaccine among
adult males in the catch-up age range of 18 to 26. Key among these, as previously outlined, is a
widespread lack of knowledge and awareness of HPV and HPV-associated disease in men. Men
consistently demonstrate lack of basic information about HPV and HPV vaccination.
Furthermore, while knowledge is not consistently predictive of HPV vaccine acceptability
(Daley et al., 2010; Ferris et al., 2009; Gerend & Barley, 2009; Gilbert et al., 2010; Reiter et al.,
2010) or intentions among men (Petrovic et al., 2011; Wheldon et al., 2011; Young et al., 2011),
knowledge and awareness are considered fundamental or background factors that operate
indirectly through more salient perceptions and beliefs (Fishbein & Ajzen, 2010). For example,
knowledge of the high prevalence and transmissibility of HPV may result in greater perceived
susceptibility to HPV infection among men. This is important because perceived susceptibility of
HPV or HPV related diseases has been shown to positively correlate with HPV vaccine
acceptance and intentions (Crosby, DiClemente, Salazar, Nash, & Younge, 2011; Daley et al.,
2010; Gerend & Barley, 2009; Gilbert et al., 2010; Reiter et al., 2010; Wheldon et al., 2011).
Therefore, the existing research that suggests men, particularly those in the vaccine-licensed age
cohort, do not feel susceptible to HPV is concerning and is a significant psychosocial barrier to
widespread vaccine uptake among this population.
In a recent study, the majority of young men (~54%) who were surveyed two months
after the approval of Gardasil for males expressed low perceived susceptibility to HPV (Crosby
et al., 2011). In turn, men with low perceived susceptibility to HPV were found to be
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significantly less likely to express a desire to receive an HPV vaccine. The association between
perceived susceptibility to HPV infection and positive intent to receive an HPV vaccine has been
found in a number of other studies in diverse populations of men (Daley et al., 2010; Gerend &
Barley, 2009; Reiter, McRee, Kadis, & Brewer, 2011).
These results suggest that health education interventions focusing on correcting
widespread misperceptions that HPV infection among men is rare may result in greater
perceptions of susceptibility and in turn create positive motivation for HPV vaccination.
However, it is well established that perceived susceptibility of a given health condition will
increase intrinsic motivation only if that health condition is also perceived as being a serious
threat to physical and or psychological well being (Fishbein & Ajzen, 2010).
Men’s general lack of knowledge regarding the clinical manifestations of HPV infection
would suggest that they would express ambiguous beliefs with regard to the seriousness of such
an infection. In fact, a wide range of perceptions regarding the seriousness of HPV infection has
been reported (Brewer et al., 2010; Bynum, Brandt, Friedman, Annang, & Tanner, 2011; Crosby
et al., 2011; Daley et al., 2010; Gerend & Barley, 2009; Katz et al., 2011; Wheldon et al., 2011;
Young et al., 2011). Presumably, the perceived severity of HPV infection would be higher
among men who are knowledgeable about the potential health consequences of such an
infection; unfortunately, these associations have not yet been reported in any of the published
literature. There is some indirect support for this hypothesis in the consistent finding that men
who express a positive belief in the potential health benefits of HPV vaccination—suggesting
that they perceive negative health consequences from HPV infection—have higher vaccine
intentions (Gerend & Barley, 2009; Gilbert et al., 2010; Wheldon et al., 2011).
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Concerns about the overall safety of HPV vaccination have also been identified as a
significant barrier to vaccine uptake in men (Liddon et al., 2010). In a recent study immediately
following the approval of Gardasil for use among males, a majority of men (67%) expressed
concern about the vaccine’s safety (Crosby et al., 2011). There was a general consensus among
the men in this survey that they did not have enough information about Gardasil and that they
should “wait awhile before deciding about getting vaccinated” because the vaccine was “too
new” (Crosby et al., 2011).. Men’s concerns about side effects associated with HPV vaccination
are commonly reported (Daley et al., 2010; Gerend & Barley, 2009; Young et al., 2011), but it is
unclear to what degree these concerns about safety are actually specific to HPV vaccination, in
contrast to more general concerns about vaccinations. Unfortunately, these studies typically
measure safety concerns specific to HPV vaccination (Crosby et al., 2011; Gerend & Barley,
2009; Reiter et al., 2011; Wheldon et al., 2011) safety concerns about vaccinations in general
(Daley et al., 2010; Ferris et al., 2009). Without measuring both indicators of safety concerns
within the same study, the subsequent analyses are unable to empirically determine the
collinearity of these factors.
Consequently, there is some evidence to suggest that while men commonly express
concerns about vaccine safety, these concerns are not very salient in their appraisals of their
overall vaccine intentions. This is evidenced by consistent null findings for safety concerns in
multivariable statistical models of HPV vaccine intentions (Daley et al., 2010; Gerend & Barley,
2009; Reiter et al., 2011; Wheldon et al., 2011). Studies that do find positive associations
between safety concerns and vaccine intentions typically limit their analyses to zero-order
correlations, and are therefore unable to control for spurious relationships (Ferris et al., 2009).
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In addition, expressed concern about vaccine safety may actually be an indicator of a
more general negative attitude toward recommended health behaviors. In a recent study
assessing the associations between HPV vaccine intentions and a variety of health behaviors,
there was a positive association between wearing a seatbelt and vaccine intentions. In this same
study, vaccine intentions were not associated with being “extremely concerned” about vaccine
safety (Ferris et al., 2009). Instead, one of the more significant differences between these men
was the degree to which they believed that vaccines are important. The majority (67%) of men
who wanted the HPV vaccine believed that it is “extremely important” to get vaccinated for all
recommended vaccines. Collectively, these findings suggest that concerns over vaccine safety
are of less importance in HPV vaccine-related decision-making than are more positive
dispositions toward health behaviors (e.g., general vaccinations, seatbelt use).
Other barriers, such as the actual or perceived cost of vaccination, demonstrate much
more stable associations with HPV vaccine intentions (Gerend & Barley, 2009; Wheldon et al.,
2011; Young et al., 2011). The current cost of the HPV vaccine series (approximately $400.00)
is far greater than the out-of-pocket cost men found to be acceptable for this vaccine (Gilbert et
al., 2010). Consequently, men have indicated that the high cost of the vaccine series is a primary
reason that they would not be immunized (Crosby et al., 2011). The negative association
between cost and HPV vaccine intention was also commonly reported as a barrier to vaccination
among women (Brewer & Fazekas, 2007). But recent research that controlled for cost in the
study design has demonstrated that cost may actually be of less concern than indicated by
statistical models (Vanderpool, Casey, & Crosby, 2010). Additional research needs to clarify this
relationship but it is clear that third party payers will play an important role in ensuring vaccine
uptake across socioeconomic strata.
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An often-overlooked barrier to vaccine promotion among young men is the lack of
healthcare utilization by this demographic (Mansfield, Addis, & Mahalik, 2003). Men,
independent of age, are much less likely than women to utilize routine medical services such as
an annual physical exam (Chabot, Lewis, de Bocanegra, & Darney, 2011; Vaidya, Partha, &
Karmakar, 2012). The lack of interaction with the healthcare system limits the opportunities of
healthcare providers to counsel eligible men about HPV vaccination. This is a significant barrier
considering that provider recommendation has been shown to be one of the strongest predictors
of HPV catch-up vaccination among women (Brewer & Fazekas, 2007; Rosenthal et al., 2011)
and there is growing evidence that men are generally more accepting of vaccination when
recommended by a healthcare provider (Daley et al., 2011; Ferris et al., 2009; Reiter et al.,
2011). Furthermore, providers have indicated a willingness to recommend HPV vaccination to
their male patients and are therefore a vital resource in vaccine promotion efforts (Zimet &
Rosenthal, 2010). Future studies should assess the ability to overcome access barriers by offering
vaccine in informal settings where men are more likely to be engaged (Kierans, Robertson, &
Mair, 2007).
Psychosocial issues surrounding HPV vaccination of male sexual minorities
There is a growing amount of behavioral research focused specifically on HPV
vaccination among gay, bisexual, and other men who have sex with men referred to as “MSM”
from this point forward) that warrants further consideration (Nadarzynski et al., 2014). It has
been argued that MSM—as a subpopulation of men—stand to receive the greatest direct benefit
from HPV vaccination due to their increased risk of anal cancer (Palefsky, 2010a, 2010b). As
early as 2005, researchers began assessing HPV-related knowledge and beliefs among MSM
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living in large urban cities (Tider et al., 2005). This research demonstrated a general lack of
knowledge about HPV infection similar to that found among men in general.
Collectively the body of behavioral research on HPV and MSM demonstrate low levels
of knowledge and concern about HPV (Nadarzynski et al., 2014). Comparisons of MSM with
heterosexual men have found that a greater proportion of MSM had previously heard of HPV
and had greater awareness of HPV related diseases in men (Brewer et al., 2010). Despite these
statistically significant differences, the overall knowledge of HPV in this study was low. The
most poorly understood aspect of HPV infection in men is the clinical manifestations of HPV
with regard to non-cervical HPV-associated cancers (Reiter et al., 2011; Wheldon et al., 2011).
Despite the limited information about HPV and HPV vaccination reported by the
majority of MSM surveyed, the acceptability of HPV vaccination among this population widely
varies from study to study (Nadarzynski et al., 2014). Two studies operationalizing vaccine
intentionality as a multidimensional construct, reported disparate rates of vaccine intentions
among MSM (Reiter et al., 2011; Wheldon et al., 2011). Wheldon et al. reported (2011) that only
36% of the men in their study were considered likely to get vaccinated even after they were
provided basic information about HPV-vaccines and HPV-associated diseases. By comparison,
Reiter and colleagues found 74% of MSM in their study were willing to receive HPV vaccine
(Reiter et al., 2011). There are a few possible explanations for these findings. For instance, there
are notable differences in the age of respondents in these studies. Older men with a greater
number of lifetime sexual partners may perceive themselves at greater risk of HPV-related
diseases and therefore may express more willingness to receive HPV vaccine. Lower vaccine
intentions were found in the study that sampled MSM between the ages of 18 and 29 (Wheldon
et al., 2011); whereas, the higher estimate of vaccine acceptability resulted from a sample
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inclusive of men as old as 59 (Reiter et al., 2011). In fact, Thomas and Goldstone (2011)—in
their study of off-label HPV vaccination of MSM attending an anorectal surgical clinic—
reported high demand for HPV vaccination among MSM in their mid-to-late 30s.
Another important difference between these two studies is that Gardasil was approved
and available for use in men at the time of data collection of the latter investigation. This enabled
the researchers to specify a timeframe (i.e., within the next 12 months) in which participants
rated their intentions to get vaccinated (Wheldon et al., 2011). In the prior study, intentionality
was measured with regard to a hypothetical vaccine in which participants rated the likelihood
that they would get vaccinated at some point in the future (Reiter et al., 2011). Research across a
variety of health domains has consistently found better predictive validity from measures of
intention that specify a time-based context as it relates to the performance of a target behavior
(Fishbein & Ajzen, 2010). Therefore, the more precise measure of vaccine intentionality is
theoretically more predictive of actual vaccination. In this case, the more precise measure
revealed lower vaccine intentions (Wheldon et al., 2011).
Secondary prevention efforts aimed at decreasing morbidity and mortality of HPV-related
diseases may be of particular value given the limited efficacy of prophylactic vaccination of men
who have likely been previously exposed to multiple HPV types. Gay men’s health advocates
who identified anal cancer as a gay health threat in the late 1990s proactively advocated for
secondary prevention options, such as the anal Pap smear (Epstein, 2010). The social and
political organizations that emerged from the HIV/AIDS epidemic were brought to bear against
“heteronormative medical assumptions” that rendered anal cancer as an invisible disease for
which no preventive interventions were available (Epstein, 2010, p. 69). To date, there is no
official indication with regard to the use of anal Pap smear for the screening of anal cancer or
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precancerous lesions; although, there is a growing body of research which suggests that regular
cytological screening is a useful and cost effective measure for the secondary prevention of anal
cancer in both HIV-negative and –positive MSM (Park & Palefsky, 2010). Other studies have
examined the addition of HPV reflex testing to screening protocols to increase the detection of
anal cancer development (Goldstone, Enyinna, & Davis, 2009); however, the exiting literature is
limited by observational study designs (Chiao, Giordano, Palefsky, Tyring, & Serag, 2006) and
lack a clear understanding of the most important outcome to measure. Randomized clinical trials
are still needed in order to determine the efficacy of anal cytology screening and to inform
screening guidelines for the secondary prevention of anal cancer.
Based on the available research it is clear that prophylactic HPV vaccination represents
the most viable and effective prevention strategy currently available to reduce the future
incidence of HPV and its associated diseases among younger generations of MSM (i.e., those
under age 27 years). Due to elevated risk for anal cancer, a concerted effort to vaccinate MSM
up through age 26 years is warranted; however, secondary prevention through early detection of
anal disease will remain important for a large number of MSM who will not benefit from
vaccination. Health behavior research is needed in order to assess the acceptability of these
prevention efforts among MSM and to create vaccine promotion programs tailored for this
population.
Preliminary Data
A preliminary study was completed to identify psychosocial correlates of HPV vaccine
intentions among young MSM (Wheldon, Buhi, & Daley, 2013; Wheldon et al., 2011), and to
assess the utility of the Health Belief Model (Rosenstock, 1974) and Theory of Planned Behavior
(Ajzen, 1991)in predicting intent to receive HPV vaccine. The sample included a total of 179
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men between the ages of 18 and 29 years (Mean age = 22) who identified as gay or bisexual or
who had a history of sexual activity with men. These men were recruited in the fall of 2010
through gay and lesbian student organizations at 23 colleges and universities across the
Southeastern U.S. and through a social networking Internet site.
Similar to previous findings, the majority of young MSM (93%) in this study had heard
of HPV prior to participation, but were generally unaware of the causal association of HPV with
anal, penile, and oral cancers. Only 26% were aware of the availability of an HPV vaccine for
males. Just 12% of young MSM indicated that they intended to get vaccinated within the next
year yet 66% indicated that they would like to learn more about the vaccine. Constructs from the
Health Belief Model (HBM) and Theory of Planned Behavior (TPB) explained a large
proportion of the variance in a composite index of vaccine intentions (48% and 46%,
respectively). However, the percent of explained variance changed very little (~5%) in a
combined model (HBM + TPB), indicating redundancy in the explanatory power of these
theories.
The problem of overlap in constructs from the HBM and TPB has been extensively
discussed, and an alternative model has been developed that integrates concepts from the HBM
and TPB, as well as from social cognitive theory (Fishbein et al., 2001). The resulting model,
called the Integrated Model of Behavioral Prediction (IM), brings together theoretical constructs
proven to be proximate determinants of health behaviors. The IM was used as the theoretical
foundation for this study. These theoretical approaches will be discussed in more detail below.
Theoretical Framework
It has been well established that health promotion and behavior change interventions are
more effective if they are based in behavioral theory (Green, 2000). As a set of interrelated
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concepts, definitions, and propositions that present a systematic view of phenomena (Glanz &
Rimer, 2005), theory enables researchers and practitioners to condense and organize knowledge,
as well as to explain and predict specific behaviors (e.g., HPV vaccination). Thus researchers are
able to build generalizable knowledge within a field or discipline by building theory, testing
theories, and adjusting theories with findings from empirical investigations. These are the
foundational activities of all scientific fields. Therefore, a well-defined theoretical approach is
necessary to study HPV-related prevention behaviors if the purpose of that study is to develop
and evaluate scientific knowledge needed for prevention activities.
HPV preventive behaviors, such as vaccination, can (and should) be studied from a
variety of perspectives including that of the priority population (young gay and bisexual men in
this study), health care providers who administer the vaccine, community-based organizations
that serve the priority population, as well as through the analysis of social institutions (e.g.,
media). A first step is to assess what the priority population knows about the health risks and the
preventive behavior, as well their readiness or intention to engage in the behavior. Social and
behavioral science theories are needed in order identify and understand the psychological and
social factors that determine an individual’s acceptance of a medical intervention and their
readiness to complete that intervention. What follows is a discussion of key health behavior
theories focusing on individual decision-making and behavior.
Theories of health behavior
Intrapersonal level theories posit that the most proximate determinants of a given health
behavior are the affect, behavior, and cognitions of the individual actor. A number of
intrapersonal health behavior theories have been articulated, each conceptualizing the
relationships among a number of key concepts in distinct ways (Noar & Zimmerman, 2005). The
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Health Belief Model (HBM), the Theory of Planned Behavior (TPB), and Social Cognitive
Theory (SCT) are commonly used theoretical approaches to explain discrete health behaviors
and to inform behavioral interventions.
Health Belief Model (HBM)
The intellectual roots of the HBM stem largely from the field of psychology, and most
notably from the German-American psychologist Kurt Lewin and his developmental field theory
(Glanz & Rimer, 2005). Lewin, credited as the founder of modern social psychology,
emphasized the study of individual-environment interactions as key to understanding human
behavior. In contrast to behaviorism, the dominant paradigm at the time, Lewin’s Field Theory
understood behavior as purposive and a product of an individual’s personality, perceptions, and
social interactions. The social environment (or “life space”) was of particular importance. Lewin
conceptualized this environment as a field containing behavioral objects in which the individual
actor appraised as either desirable or undesirable (i.e., positive and negative valance)
(Rosenstock, 1974). One could then predict an individual’s behavior by assessing this appraisal
process. Individuals would act in ways to avoid objects perceived as negative and to move
toward or engage objects perceived as positive.
In the early 1950s, social psychologists Rosenstock, Hochbaum, and Kegels developed
the HBM while working in the U.S. Public Health Service (Rosenstock, 1974). The original
intent of the HBM was to explain why individuals were not taking advantage of a free
tuberculosis health-screening program. The HBM includes elements from Lewin’s field theory
and emphasizes the subjective perceptions of the individual in understanding health behavior
(Maiman & Becker, 1974). Diseases were understood as objects in which an individual
perceived as negative, and would therefore behave in ways that would move the individual away
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from that object (i.e., prevent or treat the disease). But in order for this appraisal to occur, the
individual must first perceive himself or herself at risk for the disease.
The HBM conceptualizes these cognitive processes into four key constructs: (1)
perceived susceptibility, (2) perceived severity, (3) perceived benefits, and (4) perceived barriers.
It was proposed that perceived susceptibility (individual's perception of the risk of
illness/disease) and perceived severity (beliefs about the physical and social consequences of the
illness/disease) form the threat element that motivates action; whereas, perceived benefits
(beliefs about the benefits of criterion specific health behavior) and barriers (beliefs about the
real or imagined costs of the criterion specific behavior) provide information about the likely
path to action. Two additional constructs, cues to action and self-efficacy, are also used in the
HBM. Cues to action, although an underdeveloped construct in the model, describe those
somatic and/or environmental events that elicit action. Self-efficacy describes an individual’s
confidence in his/her ability to take action in a variety of situations or circumstances.
The HBM also emphasizes the role of modifying factors that may attenuate the
relationship among the constructs. These modifying factors are often conceptualized as
sociodemographic influences, but could also include knowledge as well as personality
characteristics that may influence individual perceptions. The relationships among the constructs
themselves are not well conceptualized in the HBM. In certain circumstances, modifying factors
may actually be antecedents to perceived threat, which is often the case with knowledge.
Similarly, perceived barriers or benefits may act as modifying variables, or they may mediate the
relationship between perceived threat and the desired health behavior. These structural
ambiguities have significant ramifications for how this model is applied in research and practice.
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Theory of Planned Behavior (TPB)
The Theory of Planned Behavior (TPB) is the result of an adaptation of the Theory of
Reasoned Action (TRA) (Fishbein, Triandis, Kanfer, et al., 2001). Social psychologist Martin
Fishbein developed the TRA to overcome the limitations of behavioral research that
conceptualized attitudes as the most proximate cause of behavior. The problem was that, across
many studies and behavioral domains, attitudes were inconsistently correlated with behavior.
Given the equivocal nature of these findings, Fishbein introduced the TRA, which
conceptualized behavioral intention as the factor mediating the relationship between attitudes
and behavior. The TRA includes three main constructs: (1) Behavioral intentions, (2) attitudes,
and (3) subjective norms.
Behavioral intentions are said to capture the motivational qualities that lead to adoption
of a behavior, and are theorized to be a function of attitudes and subjective norms. Attitudes are
further subdivided into behavioral beliefs and evaluations of behavioral outcomes. Essentially,
attitudes are “latent dispositions or tendencies to respond with some degree of favorableness or
unfavorableness to a psychological object” (p. 76) and are composed of beliefs regarding the
attributes and outcomes of the object (Fishbein & Ajzen, 2010). The evaluation, or appraisal, of
these beliefs leads to the formation of attitudes. Similarly, subjective norms are conceptualized
as the normative beliefs and the motivation to comply with these beliefs. Normative beliefs refer
to the approval or disapproval of others within an individual’s social environment. Subjective
norms are formed when these beliefs are weighted by an individual’s evaluation of how
motivated he or she is to comply with those in their network.
The TPB includes these important constructs, with the addition of perceived behavioral
control (PBC). Ajzen argued that an individual, despite having positive attitudes and normative
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support for a behavior, might be inhibited by external factors (Ajzen, 1991). Therefore, PBC was
added to account for individual volition to perform a behavior. Like attitudes and subjective
norms, PBC is composed of a belief and an evaluative component. Control beliefs are an
individual’s beliefs regarding his or her ability to perform a given behavior based on what
external factors will inhibit or facilitate their ability to act. In PBC, these beliefs are weighted by
the perceived strength of these factors to inhibit or facilitate behavioral performance. It is
theorized that the importance of PBC is diminished when there is a high degree of volition
associated with a specific behavior (Fishbein & Ajzen, 2010).
The relationships among constructs in the TPB, unlike those in the HBM, are clearly
defined. Attitudes, subjective norms, and perceived control are all theorized to have a direct
effect on intentions to perform a given behavior, which in turn is said to be a proximate cause of
behavioral performance. However, the strength of the relationship between any of the three main
constructs and behavioral intention will vary according the specific behavior under investigation.
In general, if an individual believes that a given behavior will lead to a desired outcome, that
important and respected people in his/her life are supportive of the behavior, and that there are
strong external facilitators but few barriers, then it is theorized that behavioral intentions will be
strong for the behavior and will lead to behavioral performance.
Social Cognitive Theory
Alfred Bandura developed Social Learning Theory, now Social Cognitive Theory (SCT),
in a response to the limitations of the then dominant behaviorism paradigm. This new approach
to learning emphasized the role of the social environment in determining behavior, and in
particular, the importance of the interaction between the individual actor and the social
environment. The most recent iterations of this theory were heavily influenced by the emergence
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of the cognitive paradigm in psychology, which lead to a greater emphasis on the cognitive
processes in learning and behavior (Bandura, 2001). The result is the current form of the SCT,
which conceptualizes behavior as the product of intrapersonal and interpersonal factors. In other
words, individual level factors interact with interpersonal factors to influence behavior; however,
the SCT also posits that an individual can affect change in the environment and regulate their
own behavior. This relationship is represented by the concept of reciprocal determinism. Other
organizing concepts include psychological determinants of behavior, observational learning,
environmental determinants of behavior, and moral disengagement.
Psychological determinants of behavior are inclusive of those concepts dealing with
individual beliefs and perceptions. There are three key concepts that are grouped into
psychological determinants: outcome expectations, self-efficacy, and collective efficacy.
Outcome expectations are an individual’s beliefs about the outcome of a particular behavior, and
the value he or she places on this outcome. This conceptual definition is nearly identical to the
concept of behavioral beliefs from the TPB. Self-efficacy describes an individual’s confidence in
his/her ability to take action in a variety of situations or circumstances. Similarly, collective
efficacy in the SCT refers to an individual’s confidence in the ability of a group, community, or
organization to affect change in some desirable outcome.
Observational learning is learning through observation, or by observing the behavior of
others. This can occur by observing someone in real life or through some other media such as
video, audio, or text. The SCT proposes four processes involved in observational learning:
attention, retention, production, and motivation. Observational learning is facilitated if the
learner is attentive to the modeling of the behavior, is able to retain the information observed
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(either directly or through interaction with some media), is able to perform the behavior, and is
motivated to perform the behavior.
There are two concepts inclusive of environmental determinants of behavior. The first
concept, incentive motivation, is adapted from operant conditioning and includes the use of
rewards and punishments to inhibit or reinforce behavior. Similarly, facilitation includes the
resources, skills, and environmental aspects that are constructed to encourage the adoption of a
specific behavior. While operant conditioning and facilitation represent those environmental
conditions that either increase or decrease the probability of performing a specific behavior, self
regulation is inclusive of cognitive strategies that an individual utilizes to monitor their own
behavior, set goals, seek feedback, reward himself or herself, talk through a problem or barrier,
and enlist support from others.
And finally, moral disengagement is a concept that represents the means by which
individuals divorce themselves from moral standards and expectations in order to justify some
ethically questionable behavior. Moral disengagement is said to operate through four cognitive
processes: euphemistic labeling, dehumanization and attribution of blame, diffusion and
displacement of responsibility, and perceived moral justification. Euphemistic labeling is said to
enable moral disengagement by using descriptions or words of morally questionable actions that
downplay the emotional or social impact. Similarly, through the dehumanization and
construction of an in-group/out-group mentality, individuals are able to justify actions and apply
blame that would not be acceptable in other circumstances. Conversely, diffusion and
displacement of responsibility attempts to divert or minimize the consequences resulting from
one’s actions. Perceived moral justification is the attempt to reverse the perception of an action
by constructing it as a needed benefit rather than an objectionable act.
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An integrative framework
Despite the similarities among the constructs proposed by these health behavior theories,
they are typically understood and applied in research and practice as independent theoretical
approaches. There have been surprisingly few attempts to empirically compare the predictive
validity of these models or to clarify inconsistent conceptual definitions and measurements, as
well as poorly explicated causal propositions (Fishbein et al., 2001; Noar & Zimmerman, 2005;
Painter, Borba, Hynes, Mays, & Glanz, 2008; Weinstein, 1993, 2007). The absence of these vital
research activities impede the scientific growth of health behavior research, restricts the
cumulative body of knowledge created from empirical investigation, and ultimately limits the
creation of effective health behavior interventions (Noar & Zimmerman, 2005).
In an attempt to move the science of behavior research forward, key authors of the most
widely used health behavior theories convened at a National Institute of Mental Health workshop
to discuss issues regarding redundancy in conceptual definitions, appropriate measurement of
key constructs, and propositional hypothesis among constructs (Fishbein et al., 2001). The
Integrative Model of Behavioral Prediction (IM) is the result of these discussions (Fishbein,
2009).
The IM posits—that given appropriate awareness, knowledge, and skills, and in the
absence of significant environmental constraints—behavioral intention, or readiness to act, is the
mechanism through which attitudes, perceived norms, and perceptions of personal agency affect
behavior (Fishbein, 2009). The intervening role of behavioral intention was previously
highlighted in the TRA and TPB, but was absent from the HBM and SCT. As such, the IM
conceptualizes behavioral intention as the necessary determinant of any given behavior; and,
when measured on a continuum of the strength of a persons intention, it is thought to encompass
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the concept of readiness that was previously introduced in stages of change models (DiClemente
& Prochaska, 1986). Individual health beliefs and perceptions are therefore understood to
influence behavior indirectly through behavioral intention.
The strength of behavioral intentions to either perform or abstain from a given health
behavior are proposed to be a function of (1) attitudes toward performing the behavior, (2)
perceived normative influence with regard to the behavior, and (3) self-efficacy or perceived
control over one’s ability to successfully perform the behavior (Fishbein, 2009). These
propositions are nearly identical to those in the TPB, except that in the IM Fishbein argues that
the concept of perceived behavioral control is identical to self-efficacy as defined by Afred
Bandura in the SCT (Fishbein & Ajzen, 2010). As such, these constructs are simply defined as
personal agency in the IM. Thus, attitudes, perceived norms, and personal agency are theorized
to account for a substantial amount of the variation in behavioral intentions, though the strengths
of the relationships are thought to vary across different populations and behavioral domains.
Identifying the underlying beliefs and cognitive processes of these three psychosocial
factors are of fundamental importance to designing effective behavioral interventions. As
explicated in the IM, attitudes, perceived norms, and personal agency result from a process of
cognitive evaluation of salient beliefs regarding the possible outcomes of a behavior, the
normative proscriptions, and perceived barriers and/or facilitators. In other words, attitudes are
formed from an individual’s evaluation of beliefs regarding the outcome expectancies of a
behavior including the positive and negative results. Therefore, behavioral beliefs are thought to
encompass the physical, psychological, or social outcome expectancies described in the SCT, as
well as the perceived benefits and barriers from the HBM. Similarly, normative influences and
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personal agency are thought to result from cognitive appraisals of injunctive and describe
normative beliefs as well as efficacy-related beliefs, respectively.
There are a number of additional constructs labeled as “background influences” in the IM
that were identified during the NIMH theorist workshop (Fishbein et al., 2001). These include
socio-demographic factors, knowledge, and other individual difference variables (e.g., perceived
threat/risk, personality, mood, and emotions). Background influences, such as perceived threat,
are theorized to indirectly affect intentions and subsequent behavior by contributing to
underlying mental model regarding a given behavior. This view stands in contrast to the
propositions explicated in the HBM that conceptualize perceived threat as a direct predictor of
health behavior. The role of perceived threat, or risk perception more generally, as a direct
determinant of a given health behavior has also been called into question by other health
behavior theorists (Leventhal, Kelly, & Leventhal, 1999) and is equivocal in the empirical
literature (Brewer et al., 2007; Floyd & Prentice-Dunn, 2000; Harrison, Mullen, & Green, 1992).
However, the importance and causal relationship of perceived threat to health behavior is an
empirical question and will ultimately be determined through ongoing research.
The IM is best suited for a study of HPV vaccination in adult men for a number of
important reasons. First among these is its conceptualization of behavioral intentions as a
mediating variable that can stand as a proxy measure of vaccine initiation. The IM also
incorporates key constructs from multiple health behavior theories, which increases its
explanatory power and reduces issues of multicollinearity involved in multivariate statistical
analyses. Finally, the IM clearly defines causal propositions including intervening relationships
that are important for future intervention planning.
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A theoretical approach to HPV vaccine promotion among male sexual minorities
According to the IM, the most proximate determinant of HPV vaccination among young
gay and bisexual men (YMSM) is a strong behavioral intention to receive the vaccine. Thus,
behavioral intention is an important outcome measure for HPV vaccination behavioral research
given that few men—and even fewer YMSM—will have initiated the vaccine series. Therefore,
intention provides the closest proxy measure of vaccination and allows for better estimates of
future vaccine uptake in this population.
Understanding the factors that contribute to an individual’s intention or readiness to
receive the HPV vaccine is also necessary in order to effectively communicate and educate the
public in a way that will increase vaccine uptake. The IM has an advantage over other
individual-level health behavior theories in that it identifies the most proximal determinates of
behavior from decades of empirical research covering a variety of health domains and
incorporates them into a comprehensive model. This not only reduces potential issues of
multicollinearity among redundant constructs, but it also specifies structural relationships among
these constructs, that when empirically validated, can help to identify modifiable factors for
targeted interventions (e.g., specific beliefs about HPV vaccination).
According to the propositions present in the IM, in order for gay and bisexual men to
form strong behavioral intentions toward receiving the HPV vaccine, they first need to (see
Figure 1): (1) have positive attitudes towards HPV vaccination; (2) perceive that valued and
respected friends, family, and/or significant others will support and encourage them to receive
the HPV vaccine; and (3) feel confident in their ability to perform all of the tasks required to
receive the vaccine (e.g., identify a health care provider who can administer the vaccine, discuss
the vaccine with a health care provider etc.). Collectively, these three constructs (Attitudes,

44

Perceived Norms, and Personal Agency/Self-efficacy) represent the most proximate determinants
of behavioral intention to initiate HPV vaccination; however, the strength of the relationships
between any one of these determents and behavioral intention will vary across populations and
within populations depending on relevant background characteristics (See Figure 1). For
example, MSM with stronger links to established gay communities might rely more on
normative influences than MSM who are isolated from such communities. The objective of
empirical research is to determine if the target behavior is primarily under attitudinal, normative,
and/or control influences, which is accomplished by quantifying the explanatory power of each
construct with respect to behavioral intentions.
In addition, the propositional structure of the IM places special emphasis on the
underlying beliefs, or antecedents, of the most proximate determinants of behavioral intention.
As indicated by the IM, attitudes are formed through the appraisal of beliefs—or in other words,
an individual’s evaluation of their beliefs—regarding the perceived outcomes of a given
behavior. The valance and weight of these beliefs are the indicators of the attitude toward the
behavior. For example, if a young man believes that the HPV vaccine will help prevent him from
developing anal cancer later in life, and if he values that outcome, then it is theorized that his
attitudes toward the HPV vaccine will reflect these beliefs. However, this is but one example of a
series of possible outcome beliefs that collectively contribute to the formation of attitudes toward
the HPV vaccine. The same is true for the valances and weights that underlie the formation of
evaluative beliefs with regard to perceived norms and personal agency.
Elicitation research is the primary empirical tool used to describe the most salient
outcome, normative, and agency-related beliefs relevant to the priority population (Middlestadt,
Bhattacharyya, Rosenbaum, Fishbein, & Shepherd, 1996). Interventions aimed at influencing
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attitudes, perceived norms, and perceived agency/self-efficacy would therefore attempt to
influence these salient beliefs. It is this combination of clearly explicated explanatory constructs
and propositions (i.e., the reasoned action approach emphasizing proximal determinants of
behavior) with population-specific antecedent beliefs that strengthen the IM as a useful
theoretical framework for identifying personal determinants of behavior and describing change
objectives for intervention programs.

Figure 1: An integrated theoretical model of HPV vaccine promotion
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CHAPTER 3: METHODS

The long-term goal of this research is to decrease the incidence of anal cancer and other
HPV-related diseases among MSM by preventing infection of HPV types -6, -11, -16, and -18
through prophylactic vaccination. The purpose of this research was to understand the factors that
were important to young MSM when making decisions about HPV vaccination. The Integrative
Model of Behavioral Prediction (IM) was used as the theoretical framework for this study. The
following specific aims were addressed:
1. (a) Describe salient behavioral, normative, efficacy, and control beliefs related to HPV
vaccination among young MSM; and (b) Determine factors that underlie these beliefs
2. Identify information needs and trusted sources of information regarding HPV vaccination
among young MSM
3. Develop and test a structural equation model guided by the Integrative Model of
Behavioral Prediction that identifies the psychosocial determinants of young MSM’s
HPV vaccine intentions
Mixed-Methods Study Design
A multi-phased, mixed-methods, cross-sectional approach was used to comprehensively
address these aims and to build upon the theoretical and empirical research previously described.
By combining methods inclusive of both qualitative and quantitative approaches, this research
was able to provide an in-depth understanding of the beliefs, perceptions, and sociocultural
factors underlying HPV vaccine decision-making. This approach allowed for the elicitation of
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salient beliefs surrounding HPV vaccination specifically, but also allowed the flexibility to
explore broader psychosocial issues that may indirectly impact HPV vaccine related attitudes and
beliefs. The qualitative methods in this study provided rich descriptions of the theoretical
constructs and conceptually extended the integrative model to better understand decision-making
processes regarding HPV vaccination among young MSM. The quantitative methods allowed for
the systematic testing of the proposed theoretical model and for the identification of those
psychosocial factors most predictive of HPV vaccine intentions.
The overall study design is displayed in Figure 2 and includes specific actions (i.e.,
conducting Phases 1, 2, and 3), inputs/outputs (i.e., the findings), and the products (i.e., how the
findings were used). The mixed-method design employed in this study followed a three-phase
sequential approach starting with semi-structured qualitative interviews (Phase 1). Findings from
these interviews included salient beliefs and background factors that were used to construct the
measures used in the quantitative survey (Phase 2) and the open-ended survey items used in the
qualitative survey (Phase 3). Findings from Phase 1 were also used to create a vignette for Phase
3.
The quantitative survey (Phase 2) provided a direct test of the theoretical model, while
the qualitative survey (Phase 3) provided confirmation of the salient beliefs and background
factors identified in Phase 1 and elicited information regarding sources of HPV-related
information and vaccination. Phase 3 consisted of a subsample of participants from Phase 2. A
major strength of this research design is that aims 1 and 3—both providing valuable information
for health education interventions—are addressed by two distinct methods with two separate
samples allowing for the triangulation of data and methods.
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Figure 2: Study design

Priority Population
The goal of this research is to inform health education interventions that will increase
HPV vaccine uptake among young adult MSM; however, since the HPV vaccine has only
recently been approved for males, and the number of young MSM who have actually received
the HPV is very small (Reiter, McRee, Katz, & Paskett, 2015), it is not possible at this time to
study vaccine uptake directly. The main outcome of interest for this research is intent to receive
the HPV vaccine (i.e., vaccine intentions) within the next year, which is theoretically the most
proximal determinant of future vaccination (Montano & Kasprzyk, 2008). The target population
for this research was (1) men from 18 to 26 years of age, (2) who reside in the United States, (3)
are able to read and comprehend English, (4) who have not initiated the HPV vaccine series, and
(5) who have ever engaged in sexual contact with another male or who identify as gay or
bisexual. This conceptual population includes both gay identified and non-gay identified MSM
in order to be inclusive of all those who engage, or may engage at some point, in behaviors that
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substantially increase the risk of HPV infection. It also focuses on vaccine-eligible adult males
who do not need parental permission to receive the vaccine.
Phase 1 Methods: Semi-Structured Interviews
A qualitative descriptive approach was used was used in Phase 1. This approach is less
interpretive than other qualitative methods (e.g., grounded theory) but offers a comprehensive
summary of an event or phenomena in everyday terms (Sandelowski, 2000). Individual, semistructured interviews were used to elicit perceptions, attitudes, and beliefs regarding HPV
vaccination, including information regarding trusted sources of health information and preferred
locations for vaccination. Findings from Phase 1 were used to (1) construct items for the
quantitative and qualitative surveys, (2) to fully describe an integrated theoretical model of HPV
vaccine decision-making specific to male sexual minorities, and to (3) inform the creation of a
vignette used in the open-ended, self-administered survey. The use of multiple methods also
allowed for the triangulation of data increasing the authenticity and validity of the findings
(Patton, 1999).
Sampling and recruitment
Purposive sampling was used to maximize variation with regard to HPV vaccine attitudes
and related experiences. Maximum variation sampling is an emergent approach that allows initial
interviews to guide subsequent sampling strategies rather than predetermining sampling quotas
by characteristics of the individual (e.g., age or race) (Sandelowski, 1995). This approach was
accomplished by sampling from diverse venues, organizations, and virtual sites. The principal
investigator distributed palm cards at community-based organizations that provide services (e.g.,
HIV testing, treatment, social support) for young adult MSM. Student gay pride organizations at
local colleges and universities were sent information about the study and asked to disseminate
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this information among their members. In addition to these passive recruitment methods, a direct
recruitment strategy was employed using publically available social networking mobile phone
applications. The principal investigator (PI) created profiles on social network applications.
These profiles contained the PI’s name and affiliation with the University of South Florida. All
local users of the applications could view the profiles. The PI then randomly selected users by
viewing their public profiles (filtered by age) and sending users a personalized study invitation
using the native messaging system.
A total of 22 interviews were completed before data saturation occurred. For the purpose
of this study, data saturation was defined as “the point in data collection and analysis when new
information produces little or no change to the codebook” (Guest, 2006). During the initial
phases of data analysis, men infected with HIV expressed different perspectives and experiences
with regard to their health, HPV status specifically, so the last five participants were targeted
based on self-reported HIV status (an option in the social networking applications).
Procedure
Interviews were conducted either in person (n = 14) or on the telephone (n = 8),
depending on the preference or availability of the participant, and lasted between 20 and 50
minutes. The interviews were conducted in private locations that were convenient to the
participants. Most took place at the University of South Florida. A waiver of documentation of
informed consent was granted by the USF IRB in order to maintain the confidentiality of
participants. Participants were asked to complete a brief pre-screening questionnaire that
collected demographic information. Each interview began with a verbal acknowledgment that the
participant understood the consent document and agreed to be recorded. Interviews were
recorded and transcribed (omitting identifiers).
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Incentive
All participants were remunerated in the form of a $25 gift card.
Instrument
A semi-structured interview guide was used for the Phase 1 qualitative interviews. The
interview questions (see Appendix 1) were derived from the IM and were used to elicit the
beliefs and perceptions that underlie attitudes toward HPV vaccination, perceived norms
regarding HPV vaccination, and personal agency with regard to HPV vaccination. Standard
questions for formative research using this theoretical approach were included as appropriate
(Fishbein & Ajzen, 2010). Additional questions and probes were added as new insights were
discovered through successive interviews. Content and face validity were established by eliciting
feedback from experts experienced in health behavior theory and qualitative research. The
interview questions were also piloted with members from the priority population. Questions were
assessed according to the degree to which they were appropriate, given the stated aims of the
project.
Data analysis
Descriptive qualitative content analysis was used to summarize the informational content
of the data (Elo & Kyngäs, 2008). Rather than approaching data analysis without a priori
theoretical framework, as is common in other types of qualitative analyses (e.g., grounded
theory), a combination of deductive (or “directed”) and inductive content analytic approaches
were used (Hsieh & Shannon, 2005). This method provided rich descriptions of the proposed
theoretical constructs and conceptually extended the IM specifically with regard to the criterion
specific behavior (i.e., HPV vaccination) and the priority population (i.e., young adult MSM).
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The directed approach to content analysis is used when an existing theory has demonstrated
explanatory power with regard to a given phenomena but needs further description and
specification (Hsieh & Shannon, 2005). This type of formative phase, or elicitation phase, is an
essential step in the application of the IM for a specific health behavior (Fishbein & Ajzen,
2010). In the current study, directed content analysis was used to frame and understand the
experiences and perceptions of the participants—as expressed in the interview text—with regard
to HPV vaccination. This process was combined with an inductive approach in order to further
define the theoretical constructs, or main categories, of the IM using the words and expressions
of the participants.
All interviews were digitally recorded and transcribed verbatim. Transcripts were
imported into MAXQDA qualitative data analysis software, which was used for coding and data
reduction. No identifying information was retained in the transcripts. A five-step process—
largely based on the strategies of deductive and inductive qualitative content analysis outlined by
Elo and Kyngäs (2008)—was used as the data analytic framework. This included (1) coding the
transcripts using the main categories from the IM; (2) using in-vivo coding to identify text within
the main categories that exemplify that category; (3) classifying those in-vivo codes into more
generic categories as they relate specifically to HPV vaccination; (4) further refining those
generic categories into more specific and conceptually meaningful sub-categories; (5) and
assessing the trustworthiness of the findings. An example of this data reduction method is
presented in Figure 3.
Trustworthiness
In qualitative research, issues of validity and reliability are often approached in terms of
trustworthiness. The trustworthiness of findings from qualitative research centers on issues of
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credibility, transferability, dependability, and confirmability (Lincoln & Guba, 1985). These
issues were addressed in the current investigation by (1) employing a multi-method qualitative
research design that allows for the triangulation of methods and data; (2) maximizing diversity
among participants through purposive sampling; and (3) utilizing secondary coders to assess the
consistency of the analytic decisions made by the PI.

Figure 3: Example of the coding process

Inter-coder agreement was assessed in three distinct ways. First, after coding three
randomly selected transcripts, the degree to which the coders used each code in the codebook in
a given transcript was assessed, and secondly, the percent agreement on the frequency with
which each code was used to describe the text. A criterion of 80% agreement, as recommended
by Miles and Huberman (1994), was determined to represent sufficient reliability in the
application of the main categories. Agreement ranged from 82 to 98 percent across three
interview transcripts. Thirdly, the application of sub-codes to their representative quotes. Two
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secondary coders analyzed representative quotes using a revised codebook containing the
emergent sub-codes (see step 4 of the data analytic framework). These quotes were extracted
from the text and were determined by the PI to represent the fundamental defining characteristic
of the sub-category. Inconsistencies in the application of the sub-codes were discussed and the
codebook was revised. In the revised codebook, codes with overlapping conceptual definitions
were combined and further refined. A third coder coded the data with the revised codebook and
the percent agreement was calculated as the proportion of correctly coded text segments.
Agreement was determined to be sufficient at 84%.

Phase 2 Methods: Quantitative Internet-based Survey
Overview
A cross-sectional, close-ended, self-administered, Internet-based survey provided the data
used to quantify the behavioral intentions of young MSM to receive the HPV vaccine. Direct
measures of attitudes toward the HPV vaccine, perceived normative influences for vaccination,
and perceived behavioral control/efficacy in obtaining the vaccine were described, and the
relationships with vaccine intentions were explored. Furthermore, outcome, normative, efficacy,
and control beliefs, as well as individual evaluations of these beliefs were investigated in order to
better understand the modifiable factors underlying the formation of attitudes, perceived norms,
perceived control, and self-efficacy with regard to HPV vaccination.
Sampling and recruitment
Participants were recruited for the quantitative survey using three distinct approaches: (1)
a snowball sampling of college students affiliated with campus-based LGBT student
organizations across the Southeast United States; (2) Internet-based recruitment focused on
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social media; (3) Paid advertisements targeting young MSM using social and sexual networking
sites/apps.
A growing number of studies of young MSM demonstrate that Internet-based recruiting
strategies—particularly those focused on social and sexual networking sites—can successfully
recruit large diverse samples of sexual minority youth at low cost and in short periods of time
(Bolding, Davis, Sherr, Hart, & Elford, 2004; Carter, Ding, & Rose, 2011; Parsons, Vial, Starks,
& Golub, 2012; Ross, Månsson, Daneback, Cooper, & Tikkanen, 2005). Internet-based
recruitment strategies allow for inclusion of research participants from geographically disparate
areas and are better able to reach socially isolated individuals or “hidden” populations that may
not be available otherwise. This offers a great advantage when conducting research with young
MSM. This is particularly true for those who reside outside of large urban centers without wellestablished gay communities where venue-based recruitment strategies are difficult to
implement. Another advantage to conducting Internet-based recruitment is the flexibility of time
and resources. Banner advertisements can easily be targeted to specific populations (e.g., age,
sexual orientation) using user-generated profile information, and can accommodate small
budgets. Banner advertisements were purchased from two networking websites: a social
networking site and a sexual networking mobile application. These advertisements were targeted
to men who meet inclusion criteria for this study based on the information they entered in their
site-specific user profiles (e.g., age, location, and sexual orientation).
Procedure
Participants recruited from Internet-based social networking sites were directed to the
study website through the banner advertisements. Likewise, after successfully making contact
with a representative of a LGBT student organization (in most cases this was the organization’s
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student-elected president), the PI emailed the organization’s representative with information
describing the study and provided a URL to the study website. They were asked to forward this
information to their members who meet inclusion criteria. Participants were directed to the study
website containing informed consent information.
All participants were asked to give their consent via the electronic form. If they agreed to
participate and gave their electronic consent, they were directed to the survey hosted on a secure
server at the University of South Florida. The survey was created using Qualtrics Survey
Software and took participants an average of 13 minutes to complete. All study procedures and
instruments were reviewed and approved by the USF IRB.
Incentive
Participants could elect to enter into a drawing for one of ten $25 gift cards from
Amazon. To enter they provided an email address where the gift card could be sent. This email
address could not be linked to their survey data.
Instrument
A self-administered quantitative survey was developed from the formative elicitation
research guided by the IM (Phase 1). Self-administered surveys can be given over large
geographic areas and offer a sense of privacy and anonymity for research participants. Internetbased surveys are particularly useful for this research population, which is young and can
reasonably be expected to have high computer literacy.
It has been demonstrated that Internet-based surveys can increase a participant’s sense of
anonymity and help to decrease social desirability bias (Rhodes, Bowie, & Hergenrather, 2003).
Furthermore, the use of Qualtrics Survey Software allowed for the implementation of
preprogrammed skip patterns and dynamic pages. These features helped to minimize survey
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fatigue. Internet-based surveys also increase the privacy and confidentiality of participants by
allowing them to complete the survey in a location and time of their choosing and by encrypting
responses that are transmitted electronically.
Measures
Measures were constructed according to the guidelines specified for the measurement of
constructs from the IM and from the elicitation research previously described (Phase 1)
(Fishbein, 2000; Fishbein et al., 2001; Montano & Kasprzyk, 2008). The full survey instrument
can be found in appendix 2. Direct measures of attitude (A), perceived norms (N), and perceived
behavioral control (C) were measured according to standard measurement procedures (Fishbein
& Ajzen, 2010). The expectancy-value framework was used to measure indirect attitudes, norms,
and behavioral control by creating an index of beliefs weighted by their evaluation. For example,
a behavioral belief of strength bi (e.g., The HPV vaccine will help me to prevent anal cancer) is
weighted by a measure of the relevance or importance of that specific outcome ei (Preventing
anal cancer is important to me). The cross product of these two variables is the expectancy-value
score for that specific belief (biei). These scores were summed to represent an index of the salient
beliefs ( biei). This was done to create separate indexes for behavioral beliefs, normative beliefs,
and control beliefs. The behavioral, normative, and control beliefs measured in this study were
identified in Phase 1 qualitative interviews.
Intentions (INT). Three items were used to measure vaccine intentions ( = .90). They
assess intention to “find out more information about HPV,” “make an appointment to talk to a
doctor or health care provider about the HPV vaccine,” and to “get your first HPV shot.” Each
item specified a timeframe “within the next 12 months.’ Responses were recorded on a 5-point
bipolar scale (Unlikely-Likely).
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Attitude (ATT). Attitudes toward HPV vaccination were measured using a 5-point
semantic differential scale ( = .86) including the following adjectives (1) not worth it—
worthwhile, (2) harmful—beneficial, (3) a bad thing for me—a good thing for me, (4)
unimportant—important, (5) ineffective—effective. These items followed the statement,
“Overall, I think that getting the HPV vaccine is….” Higher values represent a more positive
attitude toward HPV vaccination.
Perceived norm (Norm). Three items were used to measure perceived norm ( = .70).
Two items assessed subjective norms: (1) “In general, people who are important to me would
encourage me to receive the HPV vaccine” and (2) “I can think of at least one person in my life
who would like for me to get the HPV vaccine.” One item assessed descriptive norms: (3) “Most
of my gay/bisexual male friends would get the HPV vaccine if it were offered to them free of
charge.” Responses were recorded on a 5-point bipolar scale (disagree-agree). Higher values
represent more supportive norms.
Perceived behavioral control (PBC). Three items were used to measure perceived
behavioral control ( = .70). This construct is believed to consist of perceptions of self-efficacy
and controllability (Fishbein & Ajzen, 2010). Thus, one item measured self-efficacy: (1) “I am
confident that I can get the HPV vaccine in the next 12 months.” Two items were used to
measure controllability: (2) “There are factors beyond my control that would prevent me from
getting the HPV vaccine in the next 12 months” and (3) “Getting the HPV vaccine sometime in
the next 12 months would be…Impossible for me—Possible for me.” Items 1 and 2 were
recorded on a 5-point bipolar scale (disagree-agree) and item 3 used the 5-point impossiblepossible scale. Higher values indicate higher agency.
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Behavioral beliefs (BB). Ten behavioral beliefs were measured representing physical
advantages, psychological advantages, and disadvantages/concerns associated with HPV
vaccination. For example, “It would prevent me from getting genital and anal warts,” “Feel like
there is one less thing to worry about,” and “I would have side effects from the HPV vaccine.”
Each belief item was followed by an item measuring its corresponding outcome evaluation (e.g.,
“Preventing genital and anal warts is...”). Outcome evaluations were recorded on a 5-point
bipolar scale (unimportant-important). Belief strength (bi) was recording on a 5-point bipolar
scale (unlikely-likely). The BB score is equal to biei. These scores were summed to create the BB
index for physical and psychological advantages ( biei). Higher scores represent a greater
endorsement of positive behavioral beliefs associated with HPV vaccination. The same
procedure was used to measure a belief in the side effects of HPV vaccination. In order to avoid
items with double negatives, the perceived disadvantages (e.g., “not being completely protected”
and “the vaccine may not work for me”) were only measured by their belief strength (bi).
Responses to these two items were averaged and labeled as “Low efficacy” ( = .71). A single
item was used to measure the belief that “I will contract HPV from the vaccine itself.” This
measure was also assessed using a 5-point bipolar scale (unlikely-likely). In total, 5 behavioral
belief measures were created: (1) Physical advantages, (2) Psychological advantages, (3) Low
efficacy, (4) Contract HPV, and (5) Side effects. The physical and psychological advantages
were combined ( = .90) for structural equation modeling because of their high intercorrelation.
Normative beliefs (NB). Four referents (mother, father, gay male friends, and straight
friends) were used to assess normative beliefs. Participants reported on the degree to which each
referent would be disapproving-approving of him getting the HPV vaccine (ni). Responses were
recorded on a 5-point bipolar scale. Participants could choose “not applicable” in cases where
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this person/group was not present. “Not applicable” was recoded to represent the neutral
midpoint of the scale so that a scale index could be calculated for each participant. Four
subsequent items were used to measure the degree to which responses were motivated to comply
with each referent (mi). The question stem read: “When deciding whether or not to get the HPV
vaccine, would you seriously consider the advice/opinion of…” Responses were recorded on a 5point bipolar scale (unlikely-likely). The NB score is equal to nimi. These scores were summed to
create the NB index ( nimi). Higher scores on this index represent more social influence over
HPV vaccine decisions.
Control beliefs (CB). Four control beliefs (ci) were assessed: (1) “I can find out where to
go to get vaccinated,” (2) “I will have health insurance next year,” (3) “I can find a place to get
vaccinated where I don’t need to make an appointment,” and (4) “I will get tested for HIV in the
next 12 months.” The degree to which these control beliefs would make it “more difficult” or
“much easier” for respondents to “get the HPV vaccine in the next 12 months” was assessed by
weighting the control measured on a 5-point bipolar scale (disagree-agree) with a 5-point bipolar
perceived power scale (pi) (more difficult—much easier). The CB score is equal to cipi. These
scores were summed to create the CB index ( nimi). Higher scores on this index represent a
greater perception of control over behavioral performance.
Self-efficacy (SE). Two items were used to assess the degree of confidence in getting the
HPV vaccine in the event that “you had to talk to your doctor or healthcare provider about your
sexual orientation (e.g., that you are gay or bisexual)” and “your sexual behaviors (e.g., your
sexual history).” Responses were recorded on a 5-point unipolar scale (not at all confidentextremely confident). Reponses were averaged to form a self-efficacy score ( = .90).
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Perceived threat (Threat). Four indicators of perceived threat—threat of warts on the
penis or scrotum, anal warts, anal cancer, and HPV infection—were used to construct the latent
threat variable. The indictor variables were composites created by taking the product of
perceived susceptibility (e.g., “Without the HPV vaccine, what do you think the likelihood is that
you will get anal HPV?”) with its corresponding measure of severity (e.g., “How serious would it
be for you if you became infected with HPV?”). Responses were recorded on 5-point bipolar
scales (unlikely-likely and not at all serious-extremely serious). Therefore, each composite
indicator had a theoretical range from 1 to 25 with higher values indicating greater perceptions of
a likely and serious threat. A threat scale was created to use in bivariate analyses by averaging
all four composite scores ( = .96).
Health information orientation (INFO). Three items were used to assess health
information orientation, which was defined as degree of motivation an individual has to seek out
relevant health information and to process that information (Dutta-Bergman, 2009). These items
were adapted from a previously developed and validated health information orientation scale
(Dutta-Bergman, 2009). Items were found to represent a single latent factor. The items used in
the current study were: (1) “When I take medicine, I try to get as much information as possible
about its benefits and side effects,” (2) “Before making a decision about my health, I find out
everything I can about the issue,” and (3) “It’s important to be informed about health issues
affecting gay and bisexual men.” Responses were recorded on a 5-point bipolar scale. A scale
score was calculated by taking the average of the three items ( = .80). Higher values indicate a
greater degree of orientation toward relevant health information.
Suspicion of LGBT cultural competence. Four items were used to assess suspicion of
LGBT cultural competence, which was defined as having a previously received lower quality
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healthcare as a result of sexual orientation, expressing discomfort talking to a doctor about
sexual orientation or sexual behaviors, expressing a preference that a doctor or healthcare
provider not know one’s sexual orientation, and expressing a belief that sexual orientation is not
relevant to medical care. Responses were recorded on a 5-point bipolar scale (disagree-agree). A
scale was created using the average of the three items ( = .71).
Nebraska Outness Scale-Concealment (NOS-C). The concealment subscale of the
Nebraska Outness Scale (NOS) was included in the survey with the following item stem: “How
often do you avoid talking about topics related to or otherwise indicating your sexual orientation
when interacting with members of these groups (e.g., not talking about your significant other,
changing your mannerisms)?” This was followed with 5 items: (1) members of your immediate
family (e.g., parents and siblings), (2) members of your extended family (e.g., aunts, uncles,
grandparents, cousins), (3) people you socialize with (e.g., friends and acquaintances), (4) people
at your work/school (e.g., coworkers, supervisors, instructors, students), and (5) strangers (e.g.,
someone you have a casual conversation with in line at the store). Responses were recorded on a
ratio scale ranging from never (0%) to always (100%). In previous research the NOS-C
demonstrated good internal reliability, as well as discriminant, convergent and predictive validly
(Meidlinger & Hope, 2014). Reliability was acceptable in the current study ( = .71). No
existing research has investigated the factor structure of the NOS ,so it was included as a
measured variable in the structural equation models.
Data Analysis
Data cleaning. A total of 806 respondents met inclusion criteria for age (18-26), sex at
birth (male), sexual minority status (either self identifying as gay, bisexual, or unsure and/or ever
having a male sex partner), location (United States), and HPV vaccine history (did not initiate
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HPV vaccination). A total of 225 (28%) participants exited the survey before completion. Survey
fatigue is a commonly reported problem in Internet-based surveys and similar, or even
higher,rates of non-completion have been noted in MSM Internet research (Krakower et al.,
2012). The majority of non-completers withdrew from participation prior to the midpoint of the
survey. These participants were excluded from analyses. An additional six cases were removed
because they had more than 20% of missing data. The final analytic sample consisted of 575
respondents.
Data quality. Invalid data is an issue to consider in web-based surveys (Bauermeister et
al., 2012). Automatic validation of survey items—including a mixture of forced and requested
responses—was implemented in the survey design to minimize falsification and
misrepresentations. In addition, IP addresses were examined to identify duplicate entries. There
were no duplicate IP addresses out of the 575 responses in the analytic sample. As an additional
check, surveys for participants who completed the survey in less than ten minutes (the lowest
quartile of response time) were examined for repeated patterns (e.g., skipped questions, out-ofrange responses, or inconsistent responses). Based on these criteria all 575 responses appeared
valid.
Statistical analyses. The SAS statistical software version 9.1 (SAS Institute, Cary, NC)
was used to conduct univariate and bivariate analysis. Univariate analyses were conducted on all
of the scale variables to generate measures of central tendency, distribution, and to evaluate
distributional assumptions. All of the variables violated assumptions of univariate normality;
however, the magnitudes of the sample skewness and kurtosis were small, and none surpassed an
absolute value of 2. It is suggested that values less than two represent acceptable amounts of
nonnormality (Tabachnick & Fidell, 2007). The sample size is large enough to assume that the
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distributional assumptions were met for parametric tests. Non-parametric tests were also
conducted for each analysis to check for concordance of results (e.g., Spearman rank order
correlations in place of Pearson product moment correlations).
Zero-order correlations were calculated to provide a cursory analysis of the relationships
among the scales. Mplus version 7 (Muthén & Muthén, 2007) was used to conduct Structural
Equation Modeling (SEM). SEM was used to test and modify the proposed theoretical model of
HPV vaccine intentions. SEM is useful in developing and testing theoretical models as it allows
for the simultaneous estimation of the associations among latent and measured variables and
attempts to remove measurement error from these estimates (Buhi, Goodson, & Neilands, 2007).
This allows the complete propositional structure of a theory to be tested, including direct and
indirect effects. Mplus offers a variety of features including advanced statistical methods for
estimating missing data as well as maximum likelihood estimates that are robust to violations of
normality (Muthén & Muthén, 2007). The maximum likelihood estimator with robust standard
errors was used to estimate parameters that are robust to non-normality and allowed for the full
information maximum likelihood method to handle missing data (Buhi et al., 2007; Buhi,
Goodson, & Neilands, 2008).
A two-step approach (Anderson & Gerbing, 1988) was used to build the models starting
with estimating the measurement model (fit of only the latent factors regressed on the measured
indicator variables) and then adding the structural paths (i.e., the structural model). Model fit was
evaluated for all models using the following indices: the chi-square test of goodness-of-fit index,
the Comparative Fit Index (CFI), the Standardized Root Mean Square Residual (SRMR), and
the root mean square error of approximation (RMSEA) (Hu & Bentler, 1999). Aside from the
chi-square test, which is significantly biased by sample size, goodness of fit indices do not
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produce asymptotic p-values and are thus not statistical tests of overall model fit. Therefore, the
interpretation of these indices is less objective. Hu and Benter’s (1999) guidelines were used as a
basis from which to evaluate model fit in the current investigation; however, absolute cutoff
criteria were not used as “golden rules” but as general guidelines in combination with a focus on
theoretical relevance of specified models and model modifications (Marsh, Hau, & Wen, 20004).
A good fitting model would therefore contain: (1) CFI values close to .95, (2) RMSEA values
close to .06, (3) SRMR values close to .10, and (4) provide meaningful theoretical results (Hu &
Bentler, 1999).
Phase 3 Methods: Open-Ended Qualitative Survey
An Internet-based, qualitative survey with open-ended response format and preprogrammed probing questions allowed for the exploration of salient beliefs related to HPV
vaccination from a large cross-section of young MSM with a greater degree of anonymity than is
possible with individual interviews. This method has been successfully applied in research on
stigmatized populations or when studying sensitive issues involving sexuality (Middlestadt et al.,
1996). Given the sensitive nature of the current project, increasing a participant’s sense of
anonymity may result in unique and unexpected findings. Thus this method was used as a
supplementary method to the semi-structured interviews (Phase 1).
Internet-based, qualitative surveys also allow for enhanced design capabilities to increase
the interactivity and personalization of survey questions tailored for specific respondents.
Including interactive, probing questions in Internet-based, self-administered surveys is an
innovative way of improving the quality and depth of responses to open-ended questions
(Holland & Christian, 2009). A vignette was used to provide context regarding HPV vaccination
and guide the Internet-based open-ended survey.
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Vignettes in qualitative research
Vignettes are short stories or scenarios that provide a context to which responds are asked
to answer questions (Hughes & Huby, 2002). They can include text, images, and other
multimedia to provide stimuli and add further interactions. Vignettes are commonly used in
health research to study attitudes, beliefs, and perceptions regarding sensitive issues (Barter &
Renold, 2000; Hughes & Huby, 2002). They were employed in the current study to help guide
participants through a decision-making process regarding HPV vaccination. It was discovered in
Phase 1 that young MSM had very little context in which to understand HPV vaccination;
therefore, the vignette was created using finding from those interviews. For example, anogenital
warts were a key factor in the decisions and circumstances surrounding the few men who had
already initiated HPV vaccination. In addition, men in Phase 1 had very little working
knowledge of HPV, and they identified alternative settings to offer HPV vaccination. These
points were incorporated into the vignette in the following ways: (1) key information about HPV
was provided; (2) anogenital warts were used to increase perceived threat of HPV infection; and
(3) alternative settings for vaccination were explored. The vignette can be found in Appendix 3.
Sampling and recruitment
A subsample of men from Phase 2 was recruited to complete the Phase 3 open-ended
surveys. Upon completing the Phase 2 quantitative surveys, participants were asked if they were
interested in participating in a follow-up study. They provided an email address through
Qualtrics Survey Software if they wanted to receive more information. All participants who
provided an email address (n=1,157) were invited to participate in Phase 3. A total of 1,141 of
those emails were valid. Of the 1,141 delivered emails, 361 (33%) of participants viewed the
study website and 328 began the survey. Two-hundred and forty one (73%) of the starters
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completed the survey. Respondents not meeting inclusion criteria (i.e., unvaccinated males
between the ages of 18 and 26; n = 125) were removed resulting in 116 completed surveys.
Procedure
All participants were asked to give their consent via the electronic form. If they agreed to
participate and gave their electronic consent, they were directed to the survey hosted on a secure
server at the University of South Florida. The survey was created using Qualtrics Survey
Software. The survey took an average of 32 minutes to complete. All study procedures and
instruments were reviewed and approved by research/institutional review board (IRB).
Incentive
Participants could elect to enter into a drawing for one of ten $25.00 gift cards from
Amazon. To enter they were asked to provide an email address where the gift care could be sent.
This email address could not be linked to their survey data.
Instrument
Participants completed an open-ended questionnaire based on constructs from the IM
(See Appendix 3). The questionnaire was developed by the PI with feedback and
recommendations from an expert panel of qualitative researchers. In addition, feedback from 5
members of the study population was used to assess the questionnaire for clarity, the wording of
questions, and interest and identification with the vignette. The survey contained a vignette
consisting of four main sections: (1) the opening scenario providing HPV information, (2) the
decision uncertainty scenario in which a decision to get vaccinated or not is being considered, (3)
the anal warts threat scenario, and (4) deciding on where to go to get vaccinated. Open-ended
questions followed each of the scenarios.
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Data analysis
Responses to the open-ended surveys were imported into MAXQDA for analysis. The
analytical approach from Phase 1 was used in Phase 2 in order to describe responses within the
IM framework but allow for emerging categories to be explored (See Phase 1 Data Analysis).
The revised codebook from Phase 1 provided the a priori codes. Responses to each question
were initially coded using this codebook. New codes were created as necessary. A structural
coding strategy was also used in order to explore reactions to the specific contexts provided by
the vignette. Structural coding is a question-based method that serves to index responses to
specific questions and is often used in the analysis of open-ended survey data (Saldana, 2009).
For example, responses to the question “What do you thing Brandon should do?” were indexed
(i.e., coded) according to specific decisions (e.g., “get vaccinated,” “talk to a doctor,” etc.). Data
were then sorted by decision and analyzed further to uncover more descriptive codes about that
decision.
Trustworthiness
A random selection of responses (10%) to questions from each of the four sections were
extracted and recoded by the PI and an independent coder with a Ph.D. in Public Health with
expertise in qualitative research among MSM. Discrepancies were discussed and another random
selection of responses were extracted and recoded. Agreement was greater than 80%.
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CHAPTER 4: RESULTS
Overview
Results were presented separately based on the three phases of the current study. A
synthesis of the results, and how the various methods assessed the specific aims and research
questions, will be provided in the discussion. However, it is useful here to describe the complete
study sample across the three phases.
As part of the study design, the age of participants was restricted to range from 18 to 26
encompassing vaccine-eligible adult males. The average age was 22 in each phase, and there
were similar proportions of men in the 18-20, 21-23, and 24-26 age groups. The ethno-racial
identity of participants varied considerably across the three phases. The proportion of ethnoracial minorities was highest in Phase 1, reflecting the purposive oversampling of these
populations. Across all phases approximately three in five were current college students and
most had health insurance. Overall there were a small number of self-reported HIV-infected
men, but a large percentage of respondents reported never receiving an HIV antibody test.
The majority of participants in all three phases self-identified as gay; however, a sizable
number of men identified as bisexual in Phases 2 and 3. Participants in Phase 3 were a subsample
of Phase 2 participants; thus, the demographics characteristics of these two phases were similar
aside from ethno-racial identity. There was a larger proportion of whites who completed Phase 3.
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Table 2: Descriptive characteristics of participants by study phase

Characteristic
Age [Mean (SD)]
18-20
21-23
24-26
Sexual identity
Gay
Bisexual
Heterosexual
Not sure
Other
Ethno-racial identitya
White
African American/Black
Hispanic/Latino
Asian
Native American
Pacific Islander
African
Other
College student
Yes
No
Educational attainment
Less than high school
High school / GED
Some college
2-year college degree
4-year college degree
Graduate/Professional degree
Health insurance
Yes
No
Unsure
HIV statusb
HIV-Negative
HIV-Positive
Never tested
Missing
HPV vaccination
Yes
No
Not sure

Phase 1
(N = 22)
n (%)
22 (2.58)
8 (36)
6 (27)
8 (36)

Phase 2
(N = 575)
n (%)
22 (2.43)
167 (29)
217 (38)
191 (33)

Phase 3
(N = 116)
n (%)
22 (2.11)
25 (22)
43 (37)
33 (28)

21 (95)
1 (5)
----

431 (75)
127 (22)
2 (0)
11 (2)
5 (1)

82 (71)
31 (27)
-1 (1)
2 (2)

9 (41)
5 (23)
6 (27)
1 (5)
---1 (5)

363 (63)
121 (21)
91 (16)
34 (6)
11 (2)
2 (0)
10 (2)
16 (3)

83 (72)
9 (7.8)
4 (3.4)
8 (7)
1 (1)
--11 (9)

13 (59)
9 (41)

329 (58)
241 (42)

68 (59)
48 (41)

-5 (23)
11 (50)
-5 (23)
1 (5)

16 (3)
100 (17)
254 (44)
47 (8)
132 (23)
23 (4)

-14 (12)
44 (38)
11 (10)
41 (35)
6 (5)

20 (91)
2 (9)
--

476 (83)
89 (15)
10 (2)

98 (84)
18 (16)
--

-5 (23)
-17 (78)

383 (67)
35 (6)
156 (27)
1 (0)

76 (66)
3 (3)
37 (32)
--

5 (23)
17 (78)
--

-528 (92)
47 (8)

-112 (97)
4 (3)

Note. Percentages may not add up to 100 due to rounding.
a
Some participants identified in more than one Ethnoracial category.
b
HIV status was not asked directly in Phase 1. If participants discussed being HIV positive in the interview, they were counted as positive;
otherwise, they were classified as missing.
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Phase 1 Results: Semi-Structured Interviews
A total of 22 interviews were completed in 2014 with MSM between the ages of 18 and
26. Characteristics of the study sample are presented in Table 2. Participants were on average 22
years old, and most were in college (59%) or had some type of post-secondary education. They
were diverse with nearly 60% identifying as an ethno-racial minority. Most identified as gay,
and all had been sexually active with male partners.
Five of the participants were self-reported to be HIV-positive. HIV-status was not
addressed systematically in order to determine if HIV-status would emerge during the interviews
as a salient factor surrounding HPV vaccination. Five participants identified their HIV-status as
positive, and for each of these HIV-infected participants, HIV infection was central to his
experience with the healthcare system and his subsequent view on HPV vaccination. The main
findings from the interviews are presented according to major categories from the IM along with
the more specific subcategories defined through content analysis. In Table 4, the main categories
of behavioral, normative, and control/efficacy beliefs are presented along with their generic and
subcategories. The beliefs expressed in each of these categories are represented by selected
quotes taken from the interview transcripts. Survey items that were created to measure the salient
beliefs represented in Table 4 are listed in the last column. Direct quotations are attributed to the
participants by referencing their individual participant ID numbers (e.g., P01), age, and
ethnoracial identities.
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Generic Category
Physical
advantages to
vaccination

Protects partners

Sub-Category
Lowers
risk/Promotes
health

“I don’t want to spread anything.” (P16, 24,
White)

“I could be spreading it without even realizing it.”
(P15, 20, Latino)

“You wouldn’t have to worry about giving it to
anyone else.” (P08, 19, Black)

“Do you want to have surgery on your ass? If not
go get a shot.” (P02, 26, White)

“It would be a safe bet.” (P18, 24, Multiracial)

“I would be less susceptible to anal cancer at least
from HPV.” (P12, 24, Latino)

Representative Quotes
“You're just healthier and lowering risks.” (P04,
21, Latino)

Table 3. Salient beliefs, representative quotes, and survey items
Main Category
Behavioral
beliefs

Psychological
advantages to
vaccination

Peace of mind

“Feel a little better. A little more protected.” (P09,
24, White)
“Make me feel safer.” (P16, 24, White)
“It would give me one less thing to worry about.”
(P17, 22, Black)
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Survey Items
If I got vaccinated for HPV within the next
year…

(1) It would make me healthier (Being
healthier is [very important to menot at all important to me]
(2) It would prevent me from getting
genital and anal warts
(3) It would prevent me from getting
anal cancer

If you got vaccinated for HPV within the
next year, how true are the following things
likely to happen for you? Would you...?
(4) Be less likely to spread HPV to
your future sex partners?

(5) Feel protected from HPV
(6) Feel like there is one less thing to
worry about

Supportive
referents

Risks of getting
vaccinated

Table 3 (Continued)

Normative
beliefs

Contract HPV

“Not knowing if it really works, cause you don’t
know if you technically have it.” (P12, 24, Latino)

“There is always a risk that you can contract it
from getting the vaccine...it just depends on how it
interacts with your body.” (P16, 24, White)

“My doctor would probably be the one...the first
one to say get it.” (P20, 23, Black)

“…if your body rejects it.” (P20, 23, Black)

“So I believe you’re taking a chance with getting
any type of vaccine.” (P18, 24, Multiracial)

“Every vaccine has side effects.” (P16, 24, White)

“You still have the possibility that you may get it.”
(P20, 23, Black)

“I would not feel completely protected. In this
world you can't really ever feel completely
protected.”(P09, 24, White)

Unknown
efficacy

Side effects

Health care
providers as
referent others
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How likely do you think the following
things are to happen to you if you got
vaccinated? If I got vaccinated for HPV
within the next year...

(7) I will contract HPV from the vaccine
(8) The vaccine may not work for me
(9) I would not be completely protected
from future HPV infection

(10) I would have side effects from the HPV
vaccine

Listed below are some people in your life
who may approve or disapprove of you
getting the HPV vaccine.

What do you think their opinions would be?
If you don't have a relationship with the
specific person just choose "not applicable."
1 = Very Disapproving, 3 = Neither
Approving/Disapproving, 5 = Very
Approving

(1) Your health care provider

Table 3 (Continued)
Friends as
referent others

Immediate family
members are
referent others

“To be quite honest with you, my gay male friends
are very like touch and go. We will meet up for
drinks, have a good time, kiki for a little bit, and
we leave.” (P12, 24, Latino)
“I'm pretty sure most of them are clueless about
it.” (P04, 21, Latino)
“Well my gay friends, all we do is just go out all
the time. So it’s not really something like we talk
about, you know.” (P11, 19, Latino)
“My older gay friend when I met when I was 18 I
definitely learned a lot from him. He was the first
one that told me I should go get HIV tested.” (P04,
21, Latino)
“I don't really talk too much to my family.” (P16,
24, White)
“I’m a big momma’s boy, so I think she would be
very all-pro for it, too.” (P12, 24, Latino)
“My father would have had no opinion probably
and my mother would have probably encouraged
me cause she's in the medical field so you would
have probably encouraged it.” (P01, 21, White)
“I guess just telling her that, just a conversation
you wanna avoid. Like you don’t wanna tell your
mom that you’re sexually active, so you feel like
you need to have this shot.” (P07, 19, White)
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(2) Most of your gay male friends
(3) Your straight friends

(4) Your mother
(5) Your father

Descriptive norms

Unsupportive
referents

Supportive
referents

Table 3 (Continued)

Control beliefs

External control
factors

General
acceptance

Judgment from
others

Know someone
who got HPV
vaccine

Availability

“Everyone would be supportive. I can't see anyone
saying, ‘Oh you shouldn't do that.’ " (P04, 21,
Latino)
“Why would anybody disapprove of someone
getting a vaccine.” (P09, 24, White)
“Some of the friends that I do have in particular
would probably think that I'm just being extremely
promiscuous sleeping around with guys like every
night and everything.” (P15, 20, Latino)
“She'd [his mother] be upset, ‘oh great now he's
gonna be riskier’.” (P04, 21, Latino)
“I know [about HPV vaccine] because my sister
got it.” (P12, 24, Latino)
“The one nursing student had just gotten it and I
remember I had met him. One male that I knew, a
gay male.” (P01, 21, White)
“And then there is an HPV shot for women and for
men, but like every girl in my high school had it.”
(P04, 21, Latino)
“But I think a lot of it is getting the knowledge
and information and knowing where to get the
test.” (P16, 24, White)
“If it was available on campus.” (P06, 21, White)
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(1) I can think of at least one person in my
life who would like for me to get the HPV
vaccine.

Not measured

(1) Do you personally know someone who
has gotten the HPV vaccine?

What would make it easier for you to get the
HPV Vaccine? It would make it
____________to get the HPV vaccine in the
next 12 months...
1 = more difficult to 5 = much easier for me

(1) If I could quickly find out where to get
vaccinated

Internal control
factors

Table 3 (Continued)

Efficacy beliefs

`

Cost

Convenience

Feeling
uncomfortable
disclosing

“My insurance paid for it. Had I had to pay for it I
probably would have been like...nah.” (P14, 26,
Black)
“It would be a barrier depending on the cost. I am
a poor graduate college student. I'm having
trouble paying for school let alone a vaccine.”
(P12, 24, Latino)
“Money is a big issue!” (P06, 21, White)
“I would rather go to Metro Wellness. Especially
if...Maybe if I won't like rush to get the vaccine.
I’d probably wait maybe until my next HIV test.”
(P17, 22, Black)
“And the location of the place. The time of the day
I can get it.” (P17, 22, Black)
“I just feel weird talking to someone like that
about those kind of things.” (P03, 19, Asian)
“Even when I first came out, they [health care
providers] would ask me that [sexual behavior]
and I lied. So I kind of wasn’t out. I knew I was,
and I knew I was doing things, but I…at first I was
very uncomfortable, so I kind of almost didn’t
accept it, so I didn’t say anything.” (P12, 24,
Latino)
“I'd be very selective on answering questions.
Because a lot of people aren't open...like they will
ask the question but they are not ready to receive
the answer.” (P20, 23, Black)
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(2) If my health insurance covered the
vaccine

(3) If I could get it without making an
appointment

(4) If I could get it when I get tested for HIV

(1) How confident are you in your ability to
get the HPV vaccine if you had to talk to
your doctor or healthcare provider about
your sexual behaviors (e.g., your sexual
history)?

(2) How confident are you in your ability to
get the HPV vaccine if you had to talk to
your doctor or healthcare provider about
your sexual orientation (e.g., that you are
gay or bisexual)?

Behavioral beliefs
Physical advantages to vaccination
When asked to describe the “advantages” or “good things” about getting the HPV
vaccine, most participants talked about the physical benefits to vaccination. They described how
their personal risks would be lower and that they would be doing something to promote their
health. For instance, one participant—after reading a brief fact sheet about HPV (See Appendix
4)—endorsed the belief that he would be “less susceptible to anal cancer at least from HPV”
(P12, 24, Latino). Others talked about how it would “be a safe bet” and that taking steps to
protect the “anus” was “important.” Overall, few gave specific details about preventing genital
warts or anal cancer, instead relying on general statements about how vaccination “lowers risk”
and promotes “immunity.” This seemed to reflect their limited knowledge about HPV and HPV
vaccination.
For some participants, their perceptions about the health benefits of HPV vaccination
were clearly influenced by their prior health issues/concerns. One man who described his
experience with reoccurring anal warts and their surgical excision stated, “…if it [HPV
vaccination] can prevent you from going through what I’ve gone through, it’s well worth it”
(P02, 26, White). Another man, who had experienced reoccurring anal warts, mentioned that he
wished he had received it [the HPV vaccine] before and inquired if the vaccine would prevent
him from “contracting different strains” (P21, 26, White). One participant reflected on his own
family history of cancer and how getting vaccinated would help minimize some of this risk.
Overall there was a positive attitude toward getting vaccinated, primarily resulting from
perceived health advantages.
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Psychological advantages to vaccination
In addition to the perceived physical health benefits of getting the HPV vaccine, many
participants talked about psychological advantages, including protecting future sex partners and
giving them “peace of mind.” One participant mentioned that he “wouldn’t have to worry about
giving it to anyone else” expressing a general concern about spreading STIs. The focus of these
statements was clearly on the infection itself and not on HPV-related disease. When informed
that the majority of sexually active people will become infected with HPV at some point, and
that the majority of those infections will clear without any symptoms of disease, one participant
responded: “It doesn’t matter. It’s still an STD. You’re still tainted” (P09, 24, White).
Others talked about feeling “safer,” “feeling better,” and having “one less thing to worry
about.” The following statement highlights the general focus on wellbeing and the importance of
feeling that they have taken steps to protect their health:
Knowing if I’m infected or not, you know, that would be concerning. But the fact of
knowing, “Ok, well I don’t know, but I’m taking steps in case I’m not,” that would put
my mind at ease (P12, 24, Latino).
Again this statement expresses a general concern about being “infected,” with prevention of
HPV-related disease as a secondary concern.
Risks of getting vaccinated
When asked about the “disadvantages” or “bad things” associated with getting vaccinated
for HPV, respondents reported minimal concerns over side effects. Responses to this question
tended to focus on the side effects generally associated with any vaccine or medication. For
instance, participants mentioned that “every vaccine has side effects,” (P16, 24, White) and that
people are “taking a chance with getting any type of vaccine” (P18, 24, Multiracial). There was
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also an ambiguous concern of the body “rejecting” the vaccine. The importance or value placed
on these concerns was minimal. In fact, many of the comments about side effects where phrased
in ways that minimize the concerns. For instance, one participant said, “There’s side effects for
everything, so that’s not a big worry on my plate” (P06, 21, White). Others mentioned that they
have not heard anything risky about the HPV vaccine and explicitly stated, “I know there’s antivaccine views out there, and I don’t agree with those” (P03, 19, Asian).
For the most part, concerns about the vaccine reflected doubts about its efficacy. Given
that they were all sexually active and that there is no way to test if they had been previously
exposed to HPV, they were unsure if vaccination would confer any direct benefits. Some stated
that they would “not feel completely protected” (P09, 24, White) or that they “still have the
possibility” (P20, 23, Black) of getting infected. This concern seemed to reflect the larger public
health focus on vaccinating young children.
A few participants asked whether the HPV vaccine was a “live virus” and one expressed
a concern about contracting HPV from the vaccine itself. One participant made explicit mention
of this: “There is always a risk that you can contract it from getting the vaccine…it just depends
on how it interacts with your body”(P16, 24, White).
Normative beliefs
Supportive referents
When asked what individuals or groups would approve of their decision to get the HPV
vaccine, the majority of participants expressed a very clear sentiment that this would not be a
decision that they would widely discuss with anyone prior to getting vaccinated. Some
mentioned that their “doctor would probably be the one” (P20, 23, Black) or that their doctor’s
opinion was the “only opinion that mattered” (P18, 24, Multiracial) regarding this issue. Probes
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about the support of friends or family were countered with general statements about their
expected approval or statements diminishing the influence of these individuals. One participant
stated, “I’m pretty sure most of them [his friends] are clueless about it” (P04, 21, Latino). This
same participant, along with one other, identified an older gay friend as a potential source of
health information. He stated that his older friend told him the “HPV shot came out a few months
ago” and that he “really should get it.” This recommendation was influential in his decision to
get vaccinated. In general, similarly aged peers were not considered valuable sources of
informational or emotional support regarding HPV vaccination.
Perceived support from family members was even more ambiguous. Some respondents
generally accepted that their family would be supportive but it’s not something they would
discuss with them unless there was a specific reason (e.g., parent was a medical professional).
Others rejected the idea, explaining that they didn’t talk to or were alienated from their families.
Overall the men in this sample described general perceived support for HPV vaccination
among their friends, family and medical providers; however, these referents—aside from health
care providers—were not deemed to be valuable in their decision-making process.
Unsupportive referents
There was not a strong sentiment about unsupportive friends or family, but some
participants talked about anticipated negative responses from family, and friends. In particular,
they expressed a concern that—because HPV is an STI—their mothers would assume they
wanted to get vaccine so they can “be a whore” or be “riskier.” One participant talked about
potential judgment from his straight friends who might assume he needed the vaccine because he
was “being extremely promiscuous” (P15, 20, Latino). When probed about these concerns, all of
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the participants stated that despite these potential negative assumptions, their friends and family
would still support their decision to get vaccinated.
Descriptive norms
No questions in the interview guided asked directly about descriptive norms but knowing
someone personally who has gotten the HPV vaccine came up often in conversations about HPV
knowledge. Participants were asked how they first heard about HPV (if they had) and the most
commonly mentioned source of HPV information was from female friends or family (i.e., sisters)
who had gotten vaccinated. Only one participant knew of another gay male who had received the
vaccine. In general, the overwhelming perception “about people who receive the HPV vaccine”
is that they are female.
Control and efficacy beliefs
External control factors
Participants were asked what factors or circumstances would “help you” or “make it
easier” to get vaccinated. Their responses centered around three primary reasons including
availability, cost, and convenience. Many participants expressed uncertainty about where to go to
get vaccinated. In general, participants did not see a primary care provider for regular physicals
or checkups apart from HIV testing. They tended not to have established relationships with
specific providers who they could ask about HPV vaccination. Therefore knowing where the
vaccine was available would make it easier for them to access it.
Convenience was also mentioned on multiple occasions. Participants mentioned clinics
they know of close to their homes or places of employment where they would prefer to be
vaccinated. Flexibility was highly valued in terms of where and when they could get vaccinated.
For students, getting vaccinated on campus was mostly preferred. Walk-in availability was also a
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noted facilitator. Overall participants seemed open about where to get the vaccine as long as it fit
into their schedule. This sample of men received regular HIV testing which was identified as
convenient time to get vaccinated. One participated stated: “I would rather go to metro wellness
[a local HIV testing location]. Especially if…maybe if I won’t like rush to get the vaccine. I’d
probably wait maybe until my next HIV test” (P17, 22, Black). Subsequent participants were
probed on this issue and most of them were amenable to getting vaccinated at their HIV testing
location.
By far the most significant external control factor was cost. There was a general sense
that vaccines are expensive, and participants expressed concerns that they could not afford it.
Although the majority of participants had health insurance, many were unsure if the vaccine
would be covered. In all five cases where participants were already vaccinated, they had
insurance coverage and explicitly stated that they would not have been vaccinated if they had to
pay the out-of-pocket costs.
Internal control factors
After participants were asked general question about control beliefs, they were probed
regarding their perceived self-efficacy in getting the HPV vaccine if they had to discuss aspects
of their sexuality (i.e., sexual behaviors and/or identity). For some participants, this presented no
issue at all and they described themselves as having high self-efficacy to ask for the HPV
vaccine even if they had to discuss issues of sexuality. However, other participants expressed
feeling uncomfortable disclosing their sexuality to healthcare providers. One participant stated,
“I just feel weird talking to someone like that about those kind of things” (P03, 19, Asian) Others
said they would feel “uncomfortable” and would be “very selective” about answering questions
regarding their sexual behavior.
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Background factors
Background factors were explored through general questions about health, healthcare
experiences, sexuality, and HPV. Through these open-ended discussions the PI gained a nuanced
understanding of potential background factors that underlie HPV-related beliefs and
subsequently, HPV-vaccination. A series of generic categories and sub-categories were identified
that represent these factors and allowed for the extension of the IM to included propositions
regarding the ways in which these factors might influence HPV vaccine decision-making among
young MSM. This extended framework is depicted in Figure 4 and described in detail below.

Figure 4: Extended Integrative Model of HPV vaccine decision-making among young male
sexual minorities
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Generic Category
HPV Knowledge
and Information

Sub-Category
Reaction to HPV
information

Survey Items
Information-Orientation Scale

“Ironically I have a doctor appointment next
Thursday so I'm gonna ask him about.” (P20, 23,
Black)

“I would definitely want to go get it, like right
now!” (P11, 19, Latino)

(Adapted from Dutta-Beggman, 2009)

(3) It’s important to me to be informed about
health issues affecting gay and bisexual
men

(2) Before making a decision about my
health, I find out everything I can about the
issue

(1) When I take medicine, I try to get as
much information as possible about its
benefits and side effects

Interviewer: What more information do you need
about this vaccine before you think you can make
a decision?

“Other than what are the side effects and where
the hell can I get this thing as fast as possible.”
(P12, 24, Latino)

Representative Quotes
Interviewer: What are your initial reactions about
the vaccine after hearing this information?

Table 4: Background factors important to HPV vaccination among young MSM
Main Category
Background
Factors

Information
needs

“Just think little fact sheet right here kind of
like...a wake up call to say like hey maybe it's time
for ya’ll to get tested for these diseases to get
vaccine for it. I mean you know...like I said that
little small fact sheet told so much. It told what it
is…who can get it…what it can cause. Given all
the information you need.” (P20, 23, Black)
“I’d be interested in knowing whether the vaccine
would actually kind of prevent me from
contracting different strains.” (P21, 26, White)
“Is it still as effective as you go up in age?” (P15,
20, Latino)
“It's passed by skin-to-skin contact. Even using
protection doesn't protect you? What kind of skin
to skin contact?” (P17, 22, Black)
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Table 4 (Continued)
Perceived threat

HPV-related
susceptibility

“To be honest with you I really don't think I have
it you know because I've been tested and I don't
know what tests I was being tested for but I know
I was getting tested for everything.” (P12, 24,
Latino)
“Well I was already infected with HPV at one
point. Not genital warts but a different type of
HPV. I didn't really feel like I was much at risk. I
had more than one boyfriend that had genital
warts. Not at the time I was dating them but...and I
never caught any of that stuff so I was really
happy that I didn't and I guess I really didn't feel
threatened by like genital warts.” (P18, 24,
Multiracial)
“Well the fact that it only takes one sexual partner
that automatically puts you at a 10 I think. Do I
want to water it down and say maybe six or seven
just to make myself feel better?...then yeah. It only
takes one.” (P15, 20, Latino)
“I don't really have a partner and I don't sleep
around a lot. I thought it was pretty low but it only
takes one time for you to get it so...” (P14, 26,
Black)
“Moderate because I’ve been with men who are
older than me, no more than like ten years though,
older than me, but umm I don’t know. Like if
they’ve really done like what they’ve done,
compared to what I’ve done.” (P07, 19, White)
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Please indicate on a scale of 1 to 5 how
serious you feel the following events would
be for you.
(1) If you became infected with HPV
(2) If you developed warts on or inside your
anus
(3) If you developed warts on your penis or
scrotum
(3) If you developed anal cancer

Without getting the HPV vaccine, what do
you think the chances are that you will...
(1) Get HPV
(2) Get warts on your penis or scrotum
(3) Get anal warts
(4) Get anal cancer

Table 4 (Continued)

Anogenital warts

HPV-related
severity

Had anogenital
warts

“Nobody wants cancer so it’s scary that how a
virus can go undetected of symptoms and it causes
these things…” (P03, 19, Asian)
“And I was surprised that most men who get it
never develop any symptoms. That’s startling.”
(P03, 19, Asian)
“Well it’s just, that’s scary. You know, you just
don’t know if you have it or not.” (P11, 19,
Latino)
“Oh my God it has no symptoms! So how do you
know if you got it?!” (P12, 24, Latino)
“It’s kind of crazy, it stands out too, that, you
know, most men who get HPV never develop
symptoms or health problems. So it’s kind of like
just like a sitting virus kind of thing inside of
you.” (P12, 24, Latino)
“…you could be carrying something that you
technically don’t know you have, and you could
have sex with like somebody who you’ve been
together for a long time and incidentally pass it on
to them. You know what I mean? So that’s kind of
alarming.” (P12, 24, Latino)
“He had anal warts. He had set up an appointment
with a doctor to had his removed so after he had
his removed I noticed the first one for me.” (P21,
26, White)
“HPV can come in many different forms actually.
Most common would be in genital warts. That's
personally what I have. Well I guess I don't have it
cause I've had it removed, but it still in my
system.” (P02, 26, White)
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Personal experience with anogenital warts

(1) Has a health care provider ever told you
that you had human papillomavirus or HPV?

(2) Has a health care provider ever told you
that you had genital or anal warts?

Table 4 (Continued)

Negative emotions
surrounding
disclosure

Know someone
who had
anogenital warts

Felt judged by
HCP

“I believe I was talking about my friend who had
genital warts but I’m not sure. I want to say I
probably said I heard there is some sort of vaccine
and then I'm sure she talked about it from there. I
don't remember exactly.” (P01, 21, White)
“No the guy that I was dating at the time. He
actually had warts at the time and so we thought
we were being really careful to keep me from
contracting it but we weren't very successful,
obviously...we had one sexual encounter before he
told me and I think for him he thought that
condom use would protect me against it, which
isn't actually the case.” (P21, 26, White)
“I just think that, in general, females don’t judge
as much, I guess you could say with gay men.
Umm, I always think it’s awkward to go in and
tell like a heterosexual male that I’m different than
what he is. I like to have sex with guys and anal
sex, and stuff like that, that is a difficult
conversation to have with a hetero-even if they’re
completely and fully understanding of it, to me it’s
still embarrassing. And I can relate more and I’m
probably more willing to give information to a
female than a male.” (P12, 24, Latino)
“I feel like he [his primary care physician] judges
me. I feel like if I had a provider or somebody
who is a little more open-minded... my doctor is a
staunch Republican, white dude who is like 65 and
I'm sitting there like a gay little Puerto Rican kid,
and you know, it is just always awkward when I
go to my doctor. We come from opposite ends of
the earth.” (P12, 24, Latino)
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(1) To the best of your knowledge, do you
personally know someone who has had
genital or anal warts (other than yourself)?

(2) To the best of your knowledge, do you
personally know someone who has had HPV
(other than yourself)?

Suspicion of healthcare providers

(1) I have received lower quality healthcare
services as a result of my sexual
orientation

(2) I prefer that my doctor or healthcare
provider does not know that I am
gay/bisexual

(3) I feel uncomfortable talking about my
sexual orientation or sexual behaviors with a
doctor or healthcare provider

(4) There is no reason why my doctor or
healthcare provider would need to know that
I have sex with men

Table 4 (Continued)

LGBT Cultural
Competence

Lacks knowledge
about gay health
issues

Bias toward
LGBT

“I'm not a real big person on discussing
orientation because usually if you discuss
orientation with people they tend to start shoving
you away. There is not doubt in my mind he [his
primary care physician] knew but he learned to
like form a relationship with me and my family
before he started judging me” (P20, 23, Black)
“I’m very uncomfortable receiving, especially
specialty like…when I went to go see like umm, a
gastroenterologist about issues, when he was
straight. I felt like they were judging me, I felt like
I was very singled out, I felt like they assumed
that it was cause I was gay, that’s the first
question they asked, like when I was having issues
with my colon and everything, they were like
what’s your orientation… I almost didn’t want to
tell them, because I wanted them to treat me as if
I was a straight person and not have those
preconceived notions in their head.” (P06, 21,
White)
“A gay provider would be more into or up-to-date
with newer things that are coming out. Especially
like with the threats that are more for the gay
lifestyle. Because I really don't think that my
health provider would know about HPV.” (P12,
24, Latino)
“I would just feel weird talking to someone about
that [HPV vaccine], and I would not know their
views on LGBT people. So I feel like there may
be some bias in the information that they could
give me. Even though it’s unprofessional.” (P03,
19, Asian)
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Nebraska Outness Scale- Concealment
How often do you avoid talking about topics
related to or otherwise indicating your
sexual orientation when interacting with
members of these groups (e.g., not talking
about your significant other, changing your
mannerisms)?
(1) Members of your immediate family (e.g.,
parents and siblings)
(2) Members of your extended family (e.g.,
aunts, uncles, grandparents, cousins) (2)
(3) People you socialize with (e.g., friends
and acquaintances) (3)
(4) People at your work/school (e.g.,
coworkers, supervisors, instructors,
students)
(5) Strangers (e.g., someone you have a
casual conversation with in line at the store)

Table 4 (Continued)
Management of
disclosure

Not relevant

Anonymity

“I don't think it is any of their [health care
provider] business really [his sexual behavior], but
I would've answered truthfully. Wait, would I
have answered truthfully? I think I would have.
…if you are having sex you are having sex. You
are being exposed to these diseases when you're
having sex. It’s a fact of life...like...whatever. It is
just like..it is none of your business who I am
having sex with. There is the whole stigma about
being gay that we are promiscuous people we just
go around having sex with every guy we see and
therefore are at higher risk that you
know…straight guys do that all the time too.”
(P15, 20, Latino)

“And typically that is where I go [Public Health
Department]. I guess until recent where I can go to
this care center thing. But I don't like that because
it doesn't really give the anonymity that the health
department does…it is a lot better than going to
my employer health clinic where I am sitting in a
waiting room full of people. It's different for me
because I feel like my health care provider...I
understand there is HIPA and all that stuff and
they are suppose to keep my stuff confidential.
But I live in a pretty small town and I know how
that stuff works. So I'd rather not. I go to the
health department and every time I go it is
somebody different. It never gets personal. I've
never built rapport with them.” (P12, 24, Latino)

90

HPV knowledge and information
Nearly all of the participants had heard of HPV and typically described it as a sexually
transmitted infection that has multiple “strains” and mostly affects women. The majority (55%)
mentioned a vaccine, though most were not aware that males could be vaccinated.
Approximately 41% (n = 9) of men listed genital warts as a distinctive characteristic of HPV
infection and 36% (n = 8) cancer. When cancer was mentioned it was usually limited to a generic
explanation (e.g., “life threatening diseases like cancer”) or an explicit mention of cervical
cancer. No participant mentioned anal, oral, or penile cancer (not even the 5 vaccinated men).
The main sources of HPV-related information came mostly from female friends, formal sex
education classes, and Gardasil advertisements. One participant recalled:
I know that there is a vaccine. I feel like there is the stupid commercial, well it's not
stupid it's informative. It was like…primarily for girls but now they are doing it for guys
as well…the HPV vaccine. (P15, 20, Latino)
After providing basic information about HPV and HPV-vaccination for males (see
Appendix 4), participants were asked: “What are your initial reactions about the vaccine after
hearing this information?” Some of the men expressed a high level of interest and enthusiasm for
getting vaccinated: “…what are the side effects and where the hell can I get this thing as fast as
possible” (P12, 24, Latino)! Others expressed intention to speak with their doctors about the
vaccine in the near future.
To probe more about their information needs, they were asked: “What is the minimal
amount of information you need about this vaccine before you think you can make a decision?”
Some of the men asked basic questions about HPV or the vaccine. These questions typically
related to: (1) the effectiveness of the vaccine in older males, in males who have already been
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sexually active, or in males who have already been exposed to HPV; (2) the side effects
associated with getting vaccinated; and (3) the types of sexual behaviors that spread HPV.
Telling them that HPV can be transmitted from “skin-to-skin” contact was too ambitious and
usually prompted more questions about specific behaviors. Despite these inquires during the
interviews, collectively this sample of men exhibited a high degree of acceptability and
willingness to initiate HPV vaccination.
Perceived threat of HPV infection and disease
Perceptions regarding susceptibility to HPV infection were mixed. Some men described
their risk as high considering that it “only takes one sexual partner” (P15, 20, Latino). Others
reflected on their sexual histories and relationship status. One participant responded that it was
hard for him to assess his risk because he was with his “boyfriend-partner, for almost four years”
and that they “rarely” have other sexual partners (P12, 24, Latino). It was common for
respondents to discuss their own risk in general terms like “I always use protection to keep
myself healthy” (P01, 21, White) or “I don’t sleep around a lot” (P14, 26, Black). After reading
the fact sheet one respondent stated, “I don't really think that most people are going to have
HPV. I mean…maybe gay men who don't practice safe sex” (P09, 24, White). Overall
participants seemed unsure on how to respond to questions about their susceptibility to HPV.
When asked to rate their risk of having been exposed on a scale of 1 to 10 (with 10 being the
highest risk), most of them indicated that they were at average risk (between 4 and 6). There was
also a tendency to focus on anal sex as the only risk behavior.
When informed that HPV can cause anal cancer and that MSM are at a higher risk of anal
cancer, most of the respondents described their reaction in emotional terms. They used words
like “surprising,” “sad,” “concerning,” “scary,” and “shocking.” There was also a strong
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tendency to describe the infection itself—even in the absence of disease—as distressing. In fact,
the absence of symptoms in most cases of infection was commonly noted as concern. One
respondent expressed fear saying “Well it’s just, that’s scary. You know…you just don’t know if
you have it or not” (P11, 19, Latino). Some of this worry was expressed as concern for
“spreading” HPV to their sex partners or as discomfort with the idea of a “sitting virus kind of
thing inside of you” that may cause future disease.
Anogenital warts
Personal experience with anogenital warts—either having had anogenital warts or having
had a sexual partner with anogenital warts—was closely tied to some of the participants’
attitudes and beliefs surrounding HPV and HPV vaccination. Four out of the five participants
who had received HPV vaccine described anogenital warts as a primary reason for getting the
vaccine. In each of these cases, the men, or their sex partner at the time, were being treated for
anogenital warts when a doctor recommended vaccination.
Sexuality and the patient-provider relationship
The majority of the young men in this sample had previous experience talking about their
sexual behaviors in a health care setting—mostly while receiving STI testing. In almost all cases,
the healthcare provider asked them questions about their sexual behaviors. In some cases these
interactions were described as negative, affecting their expectations surrounding disclosure, their
confidence in their healthcare providers, as well as the ways in which they managed disclosure in
future interactions.
Negative emotions surrounding disclosure
Feeling ashamed, awkward, and judged were some of the emotions associated with
discussing sexual behaviors with a healthcare provider. These feelings stemmed in part from the

93

degree to which they felt their provider was comfortable with them. One participant captured this
sentiment in his comments about his primary care physician:
I feel like he judges me. I feel like if I had a provider or somebody who is a little more
open-minded... my doctor is a staunch Republican, white dude who is like 65 and I'm
sitting there like a gay little Puerto Rican kid, and you know, it is just always awkward
when I go to my doctor. We come from opposite ends of the earth. (P12, 24, Latino)
These negative experiences, or even the anticipation of a negative reaction, play a detrimental
role in the relationship between these young gay males and their healthcare providers. This is
particularly true when they are seeking treatment or information on sexual health related issues
such as HPV vaccination.
LGBT cultural competence of healthcare providers
Previous negative interactions with a health care provider influenced future expectations
and perceptions regarding the overall cultural competence of healthcare providers in dealing with
LGBT patients. There was a sense of having to know where a provider stands on issues related to
sexuality for fear that he or she may be biased or even not competent in providing care. One
participant stated:
I would just feel weird talking to someone about that [HPV vaccine], and I would not
know their views on LGBT people. So I feel like there may be some bias in the
information that they could give me. Even though it’s unprofessional. (P03, 19, Asian)
Other participants questioned whether or not they would rely on their health care provider for
information about HPV. For participants who felt confident in their providers, they tended to talk
about the established rapport and trust that was proven over the course of multiple interactions.
Some men expressed feeling more comfortable with female providers, noting that female
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providers are more comfortable with gay men. Others thought they would get better care with a
gay provider, one rationale being:
A gay provider would be more into or up-to-date with newer things that are coming out.
Especially like with the threats that are more for the gay lifestyle. Because I really don't
think that my health provider would know about HPV. (P12, 24, Latino)
The degree to which the patient-provider relationship would impact HPV vaccination was less
clear. This relationship was important if it was perceived that asking for the vaccine would
prompt a discussion of sexual behaviors. It was less important if the vaccine could be obtained
without discussion of sexual history. In other words, the relationship was important for their
comfort level regarding their sexuality, not in accepting a recommendation for vaccination.
Management of disclosure
When looking for sexual health services, some of the men I talked to will go to a clinic
focused on STI testing (e.g., public health departments, planned parenthood, university medical
services) even if they have an established relationship with a primary care provider. Because of
the perceived stigma and fear of judgment, they value the privacy and anonymity provided by
these venues when seeking sexual health services (including HPV vaccination). One participant
stated:
Because I feel like my health care provider...I understand there is HIPA and all that stuff
and they are suppose to keep my stuff confidential. But I live in a pretty small town and I
know how that stuff works. So I'd rather not. I go to the health department and every time
I go it is somebody different. It never gets personal. I've never build rapport with them.
(P12, 24, Latino)
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He actively manages situations in which he expects to be asked questions about his sexual
behavior favoring the impersonal nature of some public health clinics. A similar concern was
mentioned in another interview when the participant expressed worry that his family doctor
could not be trusted to main his confidentiality.
Another strategy that participants used to manage discussions of sexuality with healthcare
providers is to lie. If they felt particularly uncomfortable or if they believed their sexual
behaviors were irrelevant, they reported being “selective” about what they disclosed or lying
about their behaviors. Some men struggled with the idea that their sexuality was ever medically
relevant citing “sex is sex” no matter the sex of their partners:
It is just like, it is none of their business who I am having sex with. There is the whole
stigma about being gay that we are promiscuous people we just go around having sex
with every guy we see and therefore are at higher risk…straight guys do that all the time
too. (P15, 20, Latino)
While HPV did not come up directly in these conversations, it is clear that the relevance of any
discussion of sexuality to determine eligibility or appropriateness of vaccination can be a
sensitive issue for some male sexual minorities.
Trusted sources of health information
Overall men in this sample appeared accepting, interested, and engaged in discussions
surrounding HPV and HPV vaccination. Many expressed positive intentions to get vaccinated or
learn more about the vaccine. While the Internet was listed as the first source of health
information, many of the participants expressed doubt in the dependability of the health
information provided on many sites. They tended to adopt an information seeking strategy where
they looked at a number of sources—usually the first few hits on a basic Google search—and
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determined in some way if these sources were in agreement. Other standard sources of trusted
health information were healthcare providers and family members who are connected to the
healthcare industry in some way.
One interesting source of health information mentioned in several interviews were
LGBT-focused centers or groups. These included community-based organizations that offer
HIV-testing, HIV case management, and other social services for sexual and gender minorities.
Participants recalled health information presented as part of counseling during HIV testing and
during social group gatherings in which guest speakers were invited to talk about a variety of
health issues. These were described as “welcoming” and “non-judgmental” environments and
participants expressed a great deal of trust and respect for them. One participant mentioned that
he would prefer to be vaccinated at one of these locations because he was going on a regular
basis for HIV testing. In this sense it would be more convenient for him. Subsequent participants
were asked about their thoughts/feelings about getting vaccinated at this type of organization
(i.e., Community-based LGBT health clinic or HIV testing site). They were overwhelmingly in
support of that option. The main reason against this option was that the medical staff would not
know their specific medical history and thus would not be able to identify the potential health
consequences of getting vaccinated. Overall community-based LGBT organizations were
identified as a desirable alternative location for HPV vaccination.

Phase 2 Results: Quantitative Survey
Sample characteristics
See Table 2 for complete demographic characteristics of the study sample. Participants
were on average 22 years old (SD = 2.43). They were primarily white (63%) college students
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(58%) with health insurance (83%) who had a place they usually go to for “routine medical care”
(74%). The majority identified as gay (75%), but a significant proportion identified as bisexual
(22%). The number of lifetime male sexual partners was widely varied. Fifty-three (9%)
respondents reported no male partners. The median number of male sexual partners was 6
(Interquartile range = 13).
Most were HIV-negative (67%); however, over a quarter reported never being tested
(27%). Among those who have received an HIV test, 50% were not tested within the previous
year. Nearly 15% reported ever being diagnosed with Gonorrhea, Chlamydia, Syphilis, herpes,
or Trichomoniasis. Four percent reported a previous diagnosis of genital or anal warts.
Overall awareness of the HPV vaccine was limited. After being provided with the
following information, a minority of participants (39%) indicated that they had previously heard
of the HPV vaccine.
A vaccine to prevent HPV (human papillomavirus) infection is available and is referred
to by several names, such as: the HPV shot, cervical cancer vaccine, GARDASIL®, or
CERVARIX®. The HPV vaccine is approved for males Currently, the HPV vaccine
requires 3 shots given over 6 months. The HPV vaccine is proven safe and effective at
preventing genital warts and cancers caused by HPV (e.g., Anal Cancer). The HPV
vaccine is recommended by the Centers for Disease Control and Prevention (the CDC)
for men who have sex with men who are 26 years of age or younger.
Most participants (63%) also indicated that they did not personally know someone who has
received the vaccine. And only 8% indicated that a doctor or health care provider recommended
that they get the HPV vaccine (note that this study excluded men who had already initiated HPV
vaccination).
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Descriptive and bivariate statistics of HPV-related beliefs
Behavioral beliefs
The 10 behavioral beliefs elicited from Phase 1 are presented in Table 5 along with the
means for beliefs strength (b1), outcome evaluations (e1), and the product of the belief strength
and outcome evaluation (b1e1). The means associated with perceived physical and psychological
advantages were all greater than the neutral mid-point of the scale (>3) indicating an overall
positive perception of HPV vaccination. The disadvantages of vaccination were generally
perceived as unlikely to occur. Outcome evaluations were only assessed for side effects. On
average, participants indicated little concern regarding vaccine side effects. All of behavioral
beliefs had significant correlations in the expected direct with the direct measure of attitude—
that is perceived advantages positively correlated with a positive attitude toward vaccination and
perceived disadvantages negatively correlated with a positive attitude toward vaccination.
An expectancy-value index of belief strength and evaluation was calculated ( biei)
reflecting the salient physical and psychological advantages that underlie attitudes toward HPV
vaccination among this population. There was a strong positive correlation between this index
and the direct measure of attitude suggesting that the more participants endorsed this set of
behavioral beliefs, the more positive their attitude toward HPV vaccination.
Normative beliefs
Table 6 contains the normative referents assessed with regard to obtaining HPV
vaccination within the next 12 months. All of the referents were perceived as being supportive of
a decision to get vaccinated; however, the value of their influence with regard to this decision
was low (see values for mi). The degree of social influence is indicating by the expectancy-value
indicators (n1m1) with anything greater than 9 (the midpoint) indicated some degree of positive
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influence to get vaccinated. The most frequently mentioned referent group was gay male friends
who did have a degree of social influence over decisions regarding HPV vaccination. The least
influential individuals, just at the midpoint of the index, were fathers. All normative referents
contributed positively to perceived norms as indicated by moderate positive correlations.
Similarly, the expectancy-value index of normative referents ( nimi) was positively correlated
with the direct measure of perceived norms.
Control beliefs
Table 7 contains the influence of control beliefs on perceived behavioral control
associated with getting the HPV vaccine within the next 12 months. These beliefs are looking at
facilitators of vaccination. In particular, having health insurance over the next 12 months was
strongly endorsed by participants as a key factor influencing their ability to get vaccinated. An
examination of the expectancy-value indicators (c1p1) shows that health insurance is the strongest
facilitator of vaccination followed by making vaccine available at HIV testing locations. All of
the control beliefs exhibit small to moderate correlations with perceived behavioral control.
Participants expressed a moderate degree of self-efficacy in getting vaccinated if they had to
discuss their sexual orientation with a healthcare provider. Self-efficacy was also positively
associated with perceived behavioral control.
Descriptive and bivariate statistics of model variables
Scale means, standard deviations, coefficient alphas, and zero-order correlations for all
scales are presented in Table 8. All scales exhibited at least acceptable internal consistency (
>.65), which is sufficient for the purpose of this research. The mean for the main outcome
variable, HPV vaccine intentions, was greater than but close to the scale midpoint (midpoint =
3), suggesting positive vaccine intentions with widespread indecision.
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3.29
3.86
3.66

Belief
strength
(bi)
M

0.85
1.06
0.86

1.02
1.00
1.04

SD

---2.79

3.73
3.98
4.11

4.34
4.31
4.40

Outcome
evaluation
(ei)
M

---0.92

1.00
1.00
0.94

0.70
0.86
0.86

SD

---7.83

15.64
15.90
17.64
96.76

14.48
16.84
16.31

M

---4.34

5.88
6.56
5.90
29.34

5.54
5.86
5.97

SD

-0.17*
-0.22*
-0.26*
-0.25*

0.51*
0.47*
0.39*
0.53*

0.42*
0.40*
0.39*

b1e1

4.11
3.89
4.22

1.11
1.06
0.99
1.00

Correlation
b1e1 with
attitude

1.98
2.80
2.54
2.69

Table 5: Behavioral beliefs associated with HPV vaccination and correlations with attitudes
Behavioral beliefs

Physical advantages
It would make me healthier
It would prevent me from getting genital and anal warts
It would prevent me from getting anal cancer
Psychological advantages
Feel protected from HPV
Feel like there is one less thing to worry about
Less likely to spread HPV to future sex partner(s)
Expectancy-value index for physical/psychological advantages of
HPV vaccination ( biei)
Disadvantages
I will contract HPV from the vaccinea
Not completely protected from future HPV infectionsa
The vaccine may not work for mea
I would have side effects
Belief strength and outcome evaluation were measured on a 5-point bipolar scales
biei ranges from 1 to 25 with higher values indicating likely and important beliefs
a
Outcome belief was not assessed. Correlation coefficient represents correlation with belief strength and attitude
*p<.05
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n

513
445
521
531

Belief
strength
(ni)
M
3.91
3.48
4.19
3.86
SD
1.32
1.39
0.99
1.14

Motivation
to comply
(mi)
M
3.19
2.57
3.57
2.95

SD
1.66
1.59
1.43
1.44

Table 6: Normative beliefs associated with HPV vaccination and correlations with perceived norms
Normative beliefs

Mother
Father
Gay male friends
Straight friends
Expectancy-value index for normative referents ( nimi)

Belief strength and motivation to comply were measured on a 5-point bipolar scale
nimi ranges from 1 to 25 with higher values indicating supportive referents
Statistics are calculated only if referent was mentioned and participant did not indicate “not applicable”
Values of 3 (neutral mid-point of scales) were imputed for participants who chose “not applicable” in calculations of nimi

3.42

Belief
strength
(ci)
M
3.85
4.20
3.13
3.87

1.26

SD
1.01
1.02
1.10
1.13

Perceived
power (pi)
M
4.09
4.02
4.44
4.04

SD
1.07
1.21
1.02
1.23

n1m1
M
13.29
9.83
15.35
12.00
48.65

M
15.79
18.97
12.44
16.21
63.15

c1p1

Table 7: Control beliefs associated with HPV vaccination and correlations with perceived behavioral control
Control beliefs

Find out where to get vaccinated
Have health insurance
Don’t need an appointment
Available at HIV testing location
Expectancy-value index control factors ( cipi)
Perceived self-efficacy

Belief strength and outcome evaluation were measured on a 5-point bipolar scale.
cipi ranges from 1 to 25 with higher values indicating stronger control beliefs that can help facilitate HPV vaccination
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SD
8.72
8.10
7.58
7.55
22.96

SD
6.10
6.45
5.90
7.24
0.85

Correlation
n1m1 with
norm

0.40*
0.33*
0.39*
0.35*
0.45*

Correlation
c1p1 with
PBC

0.37*
0.44*
0.22*
0.18*
0.42*
0.42*

1
-.47*
.47*
.54*
-.19*
.00
-.06
.43*
.26*
.27*
.35*
.14*
.28*
.26*
-.02
-.04
3.26
1.07
.90
-.46*
.50*
-.27*
-.17*
-.25*
.39*
.18*
.16*
.30*
.11*
.27*
.12*
.00
.04
4.23
.80
.86

2
-.68*
-.19*
.03
-.02
.49*
.31*
.14*
.33*
.22*
.33*
.26*
.02
-.04
47.57
15.20
.85

3

--.21*
.01
-.01
.54*
.38*
.20*
.38*
.17*
.35*
.32*
.02
-.00
49.19
16.82
.91

4

-.51*
.45*
-.14*
-.12*
-.16*
-.16*
-.09*
-.08
.09*
.06
-.01
2.67
.90
.71

5

-.51*
-.01
.06
-.14*
-.10*
-.02
.07
-.05
.16*
-.12*
1.97
1.11
--

6

--.01
-.04
-.16*
-.03*
-.03*
.08
.06
.13*
-.01
7.84
4.34
--

7

-.45*
.17*
.30*
.16*
.27*
.23*
-.01
-.12*
3.75
.79
.70

8

-.13*
.32*
.20*
.24*
.21*
-.10*
-.02
48.66
22.96
.76

9

-.42*
.24*
.07*
.18*
-.13*
-.04
3.76
.85
.70

10

-.23*
.18*
.35*
-.10*
.01
63.15
18.06
.66

11

-.04
.23*
-.51*
-.23*
3.42
1.26
.90

12

-.08*
.01
.03
9.51
4.99
.96

13

--.16*
-.03
4.24
.69
.80

14

-.22*
2.49
.86
.71

15

-45.66
26.08
.71

16

Table 8: Scale means, standard deviations, coefficient alphas and zero-order correlations for scales
1. Intention
2. Attitude
3. PHY Advantages
4. PSY Advantages
5. Low efficacy
6. Contract HPV
7. Side effects
8. Norms
9. Normative beliefs
10. PBC
11. Control beliefs
12. Self-efficacy
13. Threat
14. Information-O
15. LGBT-SUS
16. Concealment
Mean
Standard Deviation
Cronbach’s alpha

PHY = Physical; PSY = Psychological; PBC = Perceived behavioral control; Information-O = Information orientation; LGBT-SUS = Suspicion of LGBT cultural competence Scale; Concealment =
Nebraska Outness Scale-Concealment Subscale
*p<.05
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Overall participants expressed positive attitudes toward vaccination, supportive norms, and
perceived control over their decision to get vaccinated. The mean perceived threat score was
below the scale midpoint (midpoint = 12.5) indicating low levels of concern among this sample.
Zero-order correlations provided initial support for the proposed relationships. As
expected, attitudes, norms, and perceived control/efficacy exhibited statistically significant
correlations with behavioral intention. In turn, each of these main determinants of intention were
significantly correlated with their respective belief measures (i.e., attitudes with behavioral
beliefs, norms with normative beliefs, and perceived behavioral control with control and efficacy
beliefs). Notable relationships among background factors include: (1) positive correlations
between perceived threat and behavioral beliefs; (2) positive correlations between information
orientation and behavioral beliefs; (3) negative correlation between Outness-concealment and
self-efficacy; (4) negative correlation between LGBT-SUS and self-efficacy; and (5) positive
correlation between LGBT-SUS and Outness-concealment.
Test of an integrative model of HPV vaccine decision-making
Structural equation modeling was used to test a comprehensive model of HPV vaccine
decision-making. In addition to the propositions examined above, the following relationships
were also modeled because of the theoretical importance identified in Phase 1 qualitative
interviews (See Figure 4): (1) HIV-positive men will exhibit higher levels of perceived threat
than HIV-negative men; (2) men in monogamous relationships will exhibit lower levels of
perceived threat compared to men not in monogamous relationships; (3) men with a history of
anogenital warts will exhibit higher levels of perceived threat compared to other men; (4)
knowing someone who received the HPV vaccine will be positively associated with normative
beliefs; (5) bisexually identified men will score higher on outness-concealment than other MSM;
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(6) bisexually identified men will score higher on the LGBT-SUS scale; (7) outness-concealment
will be positively associated with LGBT-SUS.
Measurement model
Confirmatory factor analysis of the measurement model found poor absolute fit of the
data to the latent factors,

2

(df) = 4.28.76 (254), p<.001; however, the chi-square test is highly

sensitive to sample size so additional fit indices were examined. All three fit indices suggested
the measurement model fit the data well (RMSEA = .04 [90% CI: .03, .04], CFI = .97, SRMR =
.04). Item-to-factor correlations are presented in Table 9. All items significantly loaded on their
respective factor. No modifications to the measurement model were warranted.
Structural model
The initial structural model tested 28 propositions or structural relationships. This model
had poor fit among all but one of the indices examine:

2

(df) = 1808.28 (640), p<.001; RMSEA

= 0.06 [90% CI:.05, .06]; CFI = .85; SRMR = .10. The following relationships were not
statistically significant (p > .05): Low efficacy Attitudes (B = -.04; 95% CI = -.11, .04);
Contract HPV Attitudes (B = -.04; 95% CI = -.10, .02); Perceived Threat Contract HPV (B =
.02; 95% CI = .00, .04); Communication-orientation Contract HPV (B = -.09; 95% CI = -.24,
.06); Perceived Threat Side effects (B = .08; 95% CI = -.00, .16); Communicationorientation Side effects (B = .33; 95% CI = -.34, .93); Knew someone who got
vaccinated Normative beliefs (B = -3.73; 95% CI = -7.16, .10); and having a medical
home Control Beliefs (B = 3.11; 95% CI = .46, 5.91). These paths were removed from the
model one at a time starting with the weakest relationships (indicated by lower

values). A total

of eight paths were removed. The revised model (model 2) approximated acceptable fit: :

2

= 1132.22 (503), p<.001; RMSEA = 0.05 [90% CI:.04, .05]; CFI = .91; SRMR = .10. Mplus
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(df)

modification indices were examined to determine if any theoretically relevant paths could be
added to the model in order to increase fit. Based on this information three additional paths were
added: (1) a direct path from Physical/Psychological benefits to intention; (2) a direct path from
perceived threat to normative beliefs; and (3) a direct path from communication-orientation to
normative beliefs. In addition, control beliefs were allowed to covary with
Physical/Psychological benefits and normative beliefs. This model exhibited adequate fit and is
of theoretical importance:

2

(df) = 1265.48 (507), p<.001; RMSEA = 0.05 [90% CI:.05, .06];

CFI = .91; SRMR = .09.
Determinants of intention. Standardized parameter estimates for the final model (model
3) are depicted in Figure 5. As is shown, the largest direct effects on HPV vaccine intentions are
from Physical/Psychological benefits ( = .32, B = .01; 95% CI = .01, .01) and attitudes ( = .27,
B = .25; 95% CI = .17, .34). This is a slight deviation from the original model where the effect of
Physical/Psychological benefits is completely mediated by attitudes. Perceived norms had a
small association with intention ( = .12, B = .12; 95% CI = .02, .20). Perceived behavioral
control had a moderately strong association with intentions ( = .23, B = .31; 95% CI = .20, .44).
Structure of beliefs. There were five key characteristics of HPV-related beliefs that
underscore the main determinants of intention. This included beliefs regarding the
physical/psychological benefits of vaccination, which was strongly correlated with positive
attitudes ( = .55, B = .02; 95% CI = .01, .02). Concern about potential side effects was
negatively associated with attitudes ( = -.25, B = -.05; 95% CI = -.06, -.03). As was expected,
normative, control, and efficacy beliefs were each positively associated with their respective
determinant; however, the relative association of self-efficacy with perceived behavioral control
was low compared to the others.
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Antecedents of beliefs. The strongest antecedents of HPV-related beliefs were perceived
threat, suspicions of LGBT cultural competence, and information orientation. The larger
perceptions of threat the higher the perceived benefits of vaccination ( = .34, B = 2.27; 95% CI
= 1.82, 2.75). In addition, the perceived benefits of vaccination were higher among those with
higher levels of health information orientation ( = .31, B = 12.79; 95% CI = 8.90, 16.36). There
was also a strong negative association between those expressing suspicion of LGBT cultural
competence and self-efficacy ( = -.56, B = -1.63; 95% CI = -2.05, -1.32).
Socio-demographic targets. HIV positive men had higher levels of perceived threat ( =
.13, B = 2.34; 95% CI = .74, 3.83). Inversely, men in monogamous relationships reported lower
levels of threat ( = -.18, B = -1.67; 95% CI = -2.25, -1.04). Bisexual identification was
positively associated with both outness-concealment ( = .10, B = 5.91; 95% CI = 1.46, 10.37)
and suspicions of LGBT cultural competence ( = .21, B = .23; 95% CI = .14, .31).
Indirect effects. Indirect effects are displayed in Table 10. In general, the indirect effects
were relatively small. The most theoretically meaningful indirect effects are from the salient
belief measures to intentions, mediated by the main determinants of behavior (i.e., attitudes,
norms, perceived control/efficacy). All of these indirect paths were statistically significant and
among the largest indirect paths identified in the model.
Phase 3 Results: Open-Ended Survey
The purpose of the open-ended survey was to further identify salient beliefs, information
needs, and trusted information sources, as well as underlying background factors that influence
HPV vaccine decisions among young MSM. This was accomplished through the use of a
vignette that provided context for thinking about vaccination and subsequent open-ended
questions.
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Table 9: Item-to-factor correlations for measurement model
Latent factor title in bold

β (SE)

Vaccine Intentions
Find out more information about the HPV vaccine within the next 12 months
Make an appointment to talk to a doctor about the HPV vaccine within the next 12 months
Get your first HPV shot within the next 12 months

.72 (.03)
.93 (.02)
.94 (.01)

Direct Attitude
Not worth it - Worthwhile
Harmful - Beneficial
A bad thing for me – A good thing for me
Unimportant – Important
Ineffective - Effective

.81 (.03)
.77 (.03)
.80 (.03)
.80 (.03)
.72 (.03)

Direct Normative influence
People who are important to me would encourage me to get the HPV vaccine
I can think of at least one person in my life who would like for me to get the HPV vaccine
Most of my gay/bisexual male friends would get the HPV vaccine if it was offered to them free of
charge

.75 (.04)
.74 (.04)
.52 (.04)

Direct Perceived Behavioral Control
There are factors beyond my control that would prevent me from getting the HPV vaccine
I am confident that I can get the HPV vaccine in the next 12 months
Getting the HPV vaccine sometime in the next 12 months would be: Impossible for me—Possible
for me

.49 (.04)
.84 (.04)
.67 (.04)

Perceived Threat
Threat of HPV infection
Threat of Anal Warts
Threat of Genital Warts
Threat of Anal Cancer

.82 (.03)
.93 (.02)
.94 (.01)
.82 (.03)

Information Orientation
When I take medicine, I try to get as much information as possible about its benefits and side effects
Before making a decision about my health, I find out everything I can about the issue
It’s important to me to be informed about health issues affecting gay and bisexual men

.80 (.04)
.83 (.03)
.63 (.05)

Suspicion of LGBT Cultural Competence
I have received lower quality healthcare services as a result of my sexual orientation
I prefer that my doctor or healthcare provider does not know that I am gay/bisexual
I feel uncomfortable talking about my sexual orientation or sexual behaviors with a doctor or HCP
There is no reason why a doctor or health care provider would need to know that I have sex with
men
N = 569
All factor loadings are statistically significant (p < .05)
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.41 (.05)
.80 (.04)
.67 (.04)
.61 (.04)

Figure 5: Structural model of HPV vaccine intentions among young MSM
N = 568; Parameter estimates are standardized regression (β) weights.
Model Fit Statistics: 2 (df) = 1265.48 (507), p<.001; RMSEA = .05 (90% CI: .04-.05); CFI = .91; SRMR = .09
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Table 10: Indirect effects on HPV vaccine intention
Indirect paths
Benefits—Attitudes—Intention
Side effects—Attitudes—Intention
Normative beliefs—Norms—Intentions
External control beliefs—PBC—Intentions
Self-efficacy—PBC—Intentions
Outness—Self-efficacy—PBC—Intentions
Outness—LGBT-SUS—Self-efficacy—PBC—Intention
LGBT-SUS—Self-efficacy—PBC—Intentions
Bisexual—LGBT-SUS—Self-efficacy—PBC—Intentions
Bisexual—Outness—Self-efficacy—PBC—Intentions
Threat—Benefits—Attitudes Intentions
Information-O—Benefits—Attitudes—Intentions
HIV-Positive—Threat—Benefits—Attitudes—Intentions
Monogamous—Threat—Benefits—Attitudes—Intentions

β
.15
-.07
.06
.11
.04
-.00
-.01
-.02
-.00
.00
.05
.05
.02
-.02

(SE)
(.03)
(.02)
(.03)
(.03)
(.01)
(.00)
(.01)
(.01)
(.00)
(.00)
(.01)
(.01)
(.01)
(01)

p
*
*
*
*
*
ns
*
*
ns
ns
*
*
*
*

N = 568; Benefits = Physical and psychological benefits; PBC = Perceived behavioral control;
Information-O = Information orientation; LGBT-SUS = Suspicion of LGBT cultural
competence Scale; Concealment = Nebraska Outness Scale-Concealment Subscale
*p<.05

As such Phase 3 serves as a confirmatory check on the findings from the Phase 1 semi-structured
interviews. The goal of this analysis was to identify new information that was not uncovered in
the interviews and to shed more light on the decision-making process undergone by MSM when
thinking about HPV vaccination.
The results for this phase are presented along with the vignette that was used to elicit
responses. This helps to put the findings in context and highlights the key elements involved in
the decisions surrounding HPV vaccination. The first part of the vignette focused on general
HPV information as is shown below.
One respondent commented that “Most information I have heard about it was straight
female centric” (P25, 24, White), which was a belief supported by other men who made explicit
mention of cervical cancer. One participant commented that, “The statistic took me aback
because it's quite personal- it affects me on a personal level because I am gay and have anal sex
quite often” (P26, 21, Latino).
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Vignette Part 1: HPV information

Figure 6a: Part 1 of the vignette

Figure 6b: Part 1 of the vignette
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Others reiterated this thought mentioning, “For something so prevalent among MSM it
isn’t often talked about” (P27, 18, White). It was mentioned by one respondent, “cancer is a
serious disease which I didn't know men were vulnerable to based on their sexual habits” (P28,
26, White).
Of the 102 participants who commented on the information, 32% mentioned that the
asymptomatic nature of HPV infection was particularly “alarming.” There was concern that
“people can be spreading this around without realizing it” (P29, 23, White) or that they “could
pass something that doesn’t outright affect you but might the next person” (P30, 21, White). This
was also noteworthy to some men who expressed a belief that most sexually transmitted
infections result in clinical symptoms.
Anogenital warts were mentioned much less than cancer, suggesting that warts are the
most common characteristic associated with HPV among this population. In fact some
respondents explicitly mentioned that they “already knew this” or disclosed that they previously
had anogenital warts. With that said, 16% mentioned the fact that HPV can result in anogenital
warts as impactful.
Interestingly, approximately 16% of respondents commented on the age recommendation
as noteworthy. In most of these cases they were surprised of the upper age limit and inquired as
to why the vaccine isn’t recommended for men of all ages. This finding is highlighted in the
following remark: “The age recommendation also stood out to me - surely men over 26 are still
sexually active, so why are they not recommended to get it as well” (P31, 22, White)? This
suggests that even among those who are aware that the HPV vaccine is licensed for use in males,
they are unaware of the specific vaccine recommendations for MSM and the reasons behind this
recommendation.
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Vignette Part 2: Decision uncertainty

Figure 7: Part 2 of the vignette
Making a decision: what to do and why?
Out of the 102 responses regarding what Brandon should do, 47 (46%) suggested that
Brandon should consult with a doctor or primary care provider. Some specified a “trusted” or
“reliable” provider with whom Brandon would feel comfortable discussing his sexual history in
order to make a good decision about vaccination. For example, one participant stated: “He
should talk to his doctor and get advice on what to do and to see if Gardasil is the right choice for
him after being very honest about his sexual behavior” (P32, 24, White). Collectively the
primary care provider served as the main referent or source of informational support regarding
HPV vaccination.
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About 29% recommended that Brandon get tested for HPV in order to determine if he
should get vaccinated. There was a common misperception that HPV testing is routinely done
during STI screening for males. The thinking behind this recommendation is expressed in the
following quote: “The first step should be for him to determine his risk, getting tested for the
virus and based on those results, proceed with vaccination/treatment” (P23, 22, Black). Inherent
in this example, and in similar responses, is the notion that one can know his HPV “status” and
make appropriate health decisions based on that information. There was also a sense of
responsibility in knowing one’s status:
It's important to know your health status when having sex with others (moral and public
health issue). If he finds out his status he can make more informed opinions about
preventing the spread of HPV or preventing infection from HPV. (P33, 23, White)
These comments evince a limited understanding of HPV infection, available testing procedures,
as well as recommendations on vaccination.
It should be noted that the majority of comments were in favor of Brandon getting
vaccinated even if they suggested he should consult a health care provider first. However, there
was one participant who stated that Brandon “doesn’t need it” because “He's 25 and the shot is
recommended if you’re under 26 so he's close to not needing it” (P34, 25, White). This was not a
view shared by anyone else but represents an interesting perspective—and perhaps an unintended
consequence of the age-based vaccine recommendation. For other men the upper age limit
elicited a sense of urgency since they perceived themselves as coming close to “aging out.”
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Vignette Part 3: The threat of anal warts

Figure 8: Part 3 of the vignette
Deciding to get vaccinated: Good or bad?
In the vignette, Brandon made an explicit decision to get vaccinated. Out of the 102
participants who responded, 80% said they would have done the same thing (i.e., decided to get
the HPV vaccine). These men described Brandon’s decision as “reasonable,” “wise,” and
“smart.” The fact that someone Brandon knew had anal warts influenced their thinking of the
issue as is noted in the following comment:
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I think it's a good decision. The shots are definitely a no brainer over getting HPV and
anal warts. Finding out somebody you know has it makes it hit more close to home than a
poster. (P35, 22, White)
Many of their comments regarding Brandon’s decision described behavioral beliefs endorsing
the physical and psychological advantages to HPV vaccination. The same participant described
the value of vaccination:
If it's as prevalent as the poster says, then why not take the extra step to prevent against it.
Sure getting 3 shots over 6 months is a little inconvenient, but so are anal warts and
cancer. If Gardasil is effective, why not get the shots and have one less thing to worry
about? A small price to pay for peace of mind. (P24, 22, White)
Other comments referred to protecting partners and contributing “to stopping the spread of
HPV.” Overall there was a large focus on the importance of prevention and being “better safe
than sorry.” There were minimal concerns about risks associated with vaccination. While no
participant noted any specific concerns, some made statements that “you shouldn’t blindly put
something in your body, the more knowledge the better,” (P36, 21, White) and that they would
do their own research to determine if the “peace of mind outweighs the inconvenience and
whatever side effect may exist” (P37, 26, White).
Despite their own stated beliefs in the advantages to getting vaccinated, some men who
indicated they would get vaccinated explained that this was something they would approach with
little urgency. One man said he would:
Ask my doctor at my next appointment if he or she thinks I should get the HPV vaccine
(or test to see if I already have it). I don't know if I would necessarily make a new
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appointment specifically for that question, because it doesn't seem like an immediate
concern. (P33, 23, White)
Another man described his low motivation to get vaccinated:
I think that I should get the vaccine but probably not get it just because it doesn't seem
like an impending danger. Out of sight out of mind. (P38, 21, White)
Both of these men described their perceived susceptibility to HPV infection as “average” and
indicted that they were “slightly” or “somewhat” concerned about becoming infected with HPV.
These participants are in contrast to those who described themselves as “Moderately” or
“Extremely” concerned about HPV infection and who subsequently advocated for Brandon to
take more immediate action (e.g., “get the shots ASAP”).
These findings represent the importance of perceived threat in the justifications
explaining vaccine decisions. Those who perceived their risk as low referred to what they
believed as limited exposure: “Unlike Brandon I don’t hook-up and have had sex with only a few
people in my life so my chances of already contracting it would be low” (P39, 25, White).
Similarly, being in a “monogamous” relationship was used to justify a limited concern regarding
HPV infection and vaccination. Other respondents countered these claims stating, “all you need
is one exposure” (P40, 23, White) or “regardless of how much or as little he is having, it is still
possible that he will get HPV” (P41, 22, White). For some, learning that penetration isn’t
necessary for HPV transmission elicited threat. One man wrote: “…anal penetration isn’t even
necessary; you can get it through skin contact. Scary” (P42, 24, Asian).
There was some ambivalence about Brandon’s decision with 15% stating they were “Not
sure” if they would have decided to get vaccinated and 5% said they would not have been
vaccinated. These men described Brandon’s decision as “reactive” and “emotional.” They
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expressed a strong need for more information and a desire to seek medical advice prior to
making any decisions. The men selecting “Not sure” (N = 15) questioned the efficacy of getting
vaccinated in the event that they have already been exposed. This group also tended to focus on
the importance of getting tested before making a decision. Many of these comments are
represented by the following statement:
There are many factors to consider. Getting tested to see if I do not have HPV/HIV, then
looking to see where I can get the Vaccine, cost, travels, measures, actions. Although I
would have researched more on HPV then talked about it to a GP or headed to a health
clinic to find further information. Aside from this I had so many vaccines in my life that I
later found out are for other things as well, so I would need to look at my full medical
history to see if I am applicable for the vaccine, as well as other factors like allergies etc.
that may cause problems. However this would all be discussed with my doctor. (P43, 23,
Asian)
The men who indicated they would not get vaccinated described three distinct rationales: (1) they
already made a decision not to get vaccinated; (2) they do not need the vaccine because they are
not at risk; and (3) they have already been exposed to HPV so the vaccine would not confer any
benefit. One of the participants commented that “one experience isn’t enough to change my
mind” (P34, 25, White) suggesting that Brandon is reacting to a unique situation. Others
mentioned that they are “not very promiscuous” or not sexually active as reasons not to get
vaccinated.
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Vignette Part 4: Trusted sources
Preferred places to get vaccinated
The final passage of the vignette was used to determine where the participants would
prefer to go to get vaccinated as well as any issues they perceive discussing sexuality and/or
sexual behavior with their providers. The passage of the vignette read:
Brandon wanted to get the HPV vaccine but he didn’t know where to go to get it. He
doesn’t really like going to the doctor and feels a little awkward asking a healthcare
provider about the HPV vaccine since it’s an STD. He knows it’s unprofessional but
sometimes thinks that doctors judge him for his sexual behaviors.
Participants were asked “Where would you go to get the HPV vaccine if you were in Brandon’s
situation?” Seven categories of locations were described and are numbered in order of the
frequency in which they were mentioned: (1) Primary care doctor, (2) University/College health
center, (3) Walk-in or Community Clinic, (4) Planned Parenthood of STI clinic, (5) LGBTfocused/friendly clinic or provider, and (6) Pharmacy. A number of participants indicated that
they were unsure about where to go to get vaccinated.
Next, participants responded to a structured question asked about the likelihood
(unlikely-likely) of them getting vaccinated at the four hypothetical locations: (1) HIV testing
site, (2) Pharmacy with a walk-in clinic, (3) Primary care provider’s office, and (4) a communitybased health clinic servicing LGBT people. Participants were provided with a description of each
location (see appendix 3). All of the locations were acceptable by a majority of respondents (see
Table 3).
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Participants were then prompted to explain what they liked about the locations where they were
likely to get vaccinated and what they did not like about the other locations. Responses were
coded and added to Table 11 for comparison.

100%

80%
64%

57%
75%

60%

68%

40%
20%

27%
18%

20%

16%
16%

16%

HIV testing site

Pharmacy

9%

14%

0%

Unlikely

Primary care
provider

Undecided

Community-based
LGBT Health Clinic

Likely

Figure 9: Acceptability of locations for HPV vaccination

Similar responses (e.g., LGBT friendly and accepting environment) were combined into one
category. A characteristic was considered present for a location if more than one participant
mentioned it (see Table 11).
The perceived benefits associated with HIV-testing sites included convenience, which
was often described as not needing an appointment and going to a location that they already
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utilize for HIV testing. These locations were described as discrete where they did not have
established relationships with any one provider. Participants also believed that HIV-testing sites
would be LGBT friendly and have staff that is more knowledgeable about LGBT health issues.
Common concerns included the lack of availability of such locations in more rural areas, that
some participants were unfamiliar with them, and that they seemed less private than a primary
care provider’s office. There was also some concern that going to a location associated with HIV
could be stigmatizing.
Table 11: Perceived benefits and concerns of hypothetical locations to receive HPV vaccinations
Categories
Benefits
Convenient
Widely Available
Discrete
Multiple medical services
Familiar
LGBT Friendly
Focus on LGBT health
Know medical history
Privacy
Concerns
Lacks privacy
Not available
Stigmatizing
Unfamiliar
Customer-focus
Judgmental
Lacks knowledge of LGBT health
Lacks medical professionalism

HIV
testing
sites

Pharmacy

X

X
X

X
X

Primary
care
provider

LGBT Clinic

X
X
X

X
X

X
X
X
X

X
X
X
X

X
X
X
X
X
X

X
X
X

X
X
X

The primary benefits ascribed to pharmacies were their convenience and widespread
availability—although one participant noted that no pharmacies in his small town offered
medical services. The concerns over being vaccinated at a pharmacy included lack of privacy
and being unfamiliar with receiving these types of services at these locations. Participants also
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noted the customer-focus vs. patient-focus of pharmacies as well as a fear of judgmental or
unprofessional staff as concerns.
The primary care provider was the most likely source of HPV vaccination mentioned by
participants. Many of them said that they prefer this location for vaccination because their
providers were familiar to them and knew their medical history. The ability to ask for the vaccine
while receiving other medical services was also stated as a benefit. However, participants
without a primary care provider noted the lack of availability. There was some concern that
primary care providers—some of which were family doctors—would lack knowledge specific to
LGBT health issues. And although some noted the patient-provider relationship as increasing
their sense of privacy, others explicitly mentioned a concern that their provider might disclose
personal information to family members. There was also the fear that a provider might be
judgmental and some participants preferred to seek sexual health services like HPV vaccination
at other locations.
The perceived benefits of seeking vaccination at community-based LGBT health clinics
are their specific knowledge of important sexual health issues experienced by LGBT individuals
as well as their friendly and non-judgmental staff. Participants liked that these clinics are discrete
and they can go for very specialized services. Others perceived these types of clinics as lacking
privacy. Community health clinics focusing on LGBT populations are less commonly available
and many of the participants said they were unfamiliar with such clinics. There was also a
concern that the staff at these types of clinics would lack the necessary medical professionalism
as would be found at a primary care provider office.
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Sources of health information
Confidence in healthcare providers
The data thus far have demonstrated the key role of the primary healthcare provider in
providing information about HPV vaccination and the prevention of HPV-related diseases.
Participants were asked if they think their own healthcare providers are knowledge about health
issues affecting gay and bisexual men and to explain why or why not. A total of 86 responses
were recorded. Approximately 44% indicated they believed their providers were knowledgeable,
31% thought they were not knowledgeable, and 22% said they were unsure.
Confidence in their provider’s knowledge of gay/bisexual men’s health issues resulted
from previous interactions when the provider asked or answered specific questions about sexual
health. Evidence of specialized training (e.g., safe zone training) also promoted this confidence.
Others relied on assumptions. Providers in urban areas with large gay populations were assumed
to be more knowledge because of frequent interactions with gay/bisexual patients. In many cases
it was stated that in general doctors are knowledgeable about gay/bisexual men’s health issues
because they are professionals and there is an expectation that they would be well informed. But
even the trust and confidence in the competency of their doctors had its limits. Older doctors, as
well as those from “certain communities,” were described with suspicion, which was related to
an “old school” mentality, lack of up-to-date training, or judgmental attitudes.
Some of these sentiments were also described by the men who expressed a lack of
confidence in the knowledge of their provider. A general bias toward sexual minorities was
described. Some of this was based in previous experiences in which doctors were perceived as
dismissing concerns due to their ignorance of an issue or having witnessed negative treatment of
other LGBT patients. There was also some reliance on expectations that doctors don’t want to

123

think about gay/bisexual men’s health issues, avoid talking about it, or don’t take them seriously.
Living in small towns or areas without a large visible gay population was frequently noted as a
reason for these biases. And while some of the responses described explicit bias, many
participants wrote about a lack of up-to-date training and a focus on their specific patient
population that doesn’t include many openly gay/bisexual men.

Emotions surrounding disclosure
Experiences disclosing one’s sexual minority status (i.e., identity or behavior) to a health
care provider were explored through a series of questions asking about history of disclosure and
emotions surrounding disclosure experiences. Out of the 102 responses, 55% had previously
disclosed to a healthcare provider, 40% had not, and 6% could not remember. There were three
sets of comments that described the relevance of disclosing to a HCP. The more common
opinion was that it is important for a HCP to know about one’s sexual minority status because
“being gay” or engaging in certain “risks” is of medical relevance. Others thought it was
relevant but only in certain situations (these situations were not described). The minority opinion
was that sexual orientation is not relevant. One participant’s comments were particularly
informative about this issue:
It's awkward enough discussing my sex life with friends, so unless I had reason to believe
I was exposed to an STD, I don't think I'd make it my doctor's business. Even then, I
would probably leave it to “I think I was exposed, I need a test,” and leave the details up
to my doctor's imagination. I can't think of a good-enough reason that my doctor would
NEED to know I'm gay. (P31, 22, White)
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It is interesting to note that no participants who explicitly questioned the relevancy of their
sexual behaviors or identity to their medical care had previously disclosed to a HCP.
Reasons for feeling comfortable disclosing included a strong sense that HCPs are
professionals and are ultimately motivated to help people. Also they “see all kinds of people”
including those who share similar sexual activities and risks. Other reasons were based on
specific experiences with HCPs that were “welcoming,” who built rapport with their patients by
asking questions and showing non-judgmental interest/concern. It was also assumed that female
HCPs and those practicing in urban areas or at universities would be accepting.
In contrast, descriptions of disclosing as uncomfortable were based on previous
experiences where the HCP provider was perceived as reacting negatively. One participant
described his perspective as follows:
It can be very frightening and off-putting to reveal sexual behaviors because doctors do
judge. You see it on their face, body language, tone of voice, and quality of treatment,
and the length of time that they spend with you. It's not a comfortable, supporting, or
healing environment to be in and one should find all of those qualities in a doctor and at
the facility because their job is to heal, cure, and prevent illnesses. (P45, 25, Black)
Others reiterated these feelings talking about the way in which their providers “react much
differently when you say I was with my boyfriend” (P46, 24, White) or seemed “surprised” by
information about one’s sexuality.
Participants managed perceptions and expectations of judgment in four distinct ways: (1)
they avoided bringing up sexual health concerns or lying about sexual behaviors if asked
directly; (2) sought out non-judgmental providers using the characteristic outlined previously; (3)
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went to a separate clinic (e.g., planned parenthood) for sexual health services; or (4) accepted the
fact that people judge but they are not going to let it bother them.
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CHAPTER 5: DISCUSSION

The primary purpose of this study was to provide information that aids in our
understanding of the factors important to young MSM when making decisions about HPV
vaccination. Young MSM represent a distinct group with regard to HPV prevention for multiple
reasons including their disproportional risk of HPV-related anal cancers, the limited herd
immunity conferred to them through the vaccination of females, their current low vaccine
uptake, and their public health relevance as a socially marginalized population. A comprehensive
study of HPV-related attitudes, beliefs, and perceptions was undertaken and described in this
manuscript. The following discussion of these findings is presented in three sections. In section
one, I provide a summary of the major findings by addressing the three specific aims. In section
two, I outline the limitations and strengths of each phase and the overall study. And in section
three the public health implications and directions for future research are discussed.
Section I: Summary of Major Findings
Specific Aim 1a: Describe salient outcome, normative, and control beliefs
Specific aim 1a was to describe salient behavioral, normative, and control beliefs related
to HPV vaccination among young MSM. This aim was addressed using qualitative data from
Phases 1 and 3.
Behavioral beliefs
There were three salient categories of behavioral beliefs that included physical and
psychological advantages, as well as risks or concerns, associated with HPV vaccination.
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Participants did not describe any of one specific advantage or risk as being critical in
determining their attitudes toward vaccination. Instead they described the physical and
psychological benefits in somewhat generic terms unless they had a personal experience with
HPV—primarily in the form of anogenital warts. In these cases individuals were able to draw on
their own experiences, which were used to express their thoughts and feelings about vaccination.
But most of the men in the interviews and open-ended surveys lacked a specific context, or point
of reference, in which to evaluate and express their thinking about HPV vaccination.
Up until their participation in this study, most of the men had little knowledge of HPV
outside of a general understanding and a perception that HPV was a women’s health issue.
Limited HPV knowledge—particularly as it relates to the health consequences of HPV infection
in men—is widely established in the extant literature (Nadarzynski et al., 2014); however,
participants in this study—when asked in an open-ended format—were unable to describe even
basic facts about HPV. And while many did correctly identify the link between HPV infection
and anogenital warts, few understood HPV vaccination as a strategy for men to prevent this
disease. Once informed, they adopted a positive attitude toward vaccination. This was consistent
with an implicit—and sometimes explicit—value regarding health: “It’s better to be safe than
sorry.”
Similar to beliefs regarding the advantages of vaccination, those expressing a concern
over potential limits or risks of HPV vaccination were often generic and without specific details.
As a result, these beliefs did not appear to exert a strong influence over their ultimate attitude
towards HPV vaccination. In this sense, beliefs regarding the advantages and risks of HPV
vaccination appear to be largely fluid and amenable to change in this population.
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Normative beliefs
Normative beliefs—both descriptive and injunctive—were not salient factors in the way
in which participants described their beliefs regarding HPV vaccination. In fact the general
sentiment was that HPV vaccination would not be something they would openly discuss with
friends or family. The limited role of norms in deciding HPV vaccine decisions was also found
in the quantitative preliminary (Wheldon et al., 2011) and has been noted in focus group
interviews with MSM (Gutierrez et al., 2013). As sexual minorities, they appeared cognizant of
the need to conceal or manage information about their sexual behaviors from specific people in
their lives—most notably parents and heterosexual friends. This was motivated in part by a fear
of judgment. With that said, older gay friends who take on a mentor-type role were considered
influential and respected referents in some cases. Overall, the decision regarding HPV
vaccination would be a private decision made primarily in consultation with a healthcare
provider. In fact, privacy regarding this decision is important as young MSM who receive health
insurance benefits through their parents or who see a family practitioner may avoid vaccination
for fear of disclosure.
Control beliefs
External control factors identified in this study were similar to those found in previous
quantitative studies (Nadarzynski et al., 2014). These included a focus on cost, availability, and
convenience. Cost is by far the most important factor related to HPV vaccination (Nadarzynski et
al., 2014). The data from these interviews overwhelming identify cost as a “make or break”
proposition. While most participants indicated a willingness to pay a small copay, none would
accept the full out-of-pocket cost.
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Limited research is available that explores the acceptability of alterative vaccination
settings. Brewer and colleagues (Brewer, Chung, Baker, Rothholz, & Smith, 2014) identified
pharmacies as a promising setting for HPV vaccination, yet the acceptability of these locations
among MSM has not been investigated. The acceptability of alternative vaccination settings was
explored in the qualitative phases. Four distinct preferences for HPV vaccine setting were
identified.
There was a subset of men who would only be vaccinated at their primary care provider’s
office. This desire was motived by a need for their doctor to determine if the vaccine would be
safe for them given their medical histories. An established patient-provider relationship was
important for these men. Other men would likely be vaccinated at a variety of locations including
pharmacies and community-base organization offering health services. The key factor for this
group was convenience. They do not want to wait, make an appointment, or put much effort into
finding out where HPV vaccination was available. This group of men seem comfortable getting
vaccinated almost as an afterthought—for example, if vaccinations were offered during their
regular HIV testing.
Another group of men prioritized their privacy above most other considerations. This
group was more uncomfortable with disclosing aspects of their sexuality and managed their
patient-provider relationships carefully. For these men pharmacies were too public and did not
provide a suitable environment for something like HPV vaccination. If they had a good
relationship with a primary care provider, one in which they felt comfortable, they would likely
ask for the vaccine in that setting. If they did not have a comfortable and established relationship
with a primary care provider, this group may be more amenable to vaccination at a clinic that
caters to LGBT populations. For college students there was a general acceptance of being
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vaccinated at campus-based health clinics. These locations were perceived as being safe places
that were accepting and capable of addressing health concerns of male sexual minorities.
Specific Aim 1b: Determine factors that underlie these beliefs
The existing behavioral research on HPV vaccination focused specifically on MSM
consists primarily of quantitative studies and relies on standard theoretical constructs to explain
HPV vaccine intention (Nadarzynski et al., 2014; Newman, Logie, Doukas, & Asakura, 2013).
This limits models of decision-making to the most proximate determinates of intention,
acceptability, or willingness. Tailoring health education interventions for this population requires
the identification of modifiable belief structures salient to MSM when making decisions about
HPV vaccination. This is what was described as the salient beliefs. These are what need to be
changed in interventions. Insights into how to change them come from the identification of their
antecedents. In this next section, I will synthesize findings from Phases 1 and 3 (i.e., the
qualitative investigations) in order to develop general observations regarding key background
factors that inform decision-making about HPV vaccination among male sexual minorities.
The HIV lens and HPV threat
The key to understanding the way in which young MSM think about HPV prevention is
to consider the larger sociocultural impact of the HIV epidemic. This population is acutely aware
of HIV risks (Wagenaar, Sullivan, & Stephenson, 2012) and they encounter HIV messages
frequently in popular culture, as targets of research, and through pharmaceutical advertisements
(Salyer, 2001). Their decision-making process regarding HPV vaccination appears to be heavily
influenced by these sociocultural factors. Subjective risk of HPV infection (i.e., perceived threat)
was often discordant with objective facts about HPV infectivity and their sexual histories. Risk
perceptions regarding HPV infection were managed by a dedication to “safe sex,” which was
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generalized to mean condom use, infrequent anal penetration, and minimizing the exchange of
semen and blood. Thus the same set of risk factors for HIV transmission was equally applied to
perceptions of HPV transmission. When learning of the nature of HPV transmission (i.e., skinto-skin sexual contact) many participants expressed concern as if their individual “models” of
risk were challenged by this new information.
Two other key observations support the claim that HPV—and subsequent decisions
regarding vaccination—is viewed through the “lens” of the HIV epidemic. There was a focus on
“knowing your status” and “stopping the spread of HPV.” These are powerful and prevalent HIV
messages targeted toward the gay community (CDC, Act Against AIDS Campaign). Knowing
their status before making health decisions about vaccination was commonly mentioned by
participants yet belies an understanding of HPV infection, available testing procedures, and
vaccine recommendations. In the absence of knowledge of these facts, male sexual minorities
rely on heuristics informed by HIV knowledge and the wider practices in the gay community
(Meadowbrooke, Veinot, Loveluck, Hickok, & Bauermeister, 2014). These messages also appeal
to a sense of community responsibility, which was reiterated by men in this study in the form of
protecting future sex partners from HPV through testing, safe sex, and, for some, vaccination.
Specific Aim 2: Identify information needs and trusted sources of information
Information needs
Men in this study had significant deficits in their basic understanding of HPV and HPVrelated diseases. This lack of knowledge did not impact their enthusiasm for vaccination
suggesting that a minimal amount of information is needed in order for them to form vaccine
intentions. The higher-risk of anal cancer associated with HPV infection was often cited as new
information and had significant implications for the way in which participants understood the
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benefits of vaccination. Similarly, anogenital warts and HPV infection, even in the absence of
clinical disease, elicited a strong negative reaction underlying their sense of threat. Health
messages can capitalize on these emotional reactions to increase awareness of the benefits of
HPV vaccination and improve attitudes towards vaccination. Risk messages in the presence of an
effective prevention strategy can significantly influence behavior (Witte & Allen, 2000).
Patient-provider communication
Healthcare providers are perceived as the primary source of reliable information
regarding HPV vaccination. The importance of healthcare providers in HPV vaccine decisionmaking is well documented (Newman et al., 2013). In this study we call attention to issues of
sexuality and the patient-provider relationship that may serve as barriers to HPV vaccination.
Disclosure—or “coming out to a healthcare provider”—is of central importance to HPV
vaccination among adult MSM since there are different recommendations for vaccination of this
population compared to the general male population. MSM who are “out” to their healthcare
providers have more opportunity to receive recommended health services like HPV vaccination.
Meites and colleagues (2013) found that a large percent of male sexual minorities in their
national sample did not disclose to their healthcare providers, resulting in missed opportunities
for preventive services (Meites et al., 2013). In this study we identified a number of factors
related to disclosure including fear of judgment and mistreatment. Men were found to use a
variety of strategies to manage their patient-provider relations in order to avoid disclosure or to
seek out situations in which disclosure becomes more tenable. These data suggest that there is a
segment of young MSM for whom avoidance of disclosure may serve as a barrier to HPV
vaccination.
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Specific Aim 3: Test a structural equation model
The integrative model of behavioral prediction described in this study provided a good
framework from which to understand HPV vaccine decision-making among young MSM. The
overall model explained approximately 38% of HPV vaccine intentions. This model identified
key determinants of behavioral intention to get vaccinated, the structure of beliefs that influence
the key determinants, as well as the antecedents of those beliefs. The model goes one step further
to identify specific populations of MSM that may require specially tailored health messages or
other interventions. The findings from this model are summarized below.
The strongest determinant of behavioral intention was attitude. According to this model,
increasing positive attitudes toward HPV vaccination is the best strategy to affect intention and
subsequent behavior. Attitudes can be changed by increasing beliefs in physical and
psychological benefits of vaccination and decreasing concerns about side effects. Perceived
threat and information orientation serve as the key motivational factors related to perceived
advantages of vaccination. The antecedent role of perceived threat in HPV vaccine decisionmaking was identified in a previous study of young MSM (Wheldon et al., 2013). This
relationship implies that the motivation to process information pertaining to a health threat like
HPV infection (e.g., information about the advantages of vaccination) varies as a function of
perceived threat (Chen & Chaiken, 1999; Wheldon et al., 2013). As such, this theoretical model
predicts that messages regarding the advantages of HPV vaccination—and those that minimize
negative outcomes—are more likely to be systematically processed if a threat stimulus is present
(Das, de Wit, & Stroebe, 2003). Similarly, information orientation is a motivational quality that
primes an individual to process relevant information related to a health risk (Dutta-Bergman,
2009). Individuals high on health information orientation will likely require little stimulus to
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motivate information seeking and processing (Dutta-Bergman, 2009). Individuals who are low
on information orientation can best be reached through passive communication channels (DuttaBergman, 2009). For this population, that may include mobile phone sexual networking
applications (Holloway et al., 2014).
Perceived behavioral control was also a moderate predictor of vaccine intentions. As
predicted by the IM, perceived behavioral control is a function of external control beliefs and, in
this model, self-efficacy pertaining to disclosure of sexual orientation. Self-efficacy inversely
related to both the general tendency to conceal aspects of one’s sexual orientation and a
suspicion of healthcare providers. Both of these relationships have important implications for
patient-provider interactions. If the perceived LGBT cultural competency of providers were
increased, that would increase confidence in disclosing one’s sexual orientation and provide
more opportunities for healthcare providers to recommend HPV vaccination to this population of
men. The qualitative findings provide specific behaviors that providers can adopt in order to
build rapport with male sexual minorities. At the most basic level, these findings stress the
importance of asking about sexual behaviors in a way that does not confer judgment and focuses
on the relevance of this information for optimal medical care.
The exogenous variables in the model identified three subpopulations of MSM who may
benefit from targeted health education intervention. HIV-infected individuals exhibited higher
perceived threat of HPV, and ultimately higher vaccine intentions. When this relationship is
understood within the context provided by the qualitative findings, it is clear that HIV-infected
individuals have different experiences with the healthcare system and are motivated to process
information about HPV in significantly different ways given their increased risk of cancer. HIV
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status has consistently been shown to positively correlate with vaccine intentions (Newman et
al., 2013).
Typically bisexual identity has been unrelated to HPV vaccine intuitions or acceptability
(Wheldon et al., 2011) or vaccination status (Reiter et al., 2015). In this study, bisexual identity
was positively correlated with concealment of sexual orientation and suspicion of healthcare
providers. While not directly associated with vaccine intention, bisexually identified men may
not be reached through health education interventions targeting gay men. Rates of nondisclosure
of sexual minority status to healthcare providers have shown to be higher among bisexually
identified men (Durso & Meyer, 2013). Limitations of patient-provider interactions experienced
by these men can result in fewer opportunities for vaccination.
Finally, men in monogamous relationships exhibited lower levels of perceived threat.
This relationship supports the finding in the qualitative interviews where men expressed low
levels of perceived threat as a result of being in a monogamous, or semi-monogamous,
relationship. Lower perceived threat among men in relationships ultimately resulted in lower
levels of vaccine intention. Further research is needed to identify the specific targets of
behavioral intervention for this unique subpopulation.
Section II: Limitations and Strengths
Strengths
This study makes a unique contribution to the behavioral HPV vaccination literature in
several ways. (1) It is the first systematic study of HPV vaccine decision-making among MSM or
males in general that uses the IM as a theoretical framework. While several studies have
explored similar psychosocial constructs (Nadarzynski et al., 2014) as they relate to HPV
vaccination, no published research utilized a mixed methods approach to elicit salient beliefs
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directly from the priority population and then tested a structural model of those beliefs. In
addition, the IM was uniquely expanded to incorporate antecedent factors important for the
targeting and tailoring of health education interventions. (2) The sequential mixed methods study
design allowed for a comprehensive exploration of HPV vaccine decision-making. Decisionmaking processes surrounding vaccinations among adults are complex and driven by multiple
factors. The qualitative phases allowed for in-depth exploration of salient beliefs and
perceptions, while the quantitative survey provided the data needed to validate the theoretical
propositions. (3) The application of an open-ended survey using a vignette to provide context in
which to evaluate specific steps in the decision-making process was an innovative approach and
provided a rich source of data. (4) The use of structural equation modeling, which allows for a
complex representation of the theoretical constructs through the use of multivariate modeling
techniques, provided information about the direct and indirect relationship of theoretical
constructs. Mapping out the structural relationships between theoretical constructs is useful for
the subsequent application of program planning models. (5) Finally, the use of a ethno-racially
diverse community-based sample of young MSM in combination with geographically diverse
samples obtained through Internet-based research recruitment helps to increase the external
validity of findings and subsequent implications for health education interventions.
Limitations
The current study has four major limitations including the use of (1) non-probability
sampling techniques, (2) cross-sectional data, (3) proxy indicators for vaccine uptake (i.e.,
modeling vaccine intentions), and (4) mode effects of in-person, telephone, and web-based data
collection. Probability sampling techniques ensure that every individual or element within the
priority population from which the research seeks to generalize has a known non-zero probability
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of being sampled (Fowler, 1993). This is accomplished from operationalizing the conceptual
population into a sampling frame from which elements are randomly selected. External validity
is most rigorously established when a sample is randomly generated from a sampling frame that
closely approximates the conceptual population. This ensures that the sample is representative of
the population and that findings generated from the sample can be generalized to the population
within a specified range of confidence.
There are a number of issues inherent to sampling members of sexual minority
populations. The target population for this research included men who have ever engaged in
sexual contact with another male or who identify as gay or bisexual. This conceptual population
included both gay identified and non-gay identified MSM in order to be inclusive of all those
who engage, or may engage at some point, in similar behaviors that increase the risk of anal
HPV infection. This population is based on stigmatized sexual identities and sexual behaviors,
which are often concealed or “hidden.” Therefore, constructing sampling frames that closely
approximate these types of conceptual populations is inherently flawed, which results in biased
and unrepresentative samples.
In addition to the limitations inherent to the use of non-probability sampling techniques,
the use of cross-sectional data and proxy measures for behavioral performance (e.g., vaccine
uptake) limits the degree to which the IM would be directly tested. The IM posits that, in the
absence of environmental constraints, a given health behavior is determined by an individual’s
intention to perform that behavior. This proposition could not be tested using cross sectional data
since no temporal relationship can be established between behavioral intention and behavioral
performance. Furthermore, the full IM could not be tested since vaccine intention and not
vaccine behavior (i.e., getting vaccinated or not getting vaccinated) was the final outcome.
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Internet-based self-administered surveys have some significant limitations that bear
consideration. Unequal access to the Internet was a primary concern associated with this survey
method; however, the most recent data from the Pew Internet and American Life Project
estimates that approximately 95% of Americans between the ages of 18 and 29 use the Internet.
In contrast, only 56% of 18 to 30 year olds have a landline telephone in their household. The
ubiquitous use of the Internet and mobile technologies provides strong rationale for Internetbased survey research targeting younger cohorts. Internet surveys have been shown to have low
response and completion rates relative to other survey methods (Cook, Heath, & Thompson,
2000). These limitations to Internet-based survey research can present a challenge to the validity
of results utilizing this method.
Three modes were used to collect qualitative data used in this study: in-person face-toface interviews, telephone interviews, and web-based self-administered open-ended survey
items. It is unclear to what degree these data collection techniques influenced data quality. There
is a perception in qualitative research that face-to-face interviews result in the richest data,
providing more context and opportunity to build rapport, interpret non-verbal cues, and ask
probing questions (Novick, 2008). And there is some empirical support for these claims (Irvine,
2011) and also in support of the quality of data resulting from telephone interviews (Sturges &
Hanrahan, 2004).
Section III: Implications
Implications for research
Longitudinal studies are needed in order to establish temporal relationships between the
key theoretical variables identified in this investigation and to determine how well they predict
HPV vaccine initiation as the main outcome. Future research should also replicate the findings of
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the current study with diverse samples of MSM including those with lower socioeconomic status
and MSM who do not identify as gay or bisexual. HIV infected MSM are also a unique
subpopulation that was not fully represented by this research. While the current investigation
provides needed and useful information, the next steps for vaccine promotion research among
this population should include community-based needs assessments to identify environmental
barriers or factors that may facilitate vaccination of MSM in specific community locales. This
research could benefit by building on the theoretical framework utilized in the current study and
expanding it using program planning models like the social marketing framework (Kotier &
Zaltman, 1996) or an intervention mapping approach (Bartholomew, 2011).
Promoting HPV vaccination among sexual minorities can be viewed within the larger
framework of healthcare disparities experienced by this population (Institue of Medicine, 2011).
Barriers to care center on issues of discrimination and stigma and are rooted in a long history of
mistreatment of sexual minorities by healthcare systems and personnel. The charge of public
health research is to identify ways to minimize or eliminate these barriers. In the current
investigation—which focused on the individual as the unit of analysis—we identified suspicion
of healthcare providers as a potential barrier to HPV vaccination among young MSM. This
finding requires further investigation to develop valid and reliable measures of this phenomenon,
to examine how widespread these perceptions are among subpopulations of MSM, and to further
describe antecedents that facilitate these beliefs. Research in this area can benefit from and
expand upon the work done on medical mistrust among other minority populations (Benkert,
Hollie, Nordstrom, Wickson, & Bins-Emerick, 2009; Buseh, Kelber, Millon-Underwood,
Stevens, & Townsend, 2014; Guadagnolo et al., 2009).
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Implications for policy
This study identifies key points for structural interventions. Policies that allow for and
promote alternative vaccine settings can help facilitate uptake among young MSM. While
pharmacies were identified as acceptable locations for a subset of MSM, others would prefer to
get vaccinated at community-based clinics that offer HIV testing and that are perceived to be
LGBT-friendly. A model of LGBT care has been developed and put into practice by places like
Fenway Community Health in Boston and in other urban centers with established LGBT
communities (Mayer et al., 2001). The challenge is expanding this model to smaller cities. This
is an area where community-based participatory research could offer unique insights.
The age- and sex-based recommendations for HPV vaccination appear to be a source of
considerable confusion among men in this study and have created a perception that HPV is a
female problem. These perceptions appear to be enduring even after changes in vaccine policy.
And while targeted vaccine promotion campaigns can seek to modify these beliefs, simplifying
HPV vaccine policy would be the most wide reaching and impactful intervention. Given the
decreasing cost of HPV vaccine, the promise of alternative dosing schedules, the increasing
burden of HPV-related diseases, and the lack of standardized secondary screening guidelines for
men, a universal, gender neutral policy recommendation is warranted (Bonanni et al., 2014).
Implications for practice
The findings from this study have several implications for public health practice. First
among these are the implications for health education interventions to promote HPV vaccine
uptake among MSM. The final IM supported by the findings identified key modifiable
psychosocial factors including specific beliefs and perceptions that either directly or indirectly
affect behavioral intention. Risk messages can be designed to influence these beliefs and can be
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targeted to the specific subpopulations of MSM identified in the model. Promoting beliefs about
the physical and psychological benefits of vaccination can be accomplished through paring
information and risk messages. More research is needed to test specific messages, but this study
has implications for the content of these messages. Rather than framing HPV vaccination as a
cancer vaccine, which previous research has suggested (McRee, Reiter, Chantala, & Brewer,
2010), the findings from this study indicate that framing HPV vaccination as a way to prevent a
sexually transmitted infection may be particularly effect for MSM. Building on existing HIV
prevention messaging (e.g., “Stop the spread,” “protect you partners”) may also be effective.
The findings also suggest limited efficacy of interpersonal-based approach to vaccine
promotion aside from interventions targeting healthcare providers. This research underscores the
importance of LGBT cultural competency training. Currently there are no specific evidencebased clinical practices to increase competency, but there are some guidelines that can be
implemented to begin to address these issues (McNair & Hegarty, 2010).
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Appendix A: Phase 1 Interview Guide
Date: ____/_____/_____(mm/dd/yy)
Participant ID#______

Time: _______________(AM / PM)
Men4Men Health Study
IRB# Pro00012092
Interview Guide

INTRODUCTION
Thank you for taking the time to meet with me for this interview. I recognize that your time is
valuable and I appreciate your participation. Before I start, let me take some time to introduce
myself and explain why I am here to speak with you.
My name is Chris Wheldon from the University of South Florida. I am conducting a research study to
learn more about your views, beliefs, and attitudes toward health topics that affect sexually active men.
This interview is one of many interviews that will take place over the next three months. I want to know
what are your thoughts, opinions and experiences when it comes to health in your community. There
are no right or wrong answers. I am interested in finding out what you think.
The information I gather will be summarized and shared in order to find better ways to serve the health
needs of guys like you.
The interview should not last more than 45 minutes.
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SECTION 1:
BACKGROUND/ATTRIBUTE LISTING
INTERVIEWER SAY: In order to get to know you please introduce yourself and list 10 things
about yourself [Have him write them down]
Probe: I am a brother, son, student etc.
Probe: Age | Sexual Orientation | Residence | Health Insurance | Healthcare place
Race/Ethnicity | Student | Education

SECTION 2:
Health & Information
INTERVIEWER SAY: I want to talk a little about health.
1) What does it mean for you to be healthy?

2) What sort of things do you do to be healthy?

3) What do you think are some major health concerns that affect guys your age

(Probe: A lot of times we talk about “women’s health” but what comes to mind when I
say “men’s health”?
(Probe: What about specific health concerns for gay/bisexual men? How do these differ
from other men?)

4) How do you find health information? (Probe: What sources do you trust?)

5) Tell me about the last time you went to a doctor or health care provider.
(Probe: What did you see him/her for? Have you ever been tested for HIV/STIs? Where and
when was the last time?)
6) Have you ever discussed being gay/bisexual with a health care provider. Tell me about that
experience (Probe: When did this happen? Who initiated the discussion?).
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SECTION 3:
Knowledge

HPV

1) Have you every heard of human papillomavirus (or HPV)?

2) What do you know about HPV (Human Papillomavirus)?

3) How did you first hear about HPV? What sources would you trust?

4) Have you ever heard of a vaccine to prevent HPV? (If yes, what have you heard?)
5) Where did you hear about the HPV vaccine? (Probe: Which of these sources [repeat/display
response to previous question] would you trust the [most/least] to provide information about
HPV?

[Show HPV Brochure] What stands out or surprises you? What else would you like to know?
a. Based on what you know now about HPV, what do you think your risk is of [having
been/becoming] infected with HPV? Or developing an HPV related disease? What about
in 3-5 years from now? [0-10 scale]
b. When you try to calculate your risk, what first comes to mind?

Outcome beliefs
6) What do you believe are the [advantages “good things” / disadvantages “bad things”] of
receiving the HPV vaccine? How would you benefit from the HPV vaccine?

Normative beliefs
7) What individuals or groups would [approve/disapprove] if you decided to get the HPV vaccine?
Why or why not? (Probe: Friends? Family? Doctor?)

8)

What do you think about people who receive the HPV vaccine?

Efficacy/Control Beliefs
9)

What factors or circumstances would [help you/make it difficult or impossible] for you to get
the HPV vaccine?
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a. Where would you get it? [Probe: What about from a primary care provider? Would it
prevent you from receiving it if you had to discuss your sexuality?
b. How would you pay for it?
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Appendix B: Phase 2 Survey Instrument
ETH Which of the following best describes your race or ethnicity (check all that apply)?
1.
2.
3.
4.
5.
6.
7.
8.

White/Caucasian (1)
African American (2)
African (9)
Hispanic/Latino (3)
Asian (4)
Native American (5)
Pacific Islander (6)
Other (7) ____________________

SEX What sex were you assigned at birth, on your original birth certificate?
Male (1)
Female (2)
Other (Please explain) (4) ____________________

GENDER Which of the following describes your gender identity, how you think about
yourself?
Man (1)
Woman (2)
Genderqueer (3)
Transgender (4)
A gender identity not listed here (please explain) (5) ____________________

SEXOR How would you describe your sexual orientation?
Gay (1)
Bisexual (2)
Straight / heterosexual (3)
Not sure (4)
Other (5) ____________________

STUDENT Are you currently a student?
Yes (1)
No (2)
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EDU What is the highest level of education you have completed?
Less than High School (1)
High School / GED (2)
Some College (3)
2-year College Degree (4)
4-year College Degree (5)
Graduate/Professional Degree (6)

INSURANCE Do you have medical insurance coverage?
Yes (1)
No (2)
I don't know (3)

MEDPLACE Is there a place that you usually go to when you need routine medical care
(e.g., a family doctor, a specific clinic, etc)?
Yes (1)
No (2)
I don't know (3)

HIVTEST In the past 12 months, how many times have you been tested for HIV,
including times you did not get your results? *Including blood or saliva tests specific for
HIV. Do not count tests you may have had as part of a blood donation.
0 - I have not been tested for HIV in the last 12 months (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 or more times (6)

HIV What is your HIV status?
HIV - Negative (1)
HIV - Positive (2)
Never been tested for HIV (3)
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STI Have you ever been told by a health care provider that you had either Gonorrhea
("the clap"), Chlamydia, Syphilis, herpes, or Trichomoniasis ("trich")?
Yes (1)
No (2)
I don't know (3)

OUT_CON How often do you avoid talking about topics related to or otherwise
indicating your sexual orientation when interacting with members of these groups (e.g.,
not talking about your significant other, changing your mannerisms)?
______ Members of your immediate family (e.g., parents and siblings) (1)
______ Members of your extended family (e.g., aunts, uncles, grandparents, cousins) (2)
______ People you socialize with (e.g., friends and acquaintances) (3)
______ People at your work/school (e.g., coworkers, supervisors, instructors, students) (4)
______ Strangers (e.g., someone you have a casual conversation with in line at the store) (5)

HPV101_I Ever heard of HPV? A lot of guys don't know much about it. Read the info
below and then go to the next page.
HPV_HAD Has a health care provider ever told you that you had human papillomavirus
or
HPV?
Yes (1)
No (2)
I don't know (3)

HPV_WARTS Has a health care provider ever told you that you had genital or anal
warts?
Yes (1)
No (2)
I don't know (3)

KNOW_WARTS To the best of your knowledge, do you personally know someone who
has had genital or anal warts (other than yourself)?
Yes (1)
No (2)
I don't know (3)
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KNOW_HPV To the best of your knowledge, do you personally know someone who has
had HPV (other than yourself)?
Yes (1)
No (2)
I don't know (3)

VAC_AWARE Before today, have you ever heard of the HPV vaccine?
No (1)
Yes (2)
I don't know (3)

HPV_VACC Have you ever received the HPV shot?
Yes (1)
No (2)
I don't know (3)
If Yes Is Selected, Then Skip To End of Block

KNOW_VAC Do you personally know someone who has gotten the HPV vaccine?
Yes (1)
No (2)
I don't know (3)

VAC_DRREC Has a doctor or health care provider ever recommended that you get the
HPV vaccine?
Yes (1)
No (2)
I don't know (3)

VAC_INT_D1 Do you intend to get vaccinated against HPV within the next year?
Yes (1)
No (2)
I don't know (3)

VAC_I2 Now that you know a little about the HPV vaccine I would like to know if you
will get the HPV vaccine. Respond to the following statements based on what you know
right now about the HPV vaccine. How likely are you to do the following:
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INTENTION1 Find out more information about the HPV vaccine within the next 12
months
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

INTENTION2 Make an appointment to talk to a doctor about the HPV vaccine within the
next 12 months
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

INTENTION3 Get your first HPV shot within the next 12 months
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

INTENTION4 How likely are you to get the HPV vaccine if the CDC recommendation
was changed to include men older than 26?
Very Unlikely (6)
Unlikely (7)
Undecided (8)
Likely (9)
Very Likely (10)

DOSE_I Each dose can cost up to about $170, so all three shots may cost about $500.
Many health insurance companies may pay for the HPV vaccines. There are also
programs that allow some people without insurance to get a vaccine for low or no cost.
Think about what you might do in the next year. Would you...
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INTENTION5 Get the HPV vaccine if it were offered to you free of charge?
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

INTENTION6 Get the HPV vaccine if it was covered by your health insurance or
discounted to approximately $30 per dose?
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

ATT Overall, I think that getting the HPV vaccine is...
1 (1)

2 (2)

3 (3)

4 (4)

5 (5)

Not worth
it:Worthwhile (1)
Harmful:Beneficial (2)
A bad thing for me:A
good thing for me (3)
Unimportant:Important
(4)
Ineffective:Effective (5)
BB_I2 If you got vaccinated for HPV within the next year, how likely are the following
things:
BB1 It would make me healthier
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)
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BB2 It would prevent me from getting genital and anal warts
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB3 It would prevent me from getting anal cancer
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB_I3 You just told me how you think you might benefit (or not) from the HPV vaccine.
Now I'd like to know how important each of those outcomes are to you at this point in
time.
EB1 Being healthy is...
Not at all Important to me at this time (1)
Very Unimportant to me at this time (2)
Neither Important nor Unimportant to me at this time (3)
Very Important to me at this time (4)
Extremely Important to me at this time (5)

EB2 Preventing genital and anal warts is...
Not at all Important to me at this time (1)
Very Unimportant to me at this time (2)
Neither Important nor Unimportant to me at this time (3)
Very Important to me at this time (4)
Extremely Important to me at this time (5)

EB4 Preventing anal cancer is...
Not at all Important to me at this time (1)
Very Unimportant to me at this time (2)
Neither Important nor Unimportant to me at this time (3)
Very Important to me at this time (4)
Extremely Important to me at this time (5)
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BB_i4 If you got vaccinated for HPV within the next year, how true are the following
things likely to happen for you? Would you...?
BB4 Feel protected from HPV
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB5 Feel like there is one less thing to worry about
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB6 Be less likely to spread HPV to your future sex partner(s)
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB_I5 How important are these things to you currently or over the next 12 months?
EB4 Feeling protected from HPV
Not at all Important (1)
Very Unimportant (2)
Neither Important nor Unimportant (3)
Very Important (4)
Extremely Important (5)
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EB5 Not having to worry about getting HPV from my sex partner(s)
Not at all Important (1)
Very Unimportant (2)
Neither Important nor Unimportant (3)
Very Important (4)
Extremely Important (5)

EB6 Protecting my sex partner(s) from HPV
Not at all Important (1)
Very Unimportant (2)
Neither Important nor Unimportant (3)
Very Important (4)
Extremely Important (5)

BB_I6 We’ve talked to some guys who expressed some concerns about the HPV vaccine.
How likely do you think the following things are to happen to you if you got vaccinated?
If I got vaccinated for HPV within the next year…
BB7 I will contract HPV from the vaccine itself
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB8 I would not be completely protected from future HPV infection
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

BB9 The vaccine may not work for me
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)
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BB10 I would have side effects from the HPV vaccine
Very Unlikely (1)
Unlikely (2)
Undecided (3)
Likely (4)
Very Likely (5)

EB10 If you did experience side effects from the HPV vaccine, how serious do you think
that would be?
Not serious at all (1)
Not serious (2)
I'm not sure (3)
Serious (4)
Very serious (5)

NORM_I If you considered getting the HPV vaccine in the next year, there might be
people (e.g., your family) or groups (e.g., health care providers) who would think you
should or should not do so. I would like to ask you some questions about this.
NORM1 In general, people who are important to me would encourage me to receive the
HPV vaccine.
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

NORM2 I can think of at least one person in my life who would like for me to get the
HPV vaccine.
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)
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NORM3 If I decided to get the HPV vaccine within the next year, I would seek advice
from my friends or family prior to getting vaccinated.
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

NORM4 Most of my gay/bisexual male friends would get the HPV vaccine if it was
offered to them free of charge.
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

NB Listed below are some people in your life who may approve or disapprove of you
getting the HPV vaccine. What do you think their opinions would be? If you don't have a
relationship with the specific person just choose "not applicable." 1 = Very Disapproving
2 3 = Neither Approving/Disapproving 4 5 = Very Approving
______ Your Mother (24)
______ Your Father (25)
______ Most of your gay male friends (26)
______ Your straight friends (28)
______ Your health care provider (29)

MC When deciding whether or not to get the HPV vaccine, would you seriously consider
the advice/opinion of...1 = Very Unlikely23 = Undecided45 = Very Likely
______ Your mother (24)
______ Your father (25)
______ Your gay male friends (26)
______ Your straight friends (28)
______ Your healthcare provider (29)

Q73 You're swell. Hang in there! Let's assume that you decide to get the HPV vaccine in
the next 12 months (i.e., by this time next year). Select your responses to the following
statements accordingly.
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PBC1 There are factors beyond my control that would prevent me from getting the HPV
vaccine in the next 12 months
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

PBC2 I am confident that I can get the HPV vaccine in the next 12 months
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

Q168 Getting the HPV vaccine sometime in the next 12 months would be
Impossible for me (6)
(7)
(8)
(9)
Possible for me (10)

PC What would make it easier for you to get the HPV Vaccine? Tell me below. It would
make it ____________to get the HPV vaccine in the next 12 months...1 = more difficult
for me2345 = much easier for me
______ If I could quickly find out where to go to get vaccinated (1)
______ If my health insurance covered the vaccine (4)
______ If I could get it without having to make an appointment (i.e., walk-in) (3)
______ If I could get it when I get tested for HIV (6)

CB_I Tell me how much you agree or disagree with the following statements
CB1 I can find out where to go to get vaccinated
Strongly Disagree (1)
Disagree (2)
Neither Disagree nor Agree (3)
Agree (4)
Strongly Agree (5)
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CB2 I will have health insurance during the next year
Strongly Disagree (1)
Disagree (2)
Neither Disagree nor Agree (3)
Agree (4)
Strongly Agree (5)

CB3 I can find a place to get vaccinated where I don't need to make an appointment (i.e.,
walk-in)
Strongly Disagree (1)
Disagree (2)
Neither Disagree nor Agree (3)
Agree (4)
Strongly Agree (5)

CB4 I will get tested for HIV in the next 12 months
Strongly Disagree (1)
Disagree (2)
Neither Disagree nor Agree (3)
Agree (4)
Strongly Agree (5)

SE_I Assuming you decided to get the HPV vaccine.
SE_GAY1 How confident are you in your ability to get the HPV vaccine if you had to
talk to your doctor or healthcare provider about your sexual orientation (e.g., that you are
gay or bisexual)?
Not at all confident (1)
Somewhat confident (2)
Rather confident (3)
Very confident (4)
Extremely confident (5)
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SE_BEH1 How confident are you in your ability to get the HPV vaccine if you had to
talk to your doctor or healthcare provider about your sexual behaviors (e.g., your sexual
history)?
Not at all confident (1)
Somewhat confident (2)
Rather confident (3)
Very confident (4)
Extremely confident (5)

SUS Without getting the HPV vaccine, what do you think the chances are that you will…
1 = Very Unlikely 2 3 = Undecided 4 5 = Very Likely
______ Get HPV (1)
______ Get warts on your penis or scrotum (2)
______ Get anal warts (3)
______ Get anal cancer (4)

SEV Please indicate on a scale of 1 to 5 how serious you feel the following events would
be for you.
______ If you became infected with HPV (1)
______ If you developed warts on or inside your anus (2)
______ If you developed warts on your penis or scrotum (3)
______ If you developed anal cancer (4)

Q173 Ok! That's enough about HPV!!! I just have a few more questions. Remember to
enter your email at the end of the survey to enter the drawing for Amazon.com Gift
Cards.
COMM_I The next few statements focus on health information. Indicate below how
much you agree or disagree with each statement.
COMM_M1 When I take medicine, I try to get as much information as possible about its
benefits and side effects
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)
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COMM_M2 Before making a decision about my health, I find out everything I can about
the issue
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

COMM_M3 It’s important to me to be informed about health issues affecting gay and
bisexual men
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

I5 I would like to ask you about your health care experiences. When I ask about a "health
care provider" I am referring to a medical doctor or nurse who is licensed to practice
medicine. Sometimes we call them family or primary care physicians.
DISLOSE Have you ever told any health care provider that you are gay or bisexual or
that you have sex with men?
Yes (1)
No (2)
I don't know (3)

I6 Please tell me how much you agree or disagree with the following statements.
HLTCARE1 I have received lower quality healthcare services as a result of my sexual
orientation
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

180

HLTCARE2 I prefer that my doctor or healthcare provider does not know that I am
gay/bisexual
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

HLTCARE3 I feel uncomfortable talking about my sexual orientation or sexual behaviors
with a doctor or healthcare provider
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

HLTCARE4 There is no reason why my doctor or healthcare provider would need to
know that I have sex with men
Strongly Disagree (1)
Disagree (2)
Neither Agree nor Disagree (3)
Agree (4)
Strongly Agree (5)

SEX_BEH_I
Now I would like to ask you some questions about your sexual
activities and experiences. This information is very important to this study. Each person
has different sexual experiences, so some questions may not apply to you. Remember:
Your answers are anonymous!
SEX_#M In your lifetime, with how many males have you had sex?
REL Are you currently in a monogamous relationship?
Yes, with a man (1)
Yes, with a woman (2)
No (3)

Answer If Are you currently in a monogamous relationship? Yes, with a man Is Selected Or Are
you currently in a monogamous relationship? Yes, with a woman Is Selected

REL_LENGTH How long have you been in this relationship?

181

VAC_INT_D2 Last Question!!! And this is a repeat but I’m curious if you’ve changed
your mind. Do you intend to get vaccinated against HPV within the next year?
Yes (1)
No (2)
I don't know (3)

OPEN Thank you for taking the survey. On the next page you can submit your responses
and move on to enter to win a gift card. If you have any thoughts you'd like to share with
me you can do so below.
CLOSING_I You’re fabulous! Thank you for taking the time to complete this survey. If
you have any questions about the study or about HPV don’t hesitate to contact me at
cwheldon@health.usf.edu. If you are curious about the findings from this study I can
update you when I am finished. Just send me an email and let me know you are
interested. On the next page you can enter to win a gift card for your participation. If you
are one of the winners the gift card will be emailed to you. This email will not be linked
to your survey responses in any way.
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Appendix C: Phase 3 Survey Instrument
D2 What sex were you assigned at birth, on your original birth certificate?
Male (1)
Female (2)
Other (Please explain) (4) ____________________

Q61 Which of the following describes your gender identity, how you think about
yourself?
Boy/man (1)
Girl/woman (2)
Genderqueer (3)
Transgender (4)
A gender identity not listed here (please explain) (5) ____________________

D3 How would you describe your sexual orientation?
Gay (1)
Bisexual (2)
Straight / heterosexual (3)
Not sure (4)
Other (5) ____________________

D4 Which of the following best describes your race or ethnicity (check all that apply)?
9.
10.
11.
12.
13.
14.
15.
16.

White/Caucasian (1)
African American (2)
African (9)
Hispanic/Latino (3)
Asian (4)
Native American (5)
Pacific Islander (6)
Other (7) ____________________

D5 Are you currently a student?
Yes (1)
No (2)

183

D6 What is the highest level of education you have completed?
Less than High School (1)
High School / GED (2)
Some College (3)
2-year College Degree (4)
4-year College Degree (5)
Graduate/Professional Degree (6)

HLT1 Do you have medical insurance coverage?
Yes, through my employer (1)
Yes, through my school (4)
Yes, through my parents (5)
Yes, through an individual policy (6)
Yes, through medicaid or state based program (7)
Yes, through another source (8)
No, I do not currently have medical insurance (2)
I'm not sure (3)

HLT2 Is there a place that you usually go to when you need routine medical care (e.g., a
family doctor, a specific clinic, etc)?
Yes (1)
No (2)

HLT3 If you needed to see a doctor for a non-emergency issue, where would you go?
My primary care provider (1)
Clinic at my school (2)
A local walk-in clinic (3)
County public health clinic (4)
Planned Parenthood clinic (5)
Emergency room (6)
Other (please explain) (7) ____________________
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HIV2 In the past 12 months, how many times have you been tested for HIV, including
times you did not get your results? *Including blood or saliva tests specific for HIV. Do
not count tests you may have had as part of a blood donation.
0 - I have not been tested for HIV in the last 12 months (1)
1 (2)
2 (3)
3 (4)
4 (5)
5 or more times (6)

HIV3 Where do you usually go to get tested for HIV?
HIV What is your HIV status?
HIV - Negative (1)
HIV - Positive (2)
Never been tested for HIV (3)

HPV1 Has a doctor or other health care provider ever told you that you had human
papillomavirus or
HPV?
Yes (1)
No (2)
I'm not sure (3)

HPV2 Has a doctor or other health care provider ever told you that you had genital warts?
Yes (1)
No (2)
I'm not sure (3)

HPV3 A vaccine to prevent HPV infection is available and is referred to by several
names, such as: the HPV shot, cervical cancer vaccine, GARDASIL®, or CERVARIX®.
Have you ever received the HPV shot or cervical cancer vaccine?
Yes (1)
No (2)
I'm not sure (3)

Bran1 Please read Brandon's story and respond to the questions. There are 3 short
sections to his story and each has a set of questions and areas for you to provide your
thoughts. This story is based on the experiences of real people who previously
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participated in this study. Brandon is a young guy in his 20s. He isn't overly concerned
about health issues but he tries to eat healthy and stay active. He doesn't go to the doctor
often but he does try to get tested for HIV on a regular basis. He's currently single and
enjoys hanging out with his friends and meeting new guys. On a recent Friday night he
was spending an evening out with a group of friends at his favorite hangout. While
waiting in line to order, he casually scanned the fliers posted on the wall next to him.
Most of them featured hard bodied men advertising for fundraisers or party events. But
one flier caught his eye. It read “Cover your BUTT with GARDASIL. HPV affects guys,
too.” And under the large text it said…
Bran2 PLEASE READ THESE HPV FACTS
Bran3
What is HPV? Why you should care? HPV is a sexually transmitted virus
that you can get from skin-to-skin contact during all types of sexual activites. Most
people will become infected with HPV in their lifetime. Most of the time HPV has no
symptoms so people don’t know they have it. For most people, HPV goes away on its
own but if it doesn’t it can cause genital and anal warts and some types of cancers
including anal cancer. Men who have sex with men are 17 times more likely to develop
anal cancer than other men. How to prevent HPV? Gardasil—the HPV vaccine—protects
against genital warts and cancers caused by HPV. HPV vaccine is recommended for men
26 years old and younger.
StandOut What about this information stands out to you? Why does it stand out to you?
Please explain in detail.
Learn What did you learn about HPV that you didn't already know?
Prisk Without the HPV vaccine, what do you think the chance is that you will be infected
with HPV at some point in your life?
No chance (0%) (1)
Very unlikely (2)
Unlikely (3)
Average chance (50%) (4)
Likely (5)
Very likely (6)
Certain to happen (100%) (7)
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Concern How concerned are you about getting infected with HPV?
Not at all concerned (1)
Slightly concerned (2)
Somewhat concerned (3)
Moderately concerned (4)
Extremely concerned (5)

Bran4
After reading this information about HPV, Brandon was a little worried. He
thought HPV was only something women could get. And while he almost always uses
protection when he hooks up, he couldn’t help but wonder if he has HPV. But Brandon
wasn’t going to let it bother him. He got his drink and went back to his friends.
The next day Brandon googled HPV vaccine and read more about it. He read that
GARDASIL is given as 3 injections over 6 months and that the ideal time to get
vaccinated is before becoming infected with HPV. Brandon isn’t sure if he can be
vaccinated. He’s not what his friends would consider “slutty” but he certainly isn’t a
virgin either. He wonders how he would know if he’s been exposed to HPV.
Decision1 What do you think Brandon should do? I think Brandon should...(explain in
detail)
Q67 Why should he do that? I think Brandon should do that because...(explain in detail)
Decision2 What would you do if you were in Brandon’s situation? Please explain why. If
I were in Brandon’s situation, I would...
BranThreat A few weeks passed and Brandon mostly forgot about HPV until one
afternoon the topic came up while he was hanging out with his friend Jeremy. Jeremy and
Brandon are best friends, and they share everything. It turns out Jeremy just found out he
has anal warts! He told Brandon he was having some “issues down there” so he went to
get it checked out. He spared Brandon the details but told him that, “they aren’t pretty."
Luckily the warts were all on the outside around his anus so the doctor was able to freeze
them off so he didn’t need surgery. Jeremy was worried that the warts might come back
since there is no cure. Brandon was supportive as usual and reassured his friend. But deep
down he was freaking out. After hearing about Jeremy’s experience Brandon decided that
he wanted to get the HPV vaccine. He didn’t EVER want to get anal warts. He didn’t
care if he had already been exposed to HPV. If there was any chance that the HPV
vaccine would prevent warts or cancer he thought it was worth it.
Threat1 What do you think about Brandon’s decision? I think that Brandon's decision...
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Threat 1b Would you have decided to do the same thing (i.e., decide to get the HPV
vaccine)?
Yes (1)
No (2)
I'm not sure (3)

Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)? No
Is Selected

Threat2_N Why would you decide NOT to get vaccinated?
Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)?
Yes Is Selected

Threat2_Y Why would you decide to get vaccinated?
Answer If Would you have decided to do the same thing (i.e., decide to get the HPV vaccine)?
I'm not sure Is Selected

Threat2_U What are you unsure about?
Answer If Do you have medical insurance coverage? No, I do not currently have medical
insurance Is Not Selected And Do you have medical insurance coverage? I'm not sure Is Not
Selected And Is there a place that you usually go to when you need routine medical care (e.g., a
family doctor... No Is Selected

BranGet1
Brandon wanted to get the HPV vaccine but he didn’t know where to go
to get it. He had health insurance but didn’t have a regular doctor or a place he usually
goes to for care. He doesn’t like going to the doctor and feels a little awkward asking a
health care provider about the HPV vaccine since it’s an STD. He knows it's
unprofessional but sometimes thinks that doctors judge him for his sexual behaviors.
Disclose Have you ever told any health care provider that you are
${q://QID9/ChoiceGroup/SelectedChoices} or that you have sex with men?
Yes (1)
No (2)
I don't remember (3)

Answer If
Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it.
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for care.
He doesn’t... Is Displayed

Get1 Where would you go to get the HPV vaccine if you were in Brandon’s situation?
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Answer If
Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it.
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for
care... Is Displayed

Disclose1 How do you feel about talking to your health care provider about your sexual
behavior (example: telling him or her you've had male partners)? Do you feel like they
judge you? Why or why not?
Answer If
Brandon wants to get the HPV vaccine but he doesn’t know where to go to get it.
He has health insurance but doesn’t have a regular doctor or a place he usually goes to for care.
He doesn’t... Is Displayed

Trust1 Do you think that your doctor or health care providers are knowledgeable about
the health issues that gay and bisexual men have to deal with? Why or why not?
BranGet2
Brandon wants to get the HPV vaccine but he doesn’t know where to go
to get it. He has health insurance and a regular doctor he sees, but he feels a little
awkward asking his doctor for the HPV vaccine. He knows it's unprofessional but
sometimes he thinks that his doctor judges him for his sexual behaviors.
Get2 Where would you go to get the HPV vaccine if you were in Brandon’s situation?
Disclose2 How do you feel about talking to your health care provider about your sexual
behavior (example: telling him or her you've had male partners)? Do you feel like they
judge you? Why or why not?
Trust2 Do you think that your doctor or health care providers are knowledgeable about
the health issues that gay and bisexual men have to deal with? Why or why not?
BranGet3
Brandon wants to get the HPV vaccine but he doesn’t know where to go
to get it. He does not have health insurance and is worried that the vaccine is too
expensive. He read that out of pocket the vaccine could cost almost $500 for all 3 shots.
Recom3 What would you recommend that Brandon do?
Decide3 What would you do if you were in Brandon’s situation?
Get3 Where would you go to get the the HPV vaccine if you wanted it?
Bran5
Even if he could find some way to get the HPV vaccine Brandon doesn’t like
going to the doctor and feels a little awkward asking a health care provider about the
HPV vaccine since it’s an STD. He knows its unprofessional but sometimes thinks that
doctors judge him for his sexual behaviors.
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Decide5 How do you feel about talking to your health care provider about your sexual
behavior (example: telling him or her you've had male partners)? Do you feel like they
judge you? Why or why not?
Trust5 Do you think that your doctor or health care providers are knowledgeable about
the health issues that gay and bisexual men have to deal with? Why or why not?
Context
Brandon ended up getting vaccinated for HPV and felt good about his
decision. He felt that he did something that will help to protect his health as well as the
health of his partners. He found several different locations in his area where he could get
the HPV vaccine at an affordable price. These included:
A HIV-testing site or
clinic that offers vaccination in addition to HIV testing. No appointment is usually
needed. Many of these clinics offer medication and case management for people infected
with HIV. Some of these organizations now offer HPV vaccination as part of there
services for gay and bisexual men. A pharmacy with a walk-in clinic (e.g., CVS,
Walgreens, Target, Walmart, Arlington, and others). These walk-in clinics provide basic
health care services including vaccinations. A primary care providers office where you
can receive routine medical care. This may be a "family doctor"or an in-network doctor
affiliated with a health insurance organization. Community-based organization that
“promotes a healthy environment for all regardless of race, ethnicity, religion, sexual
orientation, gender identity, age or economic status.” They offer a number of health and
social services and even a weekly social group for young lesbian, gay, bisexual,
transgender and queer youth.
PlacesC Assuming you wanted to get the HPV vaccine, indicate below if you would be
likely or unlikely to get the HPV vaccination at any of these locations.
Unlikely (1)

Undecided (2)

Likely (4)

HIV testing site (5)
Pharmacy with a
walk-in clinic (8)
Primary care
provider office (9)
Community-based
organization serving
LGBT people (10)

PlacesO Are there any other locations that you would prefer to get the HPV vaccine?
Please explain below.
Thank you very much for taking the time to complete this survey. Two last important
questions.
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Intention Based on what you know right now about HPV and the HPV vaccine, how
likely is it that you will receive your first HPV shot by this time next year?
Very Unlikely (1)
Unlikely (2)
Somewhat Unlikely (3)
Undecided (4)
Somewhat Likely (5)
Likely (6)
Very Likely (7)

IntentionO You said that you are "${q://QID82/ChoiceGroup/SelectedChoices}" to get
your first HPV shot by this time next year. Why did you select this response? Is there
anything you would like to know about the vaccine before making your decision?
OPEN Thank you for taking the survey. On the next page you can submit your responses
and move on to enter to win a gift card. If you have any thoughts you'd like to share with
me you can do so below.
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Appendix D: IRB Approval

March 18, 2013
Christopher Wheldon
Community and Family Health
13201 Bruce B. Downs Blvd., MDC 56
Tampa, FL 33612
RE:
IRB#:
Title:

Expedited Approval for Initial Review
Pro00012092
Men4Men Health Study

Study Approval Period: 3/18/2013 to 3/18/2014
Dear Mr. Wheldon:
On 3/18/2013, the Institutional Review Board (IRB) reviewed and APPROVED the above
application and all documents outlined below.
Approved Item(s):
Protocol Document(s):
Diss_IRB_Protocol (APA 6).docx
Consent/Assent Document(s)*:
Name
Phase 1A In person IC
Phase 1A online IC
Phase 1B and 2 Online IC
All consent forms granted a Waiver of Informed Consent Documentation

Version
0.01
0.01
0.01

*Please use only the official IRB stamped informed consent/assent document(s) found under the
"Attachments" tab. Please note, these consent/assent document(s) are only valid during the
approval period indicated at the top of the form(s). (Waivers are not stamped).
It was the determination of the IRB that your study qualified for expedited review which
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve
only procedures listed in one or more of the categories outlined below. The IRB may review
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR
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56.110. The research proposed in this study is categorized under the following expedited review
category:
(6) Collection of data from voice, video, digital, or image recordings made for research purposes.
(7) Research on individual or group characteristics or behavior (including, but not limited to,
research on perception, cognition, motivation, identity, language, communication, cultural
beliefs or practices, and social behavior) or research employing survey, interview, oral history,
focus group, program evaluation, human factors evaluation, or quality assurance methodologies.
Your study qualifies for a waiver of the requirements for the documentation of informed consent
as outlined in the federal regulations at 45CFR46.117(c) which states that an IRB may waive the
requirement for the investigator to obtain a signed consent form for some or all subjects.
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the
approved research must be submitted to the IRB for review and approval by an amendment.
We appreciate your dedication to the ethical conduct of human subject research at the University
of South Florida and your continued commitment to human research protections. If you have
any questions regarding this matter, please call 813-974-5638.
Sincerely,

John Schinka, Ph.D., Chairperson
USF Institutional Review Board
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3/24/2014
Christopher Wheldon
Community and Family Health
13201 Bruce B. Downs Blvd., MDC 56
Tampa, FL 33612
RE:
IRB#:
Title:

Expedited Approval for Continuing Review
CR1_Pro00012092
Men4Men Health Study

Study Approval Period: 3/20/2014 to 3/20/2015
Dear Mr. Wheldon:
On 3/20/2014, the Institutional Review Board (IRB) reviewed and APPROVED the above
application and all documents outlined below.
Approved Item(s):
Protocol Document(s):
Diss_IRB_Protocol (APA 6).docx
Please submit an amendment to the IRB within 30 days to update the recruitment flyer to
reflect the following changes: include the word "research" on the flyer and provide disclosure of
the collection of demographic information. Please update the study protocol to indicate the gift
card compensation amount of $25.
The waiver of informed consent documentation has been renewed.
The IRB determined that your study qualified for expedited review based on federal expedited
category number(s):
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(6) Collection of data from voice, video, digital, or image recordings made for research purposes.
(7) Research on individual or group characteristics or behavior (including, but not limited to,
research on perception, cognition, motivation, identity, language, communication, cultural
beliefs or practices, and social behavior) or research employing survey, interview, oral history,
focus group, program evaluation, human factors evaluation, or quality assurance methodologies.
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the
approved research must be submitted to the IRB for review and approval by an amendment.
We appreciate your dedication to the ethical conduct of human subject research at the University
of South Florida and your continued commitment to human research protections. If you have
any questions regarding this matter, please call 813-974-5638.
Sincerely,

John Schinka, Ph.D., Chairperson
USF Institutional Review Board
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